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Abstract 
Study design 
Cross sectional (Study 1) and prospective (Study 2). 
 
Background 
Chronic low back pain (LBP) is problematic with significant personal, social, and economic 
impact.  The need to screen for indicators of poor prognosis and/or stratify patients with 
LBP based on risk is highlighted in the literature.  The STarT Back Screening Tool (SBST) is 
one tool that has been developed to meet this need.  There is a growing body of evidence 
for the psychometric properties of the SBST and for the tool’s predictive and discriminative 
ability, particularly in populations with LBP of variable episode duration.  Studies have 
shown that the SBST’s performance has differed depending on the population in which it 
was evaluated.  Clinical setting, cultural context, and LBP episode duration have all 
influenced the tool’s performance.  There are a lack of studies evaluating the utility of the 
SBST in a population exclusively with chronic LBP.  While the SBST is commonly used in 
Australia, the tool is yet to be evaluated in an Australian context.  
 
Aims 
This study aimed to determine the utility of the SBST in a population exclusively with 
chronic non-specific LBP in Australia.  The aim of the cross sectional study was to profile the 
SBST risk subgroups with respect to pain, disability, and psychological measures.  The aim of 
the prospective study was to evaluate the predictive and discriminative ability of the SBST 
for pain intensity, self-reported LBP related disability, and global self-perceived change at 
one year follow-up.   
 
Methods 
Participants with dominant axial non-specific LBP of at least three months duration were 
recruited (n=290).  At baseline participants completed the SBST and data were collected on 
demographic information, pain intensity (11-point numerical rating scale [NRS]), disability 
(Roland Morris Disability Questionnaire [RMDQ]), depression/anxiety/stress (Depression 
Anxiety Depression Scale), fear avoidance beliefs (Fear Avoidance Beliefs Questionnaire 
[FABQ]), catastrophising (Pain Catastrophising Scale), perceived risk of pain persistence (11-
point NRS), self-efficacy (Pain Self-efficacy Questionnaire), and chronic pain acceptance 
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(Chronic Pain Acceptance Questionnaire).  Baseline SBST risk subgroup differences were 
examined using a one-way analysis of variance (ANOVA), Kruskal-Wallis test, or Chi Squared 
test depending on the data type and distribution.  Follow-up data were collected after one 
year (n=264).  The follow-up measures were pain intensity (NRS), disability (RMDQ), and 
global perceived change (7-point global rating of change scale).  The follow-up measures 
were dichotomised into recovered and not recovered for analysis.  The proportion of 
participants who were not recovered with respect to each of the follow-up measure was 
calculated at a cohort level and by baseline SBST risk subgroup.  The predictive ability of the 
SBST was evaluated with risk ratios (RR) using the low risk group as the reference category.  
In order to evaluate the discriminative ability of the SBST, receiver operating characteristic 
(ROC) curves were constructed and the area under the curve (AUC) was calculated for both 
the SBST total score and psychological subscale score for each of the follow-up measures.  
Likelihood ratios, sensitivity, specificity, and the diagnostic odds ratio (DOR) for the low risk 
group versus the medium/high risk group and the low/medium risk group versus the high 
risk group were calculated for the significant AUC values.  Statistical significance was 
considered to be at the p<0.05 for all analyses.   
 
Results 
At baseline, the SBST categorised 82 participants (28.3%) as low risk, 116 (40.0%) as 
medium risk, and 92 (31.7%) as high risk.  There were significant differences between the 
SBST risk subgroups for pain intensity (p≤0.001), disability (p≤0.001), and for the scores on 
the psychological questionnaires (p≤0.001 except FABQ work subscale p=0.010).  The SBST 
risk subgroups demonstrated increasingly higher levels of pain, disability, and negative 
psychological affect and cognitions as subgroup categorisation increased from low to 
medium to high risk.  Non-recovery rates at the one year follow-up were 76.1% (n=201) for 
pain, 31.4% (n=83) for disability, and 44.5% (n=117) for global perceived change.  The 
predictive ability of the SBST was the strongest for disability.  The medium risk group (RR 
2.30 [95% confidence interval (CI) 1.28, 4.10], p=0.003) and the high risk group (RR 2.86 
[1.60, 5.11], p≤0.001) had a meaningfully greater relative risk of being considered disabled 
compared to the low risk group.  The medium risk group (RR 1.25 [1.04, 1.51], p=0.013) and 
the high risk group (RR 1.26 [1.03, 1.52], p=0.020) had a statistically greater risk of non-
recovery with respect to pain but this relative risk was unlikely to be of any clinical 
significance.  Although a higher proportion of both the medium and the high risk group 
perceived themselves as not improved at the one year follow-up compared to the low risk 
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group, the difference in risk was not significant (medium risk group RR 1.12 [0.78, 1.57], 
p=0.558; high risk group RR 1.26 [0.88, 1.79], p=0.201).  The SBST’s discriminative ability for 
pain was poor with an AUC [95% CI] of 0.63 [0.55, 0.71] for both the total score and the 
psychological subscale score.  The SBST’s discriminative ability for disability was acceptable 
with an AUC of 0.71 [0.64, 0.77] for the total score and 0.67 [0.60, 0.73] for the 
psychological subscale score.  The SBST was unable to discriminate global perceived change 
with an AUC of 0.56 [0.49, 0.63] for the total score and 0.55 [0.48, 0.62] for the 
psychological subscale score.  The positive and negative likelihood ratios for pain and 
disability were both relatively close to one.  However, the positive likelihood ratios were 
higher and the negative likelihood ratios were lower for disability in comparison to pain, 
again suggesting the SBST performed better with respect to the disability measure.   
 
Conclusions 
The results of this study provide valuable information to clinicians on the usefulness and 
limitations of using the SBST in patients with chronic LBP in an Australian setting.  The SBST 
should be applied with caution for patients presenting with chronic LBP.  The SBST has 
value as a substitute for the administration of multiple full-length, unidimensional 
questionnaires to initially screen for high levels of pain, disability, and negative 
psychological affect and cognitions in clinical practice.  Therefore the tool can alert the 
clinician to the need for further assessment.  The SBST has moderate predictive and 
acceptable discriminative ability for future disability.  However, the SBST’s predictive and 
discriminative ability was relatively weak for future pain and the tool was unable to identify 
those participants who perceived themselves as improved versus not improved at the one 
year follow-up.  
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Chapter 1:  Introduction and Literature Review 
1.1 Introduction 
Chronic pain impacts upon a large proportion of the Australian population and is associated 
with interference of daily activities and high levels of psychological distress (Blyth et al., 
2001).  It has been reported that around 10-15% of patients with low back pain (LBP) 
develop chronic LBP (Balague et al., 2012).  However, in a large prospective study in an 
Australian primary care setting, nearly one third of individuals with acute LBP did not 
recover from the presenting episode within one year (Henschke et al., 2008).  Similarly, in a 
large prospective study in a primary care setting in the United States of America (USA), of 
the patients presenting with acute LBP, 25% were considered disabled and 26% had chronic 
pain two years later (Mehling et al., 2012).  Worldwide, LBP is the leading cause of years 
lived with disability (Global Burden of Disease Study 2013 Collaborators, 2015).  The 
economic burden of LBP in Australia has been estimated at $9.17 billion per year (Walker et 
al., 2003).  Healthcare practices require more effective and affordable strategies to better 
manage the rising burden of LBP (Vos et al., 2012). 
 
Viewing chronic pain as a multidimensional biopsychosocial disorder is widely accepted 
(Gatchel et al., 2007, Waddell, 2006).  Recognition of psychological factors such as anxiety, 
depression, catastrophising, low self-efficacy, and fear avoidance beliefs is considered to be 
essential to the effective management of chronic pain (Gatchel et al., 2007).  Identifying 
and targeting modifiable risk factors for poor prognosis may be one strategy to improve the 
outcomes for patients with LBP (Foster et al., 2013, Foster, 2011, Hill et al., 2011).  Clinical 
guidelines highlight the need to screen for indicators of poor prognosis in patients with 
both acute and chronic LBP (Accident Compensation Corporation, 2004, Airaksinen et al., 
2006, Chou et al., 2007, van Tulder et al., 2006, Koes et al., 2010).  One approach to 
identifying indicators of poor prognosis is through the use of screening tools (self-report 
questionnaires).  A wide range of self-report screening tools to identify factors associated 
with poor prognosis and/or stratify patients based on risk have been developed (Accident 
Compensation Corporation, 2004, Du Bois et al., 2009, Fulton-Kehoe et al., 2008, Gabel et 
al., 2011, Gabel et al., 2013, Hazard et al., 1996, Hill et al., 2008, Linton and Boersma, 2003, 
Linton et al., 2011, Marhold et al., 2002, Neubauer et al., 2006, Reis et al., 2007, Sandborgh 
et al., 2007, Shaw et al., 2009a).  The STarT Back Screening Tool (SBST) (Hill et al., 2008) is 
one such tool that screens for pain area, disability, and the presence of psychological 
factors.  The SBST has received increasing interest in both clinical and research settings.  
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The tool has been advocated by The British Pain Society for early use (from two weeks after 
the onset of pain) in the management of low back and radicular pain (Lee et al., 2013).  
Stratified care that matches patients to treatment that targets their prognostic profile is a 
promising approach to improving outcomes for patients with LBP (Foster et al., 2013).  A 
randomised controlled trial (RCT) demonstrated that stratified care based on the SBST risk 
subgroups resulted in better clinical outcomes and reduced costs compared to usual care in 
a United Kingdom (UK) primary care cohort with LBP of “mixed” or “variable” episode 
duration (i.e. participants reported acute, subacute, or chronic LBP) (Hill et al., 2011, 
Whitehurst et al., 2012).   
 
Determining the validity and utility of commonly used screening measures to identify 
obstacles to recovery is a research priority (Main and George, 2011).  The initial 
development and validation of the SBST was performed in a UK primary care setting where 
the participants had non-specific LBP of variable duration (Hill et al., 2008).  In this original 
study by Hill and colleagues (2008), approximately 60% of both the developmental and 
independent external sample reported chronic LBP as defined by pain of at least three 
months duration (Chou et al., 2007, Gatchel et al., 2007, van Tulder et al., 2006).  As 
prognostic factors may influence outcome differently depending on the clinical, social, 
and/or cultural context, investigation of a screening tool in different settings and 
populations is important in order to enhance the external validity and usefulness of the tool 
(Hockings et al., 2008, Hurley et al., 2001, Linton and Boersma, 2003, Linton and Hallden, 
1998, Margison and French, 2007, Morsø et al., 2013b).  Previous studies that have 
investigated the profile of the SBST risk subgroups and/or the prognostic value of the tool 
have clearly shown that the tool’s performance differed depending on the population in 
which it was evaluated (Field and Newell, 2012, Mehling et al., 2015, Morsø et al., 2013b, 
Morsø et al., 2014, Morsø et al., 2016, Newell et al., 2015).  Low back pain episode duration 
has been reported to be associated with outcomes (Dunn and Croft, 2006) and has 
influenced the predictive performance of screening tools, including the SBST (Hill et al., 
2008, Mehling et al., 2015, Morsø et al., 2016, Westman et al., 2008, Morsø et al., 2013b, 
Morsø et al., 2014).  Authors have made clear recommendations that the utility of the SBST 
should be evaluated in different populations (Kongsted et al., 2011, Morsø et al., 2013b, 
Mehling et al., 2015) and that LBP episode duration is an important consideration (Morsø et 
al., 2016). 
 
17 
 
To date, only one small study has evaluated the performance of the SBST in a population 
exclusively with chronic LBP (Page et al., 2015).  No previous studies have evaluated the 
predictive and discriminative ability of the SBST in an Australian context.  Therefore the 
aims of this study were to:  (i) profile the SBST risk subgroups with respect to clinical and 
psychological measures and (ii) investigate the predictive and discriminative ability of the 
SBST for pain intensity, self-reported disability, and global self-perceived change at one 
year follow-up in an Australian population exclusively with chronic non-specific LBP.   
 
1.2 Prognostic factors in chronic low back pain 
Prognostic factors for individuals with LBP are multidimensional and may include pain 
features, physical, psychological, social, work, lifestyle, and demographic factors.  
Predictors of outcome are likely to be similar for acute and chronic LBP with psychological 
factors playing an important role (Balague et al., 2012).  However, given that the natural 
course of acute and chronic LBP has been shown to be different (Dunn and Croft, 2006, 
Hayden et al., 2010, Grotle et al., 2010, Costa et al., 2012), it is likely that the specific 
factors involved, which combination of factors, or the strength of association of these 
factors with future outcomes are likely to differ depending on the duration of the LBP 
episode.  Cultural differences are also likely to influence the association between 
prognostic factors and outcomes (Morsø et al., 2013b).  In a large inception cohort of 
patients with LBP in an Australian primary care setting, there was an overlap in factors 
associated with a less favourable prognosis in patients initially presenting with acute LBP 
(Henschke et al., 2008) or chronic LBP (Costa et al., 2009).  Overlapping factors included 
high baseline pain or disability and a high perceived risk of pain persistence.  However, a 
number of factors associated with the outcomes differed between the patients presenting 
with acute versus chronic LBP in this cohort (Costa et al., 2009, Henschke et al., 2009).  
Comparably, Grotle and colleagues (2010) found that a similar set of prognostic indicators 
were associated with long term disability in both acute and chronic LBP in a primary care 
setting.  These prognostic indicators included widespread pain, catastrophising, high 
baseline disability, being unemployed, and having a high Chronic Pain Grade (Grotle et al., 
2010).  However, only baseline disability explained a large proportion of the variance in 12 
month disability outcome (Grotle et al., 2010).   
 
A systematic review reported that there was little consistent evidence for which prognostic 
factors were associated with recovery from chronic LBP (Verkerk et al., 2012).  Several 
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limitations related to the included studies in this systematic review were noted by the 
authors.  These limitations were poor quality of methodology, differences in the 
measurement of the prognostic factors, differences in the measurement and reporting of 
the outcomes, and a lack of studies that included outcomes related to quality of life and 
global perceived effect (Verkerk et al., 2012).  The relationship between prognostic factors 
and outcomes is complex and variable at a single person level whether considering acute or 
chronic LBP disorders.  Regardless of these complexities, screening tools are a feasible way 
to initially screen for prognostic factors in a clinical setting. 
 
1.3 Screening for prognostic factors 
1.3.1 Use of screening tools 
Screening for the risk of an unfavourable outcome in clinical practice is important.  
However, it has been reported that healthcare providers fail to routinely or systematically 
assess for risk factors, including psychological risk factors that may affect outcomes 
(Crawford et al., 2007, Daubs et al., 2010, Grevitt et al., 1998, Kent et al., 2009, Linton and 
Shaw, 2011, Main et al., 2010).  Optimal methods of screening are also debated and may 
include an interview format, full-length unidimensional questionnaires, or brief or lengthy 
multidimensional tools.   
 
Conflicting results are reported in the literature with respect to the value of using screening 
tools compared to using the clinician’s impression, judgement, and intuition in order to 
identify risk factors for poor prognosis or individuals at risk of a poor outcome.  Studies 
have reported that a clinician’s ability to identify psychological factors such as depression 
(Haggman et al., 2004), psychological distress (Daubs et al., 2010, Grevitt et al., 1998), or 
fear avoidance beliefs (Calley et al., 2010) was poor in comparison to that of a screening 
tool.  Similarly, other studies have reported that clinicians made inconsistent risk 
estimations using intuition alone in comparison to screening tools (Bishop and Foster, 2005, 
Hill et al., 2010a).  Another study reported that clinicians were unable to accurately identify 
which patients were more likely to fail to improve over a course of treatment (Newell et al., 
2013).  Clinicians were also unable to discriminate between patients that were likely to 
have a poor pain or disability outcome (Kongsted et al., 2015).  Unnecessary referrals based 
on the clinician’s judgment rather than on formal screening may result in low risk patients 
receiving unnecessary treatment thus inflating costs or high risk patients undergoing less 
comprehensive treatment, resulting in poorer outcomes (Hill et al., 2011).  In contrast, 
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other studies have reported that the clinician’s prognostic assessment was similar to or 
even preferred over that of a screening tool (Dagfinrud et al., 2013, Jellema et al., 2007, 
Fersum et al., 2009, Kongsted et al., 2015, Karstens et al., 2015).  A combination approach 
that includes the use of a screening questionnaire, clinical examination, and clinician 
judgement may be optimal to identify risk factors for poor prognosis or individuals at risk of 
a poor outcome (Beales et al., 2016).  
 
There are several advantages to using a screening questionnaire as an adjunct to the clinical 
examination and clinician intuition and experience in identifying potential barriers to 
recovery.  Clinicians in primary care settings are generally poorly equipped to assess 
psychological factors either due to time constraints to fully evaluate the multitude of 
variables in an interview format or due to insufficient training, knowledge, or skills 
(Crawford et al., 2007, Kent et al., 2009, Linton and Boersma, 2003, Overmeer et al., 2005).  
The use of screening questionnaires can enhance patient communication (Linton and 
Boersma, 2003, Nicholas et al., 2011) and may improve consistency in decision-making (Hill 
and Fritz, 2011). 
 
There are limitations related to the use of screening questionnaires.  The responder 
requires adequate language and literacy skills.  Clinicians may feel screening tools are too 
lengthy and impractical to use routinely in a clinical setting (Mirkhil and Kent, 2009).  Some 
clinicians may be reluctant or unprepared to explore non-medical domains (Shaw et al., 
2009b).  Others may not see the value in screening for psychological prognostic factors if 
they believe there is uncertainty about the effectiveness of interventions for patients with 
psychological barriers to recovery (Kent et al., 2009).  No screening tool will be 100% 
accurate, therefore a patient’s risk status as measured on a questionnaire may not reflect 
their true recovery trajectory.  Screening also does not direct clinicians involved in a 
patient’s care to a specific intervention (Hill and Fritz, 2011) nor can a screening tool make a 
sophisticated synthesis of patient preferences and expectations (Hill et al., 2010a).  There 
may be a danger that access to treatment could be denied to individuals who have been 
misclassified as low risk on a screening tool alone.  Finally, certain factors shown to 
demonstrate prognostic capabilities may not be modifiable through direct treatment such 
as age, sex, and pain episode duration.  Despite the aforementioned limitations, it is 
generally accepted that the use of a brief screening tool to identify patients at risk of a poor 
outcome provides a basis for further assessment and for the development of targeted 
interventions most likely to facilitate recovery.  
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1.3.2 Unidimensional versus multidimensional screening tools 
Many self-report screening questionnaires are unidimensional, consisting of several items 
each representing the same construct (Beneciuk et al., 2015).  Others are multidimensional 
and quantify overall “risk complexity” or “cumulative prognostic risk” (Beneciuk et al., 2015, 
Hill et al., 2008, Wideman et al., 2012).  A number of short, multidimensional tools have 
been developed to facilitate easy assessment of indicators of poor prognosis and/or stratify 
patients based on risk (Gabel et al., 2013, Hill et al., 2008, Linton et al., 2011). 
 
There are several advantages to using concise, multidimensional screening tools over 
unidimensional ones.  Individual prognostic factors have been shown to be relatively weak 
in predicting future outcomes (Cedraschi and Allaz, 2005, Chou and Shekelle, 2010).  A 
combination of important psychological constructs may be a more useful indicator of 
patients at risk of a poor outcome (Campbell et al., 2013).  Wideman and Sullivan (2012) 
demonstrated that the presence of a greater number of psychological risk factors (fear, 
depression, or catastrophising) reduced the likelihood of recovery with respect to pain and 
work disability.  Similarly, measuring cumulative prognostic risk with the SBST total score 
was shown to be a better predictor of a broad range of outcomes compared to the tool’s 
single construct reference measures (Wideman et al., 2012).  This literature supports that 
an increase in the number of risk factors present is linked to non-recovery and 
multidimensional tools can help identify this risk.   
 
The use of a concise, multidimensional screening tool is more practical than administering a 
battery of unidimensional, full-length questionnaires in a clinical setting as it takes less time 
to complete and score, thus reducing responder and assessor burden.  However, 
multidimensional tools do not provide detailed information on a specific construct which 
may mean that some patients require further assessment (Beneciuk et al., 2015, Beneciuk 
et al., 2013).  Nonetheless, brief, multidimensional tools are useful for initial screening in 
order to guide decision-making as to whether or not further detailed assessment with 
single construct questionnaires is required (Hill and Fritz, 2011, Main and George, 2011).  
Multidimensional screening tools such as the SBST have the capacity to replace the use of 
numerous unidimensional tools as first-line screening (Beneciuk et al., 2015, Wideman et 
al., 2012) with further research required in different populations and settings to support 
this claim. 
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1.4 STarT Back Screening Tool 
1.4.1 Development and validation 
The SBST (http://www.keele.ac.uk/sbst/startbacktool/) (Keele University) is a brief 9-item, 
multidimensional screening tool used to identify patients with non-specific LBP who have 
potentially modifiable prognostic indicators for poor outcome, specifically future disability 
(Hill et al., 2008).  It was primarily developed to subgroup patients into risk categories with 
cut-off scores based on baseline factors, rather than future outcome (Hill et al., 2010b).  
The tool was designed to support primary care or first contact care decision-making.  The 
development of the SBST was based on a review of the literature and a secondary analysis 
of a previously published RCT (Hay et al., 2005) and prospective study (Dunn and Croft, 
2005) conducted in primary care settings in the UK.  The constructs included in the tool 
were those shown to be the strongest independent predictors of future LBP related 
disability (Hill et al., 2008).  The items in the SBST can be broadly categorised as either 
physical or psychological domains and cover eight constructs (referred leg pain, comorbid 
pain, disability [two items], fear avoidance, anxiety, catastrophising, depression, and back 
pain bothersomeness; the last five items represent the psychological subscale) (Hill et al., 
2008).  The question(s) related to each SBST construct were selected from previously 
validated questionnaires or validated single questions where available (Hill et al., 2008).   
 
Items in the SBST use a dichotomised response format, agree (positive) or disagree 
(negative) with the exception of the question on back pain bothersomeness which is rated 
on a 5-point Likert scale (not at all, slightly, moderately, very much, or extremely) (Dunn and 
Croft, 2005).  The response to this question is then dichotomised with a positive response 
equating to very much or extremely bothersome.  The SBST is quick and easy to score with 
the overall total score produced by summing all positive responses with a possible overall 
total score of zero to nine with higher scores indicating greater risk complexity (Hill et al., 
2008).  The psychological subscale is independently summed for a score of zero to five (Hill 
et al., 2008).  Based on cut-off scores, patients are allocated into three risk categories for 
targeted treatment, each directing a different care pathway.  The low risk group has few 
negative prognostic indicators and is suitable for primary care management focusing on 
advice, analgesics, and education (Hill et al., 2008).  The medium risk group has an 
unfavourable prognosis with high levels of physical prognostic indicators and is suited to 
physiotherapy intervention (Hill et al., 2008).  The high risk group has a very unfavourable 
prognosis with a high level of psychological prognostic indicators and is suited to a 
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combination of cognitive-behavioural and physical management approaches (Hill et al., 
2008). 
 
The SBST’s psychometric properties including discriminant validity, internal consistency, 
and test re-test reliability were assessed in a sample of participants with non-specific LBP in 
a UK primary care setting (i.e. the developmental sample) (Hill et al., 2008).  Participants 
reported LBP of variable duration; approximately 60% of the cohort reported a LBP episode 
duration of greater than three months (Hill et al., 2008).  Reference standards for the 
developmental sample included the Roland Morris Disability Questionnaire (RMDQ) for 
disability, the Pain Catastrophising Scale (PCS) for catastrophising, the Tampa Scale for 
Kinesiophobia (TSK) for fear, the Patient Health Questionnaire-2 (PHQ-2) for depression, 
the presence of referred leg pain, and back pain bothersomeness (Hill et al., 2008).  The 
developmental sample was also used to identify cut-off scores with sensitivity and 
specificity values for allocation into the three risk groups (low, medium, and high) (Hill et 
al., 2008).  In order to minimise the chance of subjecting patients to cognitive-behavioral 
management whom in fact did not require this approach, high specificity was given priority 
over high sensitivity when the optimal cut-off scores were determined (Hill et al., 2008).  
Study results showed acceptable to outstanding discriminant validity, acceptable levels of 
internal consistency, and acceptable test re-test reliability (Hill et al., 2008).  Overall total 
scores of zero to three identified the low risk group, overall total scores of greater than 
three but less than four on the psychological subscale identified the medium risk group, 
and overall total scores of greater than three with four or more on the psychological 
subscale identified the high risk group (Hill et al., 2008).  These cut-off scores resulted in a 
distribution of 39.7% (n=52) in the low risk group, 34.4% (n=45) in the medium risk group, 
and 25.2% (n=33) in the high risk group (Hill et al., 2008).   
 
The external and predictive validity of the SBST was investigated in an independent external 
sample of participants with non-specific LBP in a primary care setting in the UK (Hill et al., 
2008).  Similar to the developmental sample, approximately 60% of the participants in the 
external sample reported LBP of greater than three months duration (Hill et al., 2008).  
Measurement and data collection procedures were the same as those for the 
developmental sample except that the PCS was replaced with the catastrophising subscale 
of the Coping Strategies Questionnaire (CSQ) and the PHQ-2 was replaced with the Hospital 
Anxiety Depression Scale (HADS).  The use of different questionnaires from the original 
validation study ensured that the results were able to be generalised to the constructs 
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measured rather than the specific instrument (Hill et al., 2008).  In the external sample, the 
proportion of participants in the low, medium, and high risk subgroup was 46.8% (n=234), 
37.2% (186), and 14.8% (n=74) respectively which was similar to the developmental sample.  
At the six month follow-up, 16.7% (n=39) of the low risk group, 53.2% (n=99) of the medium 
risk group, and 78.4% (n=58) of the high risk group had a poor disability outcome as defined 
as greater than or equal to seven on the RMDQ.  The low risk group versus the 
medium/high risk group had a positive likelihood ratio (LR+) of 2.32 [95% confidence 
interval (CI) 1.96, 2.76], negative likelihood ratio (LR-) of 0.30 [0.23, 0.40], sensitivity of 
80.1%, and specificity of 65.4% for disability at the six month follow-up (Hill et al., 2008).  
The low/medium risk group versus the high risk group had a LR+ of 5.51 [3.30, 9.28], LR- of 
0.74 [0.67, 0.81], sensitivity of 29.6% (corrected value reported as noted by Mehling and 
colleagues (2015)), and specificity of 94.6% for disability at the six month follow-up (Hill et 
al., 2008).  In order to evaluate the influence of non-modifiable demographic factors on the 
SBST’s performance, participants were stratified by age, sex, and pain episode duration (Hill 
et al., 2008).  Age and sex had a small influence on the SBST’s performance with the tool’s 
discriminative ability better in older persons and men as demonstrated by higher LR+ and 
lower LR-.  Low back pain episode duration had a stronger influence on the SBST’s 
performance.  The tool performed best when the duration of LBP ranged from one to six 
months (Hill et al., 2008). 
 
Hill and colleagues (2010b) directly compared the SBST and Örebro Musculoskeletal Pain 
Screening Questionnaire (Örebro) in a UK primary care setting where participants reported 
LBP of variable duration.  The Örebro is widely used in both clinical and research settings.  
The Örebro’s reliability, validity, and predictive and discriminative ability has been 
extensively evaluated across multiple clinical settings, populations, and countries (Dunstan 
et al., 2005, Gabel et al., 2011, Grotle et al., 2007, Grotle et al., 2005, Grotle et al., 2006, 
Heneweer et al., 2007, Hockings et al., 2008, Hurley et al., 2001, Hurley et al., 2000, Jellema 
et al., 2007, Linton and Boersma, 2003, Linton and Hallden, 1998, Maher and Grotle, 2009, 
Margison and French, 2007, Vos et al., 2009, Westman et al., 2008).  Completed SBST and 
Örebro data were available for 53% (n=130) of the participants, possibly introducing non-
response bias to the results which would have had an equal effect on both tools (Hill et al., 
2010b).  In order to identify the low, medium, and high risk group using the SBST, cut-off 
scores as described by Hill and colleagues (2008) were used.  A previously reported cut-off 
score of greater than or equal to 112 on the Örebro was used to identify patients at high 
risk while a score of 90 was used to separate the low from the medium risk group (Hurley et 
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al., 2001, Nordeman et al., 2006).  Hill and colleagues (2010b) reported a high correlation 
between the SBST total score and the psychological subscale score with the Örebro score 
(0.80 and 0.77 respectively).  The subgroup characteristics across the three risk groups were 
similar for both tools with the low risk groups almost identical in terms of pain and 
disability.  The medium risk groups differed in that the SBST’s medium risk group had 
slightly higher pain and disability scores but this was not found to be significant.  The SBST 
allocated significantly fewer patients to the high risk group (SBST 25% and Örebro 38%) and 
significantly more patients to the medium risk group (SBST 35% and Örebro 22%) compared 
to the Örebro.  The proportion of the sample in the low risk group was equal for both tools 
(40%).  The discriminative ability of the SBST (total score and psychological subscale score) 
and Örebro were similar for disability, catastrophising, fear, co-morbid pain, time-off work, 
and episode duration when compared to reference standards (Hill et al., 2010b).  The SBST 
was significantly better for discriminating bothersomeness and referred leg pain while the 
Örebro was significantly better for discriminating pain intensity (Hill et al., 2010b).  This 
study supported the SBST’s concurrent validity against a suitable reference standard (Hill et 
al., 2010b).  The authors concluded that the SBST was an appropriate alternative for 
identifying high risk patients with LBP in a primary care setting (Hill et al., 2010b).  It was 
not possible to compare the predictive ability of the SBST and Örebro due to the cross 
sectional nature of this study.    
 
A limited number of studies have evaluated the SBST’s responsiveness or sensitivity to 
change, an important psychometric property if a screening tool is to be considered useful 
as an outcome measure.  Wideman and colleagues (2012) evaluated the SBST’s sensitivity 
to physiotherapy treatment related change in comparison to the tool’s corresponding full-
length measures (RMDQ, PCS, TSK, and HADS-depression).  The authors also evaluated the 
SBST’s ability to detect clinically meaningful improvement in a number of outcomes at the 
four month follow-up (Wideman et al., 2012).  The study was undertaken in a UK sample 
where participants reported LBP of variable duration (64% of the sample had chronic LBP) 
(Wideman et al., 2012).  A reduction of three to five points on the SBST (corresponding to 
one risk category improvement) resulted in clinically meaningful improvements in 
perceived global change, pain, disability, pain catastrophising, fear of movement, and 
depression (Wideman et al., 2012).  The authors concluded that the SBST could be used 
instead of its reference standards to imply changes in pain severity, disability, fear of 
movement, and catastrophising thus improving the efficiency of reassessment in a clinical 
setting (Wideman et al., 2012).   
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Other studies have provided additional preliminary support that a change in the SBST total 
score or a change in risk subgroup stratification may be useful to monitor the response to 
treatment for patients with LBP seeking physiotherapy care (Beneciuck et al., 2014, 
Beneciuk et al., 2013) and for office workers with subacute non-specific LBP undergoing an 
online occupational postural and exercise intervention (del Pozo-Cruz et al., 2012). 
 
The SBST has been formally translated into several languages including Danish (Morsø et 
al., 2011), Spanish (Gusi et al., 2011), French (Bruyere et al., 2012), Brazilian Portuguese 
(Pilz et al., 2014), Mandarin (Luan et al., 2014), German (Aebischer et al., 2015), Persian 
(Abedi et al., 2015), and Finnish (Piironen et al., 2016).  Several of these studies have also 
investigated the psychometric properties (e.g. discriminative ability, construct validity, 
internal consistency, and test re-test reliability) of the translated SBST with favourable 
results (Aebischer et al., 2015, Luan et al., 2014, Morsø et al., 2011, Pilz et al., 2014, Abedi 
et al., 2015, Piironen et al., 2016).  To this investigator’s knowledge, aside from the English 
version, only the predictive and discriminative ability of the Danish SBST has been 
evaluated (Kongsted et al., 2015, Morsø et al., 2013b, Morsø et al., 2014, Morsø et al., 
2016). 
 
1.4.2 Other studies evaluating the STarT Back Screening Tool 
Since the original development and validation of the SBST in a primary care setting in the 
UK, a number of other studies have reported on various aspects of the performance of the 
SBST either using a cross sectional or prospective design.  The tool has since been evaluated 
in the USA (Beneciuck et al., 2014, Beneciuk et al., 2013, Beneciuk et al., 2015, Fritz et al., 
2011, George and Beneciuk, 2015, Mehling et al., 2015, Von Korff et al., 2014), Denmark 
(Kongsted et al., 2015, Kongsted et al., 2011, Morsø et al., 2013b, Morsø et al., 2013a, 
Morsø et al., 2014, Morsø et al., 2016), and Canada (Page et al., 2015).  Several studies have 
specifically evaluated the SBST in a physiotherapy clinical setting (Beneciuck et al., 2014, 
Beneciuk et al., 2013, Beneciuk et al., 2015, Fritz et al., 2011, George and Beneciuk, 2015, 
Morsø et al., 2013b, Morsø et al., 2016) or chiropractic clinical setting (Field and Newell, 
2012, Kongsted et al., 2015, Kongsted et al., 2011, Morsø et al., 2016, Newell et al., 2015, 
Page et al., 2015).  Depending on the country, physiotherapy and chiropractic clinical 
settings have additionally been described as primary or secondary care by the authors.  
Outside of a physiotherapy or chiropractic clinical setting, other studies have evaluated the 
SBST in a general practice (GP) primary care cohort (Mehling et al., 2015, Morsø et al., 
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2013b, Morsø et al., 2013a, Morsø et al., 2016, Von Korff et al., 2014, Wideman et al., 2012) 
or a cohort described as secondary care (Morsø et al., 2013a, Morsø et al., 2014, Morsø et 
al., 2016).  The performance of the SBST has varied depending on the population in which 
the tool has been applied.  A number of the key aforementioned studies will be discussed in 
further detail below.  This discussion will be organised by LBP episode duration where 
chronic LBP is defined as pain present for a period of at least three months (Chou et al., 
2007, Gatchel et al., 2007, van Tulder et al., 2006).  A summary of the key studies 
specifically evaluating the predictive utility of the SBST is shown in Table 1.1.   
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Table 1.1.  Summary of the Predictive Utility of the STarT Back Screening Tool  
Study Setting / population Outcomes / follow-up Predictive utility 
Studies in LBP of variable duration 
Hill et al., 
2008 
Primary care UK 
≈ 60% chronic LBP  
Disability (RMDQ) / 6 
months 
Yes 
Beneciuk et 
al., 2013 
Physiotherapy USA 
 49% chronic LBP 
Disability (ODQ), pain 
(NRS) / 6 months 
Yes disability 
No pain 
Beneciuck et 
al., 2014 
Physiotherapy USA 
 49% chronic LBP 
Disability (ODQ), pain 
(NRS) / 6 months 
Yes disability 
No pain 
George and 
Beneciuk, 
2015 
Physiotherapy USA 
49% chronic LBP 
Composite disability 
(RMDQ) & pain (NRS) / 6 
months 
Yes 
Field and 
Newell, 2012 
Chiropractic UK 
31% chronic LBP 
PGIC, pain, BQ / 14, 30, & 
90 days 
No 
Newell et al., 
2015 
Chiropractic UK 
47% chronic LBP 
PGIC / 14, 30, & 90 days No 
Morsø et al., 
2013b 
Primary care 
Denmark 
(GP/Physiotherapy) 
≈ 1/3 chronic LBP 
Disability (RMDQ) / 3 
months 
Yes  
High risk group 
weaker vs. UK 
primary care 
Studies in acute LBP 
Kongsted et 
al., 2015 
Chiropractic 
Denmark 
3% chronic LBP  
Disability (RMDQ), pain 
(NRS) / 2 weeks;  3 & 12 
months 
Poor for disability 
No for pain 
Mehling et al., 
2015 
Primary care USA 
100% < 30 days LBP 
Disability (RMDQ), Chronic 
Pain Risk, Composite of 
Perceived Recovery & Pain 
(NRS) / 6 months & 2 
years 
Poor for all 
outcomes 
Studies in chronic LBP 
Morsø et al., 
2014 
Secondary care 
Denmark 
≈ 80% chronic LBP  
Disability (RMDQ), pain 
(NRS) / 6 months 
Yes 
Weaker vs. Danish 
primary care  
Page et al., 
2015 
Chiropractic Canada 
100% chronic LBP 
Disability (ODQ), pain 
(NRS), PGIC / 2, 4, 6, & 12 
months 
Yes disability 
Yes pain but weaker 
No for PGIC 
LBP = low back pain; RMDQ = Roland Morris Disability Questionnaire; ODQ = Oswestry 
Disability Questionnaire; NRS = Numerical Rating Scale; PGIC = Patient Global Impression of 
Change; BQ = Bournemouth Questionnaire.   
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1.4.3 Studies in low back pain of variable duration 
The majority of studies published since the original development and validation of the SBST 
have evaluated the tool in a population with LBP of mixed or variable episode duration (i.e. 
participants reported acute, subacute, or chronic LBP) (Beneciuck et al., 2014, Beneciuk et 
al., 2013, Beneciuk et al., 2015, Field and Newell, 2012, Fritz et al., 2011, George and 
Beneciuk, 2015, Kongsted et al., 2011, Morsø et al., 2013b, Newell et al., 2015, Von Korff et 
al., 2014, Wideman et al., 2012).  Fritz and colleagues (2011) provided early preliminary 
support for the use of the SBST outside of a UK primary care setting.  These authors 
examined the SBST in a physiotherapy outpatient setting in the USA in a sample where the 
participants reported a median LBP duration of 46 days (interquartile range [IQR] 18.5-
147.0 days).  The SBST risk subgroups were associated with baseline pain intensity and 
disability scores with increasingly higher scores on these clinical measures in the low to 
medium to high risk group, lending support to the construct validity of the tool (Fritz et al., 
2011).  This study did not evaluate the psychological profile of the SBST risk subgroups.  
However, a cross sectional study in a chiropractic clinical setting in Denmark (34% of the 
sample reported chronic LBP) in the same year reported a significant association between 
the SBST risk subgroups and scores on the Major Depression Inventory (MDI), Fear 
Avoidance Beliefs Questionnaire (FABQ), and the CSQ (catastrophising subscale) (Kongsted 
et al., 2011).  Kongsted and colleagues (2011) concluded that the SBST risk subgroups were 
related to the presence of well-established psychological prognostic factors. 
 
In addition to the study by Fritz and colleagues (2011), a number of other studies have 
investigated the SBST in a physiotherapy outpatient setting in the USA, both in a cross 
sectional and prospective manner.  Beneciuk and colleagues (2013) reported that the SBST 
total score and the psychological subscale score were both significantly correlated with 
intake scores on a number of unidimensional psychological questionnaires (FABQ, PCS, TSK-
11, and PHQ-9) with the strongest correlations obtained for the PCS, TSK-11, and PHQ-9.  
Prospectively, intake pain intensity (Numerical Rating Scale [NRS]) and disability (Oswestry 
Disability Questionnaire [ODQ]) scores were the strongest predictors of clinical outcomes at 
the six month follow-up with the SBST total score and the psychological subscale score 
adding to the prediction of disability but not pain (Beneciuk et al., 2013).  Change scores on 
the SBST from intake to four week reassessment were also shown to be predictive of 
disability at the six month follow-up (Beneciuk et al., 2013).  The authors suggested that a 
change in the SBST total score may be useful for treatment monitoring (Beneciuk et al., 
2013).   
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Beneciuk and colleagues (2014) tested the predictive ability of the SBST risk subgroups 
using baseline categorisation, four week categorisation, and four week “change category” 
in the same physiotherapy outpatient setting in the USA.  The authors’ rationale was that 
change scores/change categories may provide additional information for future outcomes 
beyond that achieved with initial intake screening only.  Consistent with the results 
reported by Beneciuk and colleagues (2013), SBST intake categorisation (and four week 
change category) was not predictive of pain at the six month follow-up.  The SBST baseline 
categorisation, four week categorisation, and four week change category were all 
predictive of disability at the six month follow-up with the predictive capabilities similar 
across all three variables (Beneciuck et al., 2014).  The results of Beneciuk and colleagues 
(2013) and Beneciuk and colleagues (2014) together indicated that the SBST was not 
consistently predictive of future pain in a physiotherapy setting but the tool demonstrated 
predictive ability for future disability. 
 
George and Beneciuk (2015) further evaluated the predictive ability of the SBST for a 
composite outcome measure of pain and disability in the same physiotherapy setting in the 
USA.  The criteria for recovery was stringent with a pain intensity score of zero on a NRS 
combined with a RMDQ score of less than or equal to two equating to “recovered”.  This 
was the first, and to date the only study to look at the ability of the SBST to predict 
outcome using a composite measure of recovery.  The six month recovery rate was only 
12.6% (n=14) using the aforementioned criteria which was completely driven by failure to 
meet the pain intensity score of zero according to the authors.  The SBST was found to be a 
robust predictor of recovery status using this composite measure (George and Beneciuk, 
2015).  Higher baseline pain intensity and depressed mood (as measured by the PHQ-9) also 
uniquely contributed to non-recovery at the six month follow-up (George and Beneciuk, 
2015).  Fear avoidance, kinesiophobia, and depressive symptoms co-concurred with non-
recovery (George and Beneciuk, 2015). 
 
In a cross sectional study, Beneciuk and colleagues (2015) compared unidimensional and 
multidimensional approaches to screening for psychological distress, maladaptive coping, 
and disability in the same physiotherapy setting in the USA (49% of the sample reported 
chronic LBP).  There was a risk dependent relationship between the SBST subgroups and a 
number of full-length unidimensional psychological and disability measures (Beneciuk et al., 
2015).  The authors concluded that the SBST was a viable replacement for the 
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administration of multiple unidimensional questionnaires to identify psychological distress, 
maladaptive coping, and disability thus providing further support for the use of the SBST in 
a physiotherapy setting.   
 
Two studies have evaluated the predictive ability of the SBST in a UK chiropractic clinical 
setting where the participants reported LBP of variable duration (Field and Newell, 2012, 
Newell et al., 2015).  Field and Newell (2012) reported that the SBST risk subgroups had no 
prognostic ability for differentiating outcomes of pain, Patient Global Impression of Change 
(PGIC) rating, or Bournemouth Questionnaire (BQ) scores (a multidimensional 
questionnaire which includes subscales for pain, disability, anxiety, depression, fear 
avoidance behavior, and locus of control) at 14, 30, or 90 days following the initial 
chiropractic visit.  Newell and colleagues (2015) compared the predictive value of SBST 
intake scores to SBST scores two days following the initial chiropractic visit to help 
determine whether or not the timing of stratification was important.  STarT Back Screening 
Tool stratification at intake and two days later had no prognostic ability for PGIC at the 90 
day follow-up time point (Newell et al., 2015).  STarT Back Screening Tool stratification at 
intake and two days later also showed an inconsistent and low association with PGIC 
outcome at the 14 and 30 day follow-up time point (Newell et al., 2015).  There may be 
several reasons to explain why the SBST’s predictive performance was poor in a UK 
chiropractic clinical setting.  Although clinicians were blind to the SBST results, chiropractic 
treatment may have effectively addressed the modifiable risk factors, either consciously or 
unconsciously, which would have reduced the predictive strength of the tool (Field and 
Newell, 2012).  Outcome measures were collected much earlier than the six month follow-
up period used in the original SBST study (and subsequent studies) and this may have 
influenced the tool’s performance.  The outcome measures (PGIC and BQ) were also 
unique.  Field and Newell (2012) and Newell and colleagues (2015) used change scores 
rather than absolute scores to measure outcome.  The predictive utility of a tool can be 
different for absolute scores compared to change scores as highlighted by Kent and 
colleagues (2015) in their letter to the editor.  The original validation of the SBST used 
absolute scores (Hill et al., 2008).  Newell and colleagues (2015) proposed that the low 
response rate particularly at the 90 day follow-up time point could have resulted in 
response bias.  Finally, it may be that the SBST is limited in its predictive capacity in a 
chiropractic clinical setting compared to a primary care or physiotherapy setting.  
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Using a validated Danish language version of the SBST (Morsø et al., 2011), the tool’s 
predictive ability has been investigated in Denmark in a primary care setting with 
participants recruited from GP and physiotherapy clinics (Morsø et al., 2013b).  The SBST 
distinguished between the low and the medium risk subgroup with similar predictive ability 
for pain and disability outcome at the three month follow-up in comparison to the original 
validation study by Hill and colleagues (2008).  However, the predictive ability of the high 
risk subgroup was not as strong in the Danish primary care setting.  This may have been due 
to cross cultural differences in the influence of psychological factors on outcomes between 
the Danish and UK samples (Morsø et al., 2013b).   
 
In considering the published studies that have investigated the performance of the SBST in 
populations with LBP of variable duration, taken as a whole, the SBST appears to be a useful 
predictor of future disability in primary care and physiotherapy clinical settings both in the 
UK and outside of the UK.  The tool’s ability to predict future pain is less consistent.  The 
SBST has not performed as well in chiropractic clinical settings or when using a patient’s 
global perceived change as the measure of outcome.  
 
1.4.4 Studies in acute low back pain 
More recently, studies have explored the value of using the SBST in a population with acute 
LBP (Table 1.1).  Kongsted and colleagues (2015) investigated the accuracy with which the 
SBST could predict two week, three month, and one year pain (NRS) and disability (RMDQ) 
outcomes in a chiropractic clinical setting in Denmark.  In this study, 97% of the participants 
reported a LBP episode duration of less than three months with the majority (75%) having 
reported pain for less than two weeks.  The SBST failed to discriminate pain outcomes and 
had poor discriminative ability for disability at all follow-up time points (area under the 
curve [AUC] ranged from 0.59-0.61).  Likelihood ratios for the low, medium, and high risk 
subgroup were also all close to one indicating poor tool performance.  In addition to LBP 
episode duration, other factors may have contributed to the SBST’s poor prognostic 
performance.  As an example, the threshold to define non-recovery in this study was a 
demanding standard where a poor outcome was defined as a pain intensity of greater than 
zero on a NRS and disability was defined as a score of greater than two on the RMDQ.  The 
SBST’s poor performance in this study by Kongsted and colleagues (2015) was in keeping 
with how the tool performed in other studies in UK chiropractic clinical settings (Field and 
Newell, 2012, Newell et al., 2015).  Some possible reasons to explain the tool’s poor 
performance in chiropractic clinical settings have been discussed above. 
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Mehling and colleagues (2015) and Von Korff and colleagues (2014) both evaluated the 
performance of an item set analogous to the existing SBST in a primary care setting in the 
USA.  Mehling and colleagues (2015) evaluated this modified SBST item set in a cohort of 
patients with strictly defined acute LBP (less than 30 days duration) using the same cut-off 
scores as recommended for the original SBST.  The modified SBST item set had limited 
ability to identify patients who developed chronic pain, disability, or those patients who 
perceived themselves as not recovered at both the six month and the two year follow-up 
with the AUC for the tool’s total score ranging from 0.53-0.63 (Mehling et al., 2015).  The 
positive predictive values were lower and the likelihood ratios were closer to one than 
those reported by Hill and colleagues (2008) for the disability outcome (greater than or 
equal to seven on the RMDQ for both studies).  In contrast to the results reported by 
Mehling and colleagues (2015), this modified SBST item set performed better in a cohort of 
patients who reported LBP of variable duration (18% of the sample reported chronic LBP) 
(Von Korff et al., 2014).  Von Korff and colleagues (2014) reported acceptable prediction of 
an unfavourable outcome at the four month follow-up as measured by the Graded Chronic 
Pain Scale (a combination measure of pain intensity and activity limitation) with an AUC of 
0.75 [95% CI 0.70, 0.79].  In considering the results from the two aforementioned studies, 
LBP episode duration may at least partially account for the poor performance of this 
modified SBST item set.  Mehling and colleagues (2015) concluded that the SBST should be 
used with caution in a patient group with acute LBP using existing cut-off scores but did 
acknowledge the need for a definitive study using the original SBST item set.   
 
Morsø and colleagues (2016) performed a secondary analysis of data from three primary 
care cohorts and one secondary care cohort in order to evaluate the influence of care 
setting (chiropractic, physiotherapy, GP, and secondary care spine centre), LBP episode 
duration, and timing of follow-up on the prognostic ability of the SBST in Denmark.  When 
using disability as the outcome measure, Morsø and colleagues (2016) reported that 
participant age, type of care setting, LBP episode duration, follow-up timing, and SBST risk 
subgroup were all associated with outcome.  However, only episode duration was shown to 
affect the prognostic ability of the SBST risk subgroups (Morsø et al., 2016).  The prognostic 
ability of the high risk group compared to the low risk group was stronger when the episode 
duration was greater than two weeks (Morsø et al., 2016).  The prognostic ability of the 
medium risk group compared to the low risk group was also better when the episode 
duration was greater than 12 weeks compared to less than two weeks (Morsø et al., 2016).  
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Consistent with the results from other studies undertaken in populations where 
participants had a short duration of LBP, Morsø and colleagues (2016) concluded that the 
SBST’s predictive ability was weak in very acute patients and that episode duration should 
be considered when using the SBST.   
 
In summary, studies have shown that the SBST has limited prognostic ability in populations 
with acute or short duration LBP in comparison to populations with LBP of a variable or 
mixed duration.  This is not surprising given that the SBST was not developed or initially 
validated in a population exclusively with acute LBP.  In the original study by Hill and 
colleagues (2008), only 25% of the developmental sample and 17% of the external sample 
had pain of less than one month duration.  Hill and colleagues (2008) also highlighted that 
LBP episode duration influenced the SBST’s predictive performance.  The tool performed 
best when the duration of LBP ranged from one to six months (Hill et al., 2008). 
 
1.4.5 Studies in chronic low back pain 
The majority of studies undertaken in a population with LBP of variable duration have 
recruited samples where at least one third of that sample reported LBP of greater than 
three months duration (Table 1.1).  To date, only two studies have investigated the 
performance of the SBST in a population predominantly or exclusively with chronic LBP.  
The first study was in a secondary care setting in Denmark where approximately 80% of the 
participants reported chronic LBP (Morsø et al., 2014).  The second study was a small study 
in Canada in a chiropractic clinical setting that investigated the SBST in a population 
exclusively with chronic LBP (Page et al., 2015).  
 
The predictive and discriminative ability of the SBST for disability and pain outcome at six 
month follow-up was investigated by Morsø and colleagues (2014) and the results 
compared to those from an earlier study in a Danish primary care setting (Morsø et al., 
2013b) which has been described previously in section 1.4.3.  The predictive ability of the 
SBST for the disability outcome in the secondary care setting was not as strong as in the 
primary care setting even after adjusting for baseline differences in pain intensity and 
duration (Morsø et al., 2014).  However, the SBST showed similar discriminative ability in 
both cohorts for pain and disability with the AUC ranging from 0.66-0.73.  The weaker 
predictive ability reported in the Danish secondary care setting may have been related to 
different recovery trajectories of the two cohorts.  The two cohorts had a similar level of 
disability at baseline, both at a cohort level and when stratified by the SBST, however, at 
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the six month follow-up, the secondary care cohort had a less favourable recovery course 
which may have attenuated the predictive strength of the SBST in this group (Morsø et al., 
2014).   
 
The study by Page and colleagues (2015) was the first and until now, the only study to 
investigate the SBST in a population exclusively with chronic LBP.  The authors reported 
that the SBST total score was correlated with baseline disability (ODQ) and fear of 
movement (TSK) but not with baseline pain (NRS).  The SBST total score correlated with the 
disability outcome at the two, four, six, and 12 month follow-up but only correlated with 
the pain outcome at the 12 month follow-up.  In keeping with other studies that have used 
a PGIC scale as an outcome measure (Field and Newell, 2012, Newell et al., 2015), the SBST 
total score was not associated with PGIC at any of the follow-up time points.  The SBST total 
score showed an excellent ability to discriminate disability at the six and the 12 month 
follow-up (AUC ranged from 0.84-0.82) and an acceptable ability to discriminate pain at the 
six and the 12 month follow-up (AUC ranged from 0.73-0.71).  The SBST was unable to 
discriminate between those participants who had and had not improved according to the 
PGIC.  Limitations of this study include the small sample size (n=53 at baseline) with a 13% 
loss at the six month follow-up and an 11% loss at the 12 month follow-up.  The proportion 
of the sample with a poor outcome at each follow-up collection point was not reported.  
This study did not evaluate the association between SBST risk subgroups and outcomes or 
the psychological subscale score and outcomes. 
 
In summary, there has been limited investigation of the SBST’s performance in a population 
exclusively with chronic LBP.  Furthermore, the aforementioned studies provide 
inconsistent results on the performance of the SBST in a group with chronic LBP.  Although 
the SBST total score had an excellent ability to discriminate future disability in the study by 
Page and colleagues (2015), this study was small.  In contrast, the SBST’s discriminative 
ability for future disability was relatively weak in the study by Morsø and colleagues (2014).  
Morsø and colleagues (2014) also reported that the predictive ability of the SBST was 
relatively weak in comparison to that shown in a Danish primary care setting where the 
participants reported LBP of variable duration.  The use of the SBST in a population with 
chronic LBP warrants further investigation. 
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1.4.6 Summary - STarT Back Screening Tool performance and low back pain episode 
duration 
The literature has consistently demonstrated that the SBST risk subgroups are related to 
clinical and psychological measures when evaluated in a cross sectional manner.  However, 
the predictive and discriminative strength of the SBST has shown variability across studies.  
There are several possible reasons as to why the tool’s performance has differed across 
studies.  These possibilities include:  (a) differences in LBP episode duration of the samples, 
(b) differences in baseline characteristics of the samples including baseline risk 
stratification, (c) differences in natural recovery trajectories, (d) differences in the 
outcomes that were measured, (e) differences in how the outcomes were measured (e.g. 
absolute versus change scores; continuous vs dichotomised outcomes), (f) differences in 
the definitions/cut-off scores used to indicate non-recovery, (g) the timing of follow-up, (h) 
the clinical setting, (i) cultural influences, (j) the potential influence of treatment across the 
study period, (k) the statistical approaches used, and (l) differences in an individual’s 
prognosis due to factors unrelated to the SBST.  It should be noted that in the referenced 
studies where the cohort underwent some form of treatment (e.g. physiotherapy, 
chiropractic), this was not guided by the SBST risk subgroup or score but rather was at the 
discretion of the clinician.  Clinicians and researchers cannot assume that the SBST will 
perform similarly across settings and populations.  If the SBST is to be used with confidence 
in Australia for patients presenting with chronic LBP, the tool’s performance must be 
evaluated in this group.   
 
1.5 Limitations in the current research 
There are a number of limitations in the current research that has evaluated the SBST.  
There is a lack of studies evaluating long term outcomes with only three original studies 
evaluating outcomes beyond a follow-up period of six months (Kongsted et al., 2015, 
Mehling et al., 2015, Page et al., 2015).  Although global rating of change is a recommended 
core outcome measure (Dworkin et al., 2005), only a few studies have included this 
measure (Field and Newell, 2012, Mehling et al., 2015, Newell et al., 2015, Page et al., 2015, 
Wideman et al., 2012).  The SBST has not been adequately investigated in a population 
exclusively with chronic LBP as there has only been one small study evaluating the tool’s 
performance in this important group (Page et al., 2015).  To date, no studies have evaluated 
the relationship between the SBST and perceived risk of pain persistence, self-efficacy, and 
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chronic pain acceptance, all important constructs.  Finally, no studies have evaluated how 
the SBST performs in an Australian context. 
 
1.6 Summary of key points 
 Chronic pain can be associated with widespread suffering and limitations in 
physical, emotional, social, and occupational functioning (Breivik et al., 2006) 
resulting in significant personal, social, and economic impact. 
 The importance, strength, and interaction of prognostic factors in acute and chronic 
LBP is likely to differ depending on the duration of the LBP episode. 
 Identification and targeting of modifiable physical and psychological risk factors for 
poor prognosis may improve the outcomes for patients presenting with LBP. 
 Screening tools to identify risk factors for poor prognosis and/or stratify patients 
with LBP based on risk have been described in the literature.  The SBST has received 
significant attention in both clinical and research settings in recent years. 
 Screening tools can facilitate efficient patient triage and guide clinical decision-
making. 
 Brief, multidimensional screening tools, such as the SBST, can easily be 
implemented in clinical practice and have several advantages when compared to 
unidimensional tools. 
 There is a growing body of evidence for the psychometric properties, predictive 
ability, discriminative ability, and responsiveness of the SBST, particularly in groups 
with LBP of variable duration. 
 Studies have shown that the SBST’s performance has varied across populations 
with clinical setting, cultural context, and LBP episode duration all potentially 
influencing the tool’s performance. 
 
1.7 Basis of current research 
As described above, there are limitations in the current literature on the utility of the SBST 
that warrants further investigation.  The SBST risk subgroups have not been profiled nor has 
the tool’s predictive and discriminative ability for a range of important measures been 
adequately investigated in a population exclusively with chronic non-specific LBP yet 
clinicians apply the tool in this group.  Although the SBST is commonly used in Australia, the 
tool is yet to be evaluated in an Australian context.  Before this short, multidimensional 
screening tool can be used with confidence to guide decision-making in the population of 
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interest, further evaluation is required.  Therefore this study aimed to answer the following 
research question:  What is the utility of the SBST in a population with chronic non-specific 
LBP in Australia?   
 
1.7.1 Study 1 
The first study was a cross sectional design profiling the SBST risk subgroups with respect to 
clinical and psychological measures in an Australian population exclusively with chronic 
non-specific LBP.  The aim of this study was to describe the distribution of demographic 
variables, clinical measures of pain and disability, and psychological measures in relation to 
the SBST risk subgroups.  Specifically, Study 1 aimed to examine whether the three SBST 
risk subgroups differed with respect to:  (a) demographic variables, (b) clinical measures of 
pain and disability, and (c) psychological profile.  The results of this study could help inform 
the implementation of the SBST by providing valuable information as to whether the SBST 
would be an appropriate substitute for the administration of multiple full-length, 
unidimensional questionnaires in order to determine the risk profile of a patient presenting 
with chronic LBP in Australia. 
 
1.7.2 Study 2 
The second study was a prospective design evaluating the predictive and discriminative 
ability of the SBST for pain intensity, self-reported LBP related disability, and global self-
perceived change at one year follow-up in an Australian population exclusively with chronic 
non-specific LBP. 
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Chapter 2:  Cross Sectional Study 
2.1 Aim 
This study was a cross sectional design profiling the STarT Back Screening Tool (SBST) risk 
subgroups with respect to clinical and psychological measures in an Australian population 
exclusively with chronic non-specific low back pain (LBP).  The aim of this study was to 
describe the distribution of demographic variables, clinical measures of pain and disability, 
and psychological measures in relation to the SBST risk subgroups.  Specifically, this study 
aimed to examine whether the three SBST risk subgroups differed with respect to:  (a) 
demographic variables, (b) clinical measures of pain and disability, and (c) psychological 
profile. 
 
It was hypothesised that:  (i) there would be an incremental increase in pain intensity and 
disability in the SBST risk subgroups with the high risk subgroup having the highest level of 
pain and disability and (ii) the scores on the psychological measures would incrementally 
increase (or decrease for the positive constructs of self-efficacy and chronic pain 
acceptance) across the SBST risk subgroups with the high risk subgroup having the highest 
negative psychological affect and cognitions. 
 
The results of this study could help inform the implementation of the SBST by providing 
valuable information as to whether the SBST would be an appropriate substitute for the 
administration of multiple full-length, unidimensional questionnaires in order to determine 
the risk profile of a patient presenting with chronic LBP in Australia.  
 
2.2 Methods 
A cross sectional analysis was performed on baseline data obtained from a longitudinal 
study which evaluated the presence of multidimensional subgroups in a population with 
chronic non-specific LBP (Rabey et al., 2015).  Data were collected between November 15, 
2012 and January 3, 2014.  Participants were recruited from private physiotherapy, 
psychology, and pain management clinics in Perth, Western Australia and via multimedia 
advertisements (newspaper, social media, radio, and television) circulated throughout the 
general community in both metropolitan and regional Western Australia.    
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2.2.1 Participants 
The inclusion criteria were:   
 Age between 18 and 70 years inclusive. 
 Dominant axial non-specific LBP.  Non-specific LBP is defined as pain occurring 
primarily in the low back which cannot be attributed to specific pathology such as 
infection, malignancy, fracture, an inflammatory disorder, cauda equina syndrome, 
spinal stenosis, radiculopathy, or a radicular pain disorder (Balague et al., 2012, 
Chou et al., 2007).  Dominant axial LBP was defined as pain between T12 and the 
gluteal fold with 60% or more LBP according to the following question:  “Which 
situation describes your pain over the past four weeks the best?  100% of the pain 
in the low back, 80% of the pain in the low back and 20% in the leg(s), 60% of the 
pain in the low back and 40% in the leg(s), 50% of the pain in the low back and 50% 
in the leg(s), 40% of the pain in the low back and 60% in the leg(s), or 20% of the 
pain in the low back and 80% in the leg(s).”  This question reliably differentiates 
patients with dominant LBP versus dominant leg pain (Wai et al., 2009), reducing 
the likelihood of participants with radiculopathy or radicular pain being included in 
this study.   
 Low back pain present for greater than or equal to three months.  Chronic pain is 
commonly defined as prolonged or persistent pain of at least three months 
duration (Chou et al., 2007, Gatchel et al., 2007, van Tulder et al., 2006). 
 Baseline pain intensity in the last week of greater than or equal to two on an 11-
point Numerical Rating Scale (NRS).  Participants were asked:  “On average over the 
past week how bad has your pain been?” with a scale anchor of zero indicating no 
pain and 10 indicating the worst pain imaginable (Dworkin et al., 2005, Manniche 
et al., 1994).  The NRS is a valid, reliable, and responsive measure of pain intensity 
(Dworkin et al., 2005). 
 Low back pain related disability of greater than or equal to five on the Roland 
Morris Disability Questionnaire (RMDQ).  The RMDQ consists of 24 statements 
about activity limitations due to back pain.  The response to each statement is 
marked as either yes or no where a positive (yes) response scores one point.  Scores 
range from zero (no disability) to 24 (severely disabled).  The RMDQ is valid, 
reliable, and responsive to change (Kuijer et al., 2005, Roland and Fairbank, 2000, 
Roland and Morris, 1983). 
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Participants were excluded if they were unable to understand English, were pregnant, had a 
diagnosed neurological condition, had serious spinal pathology (e.g. cancer, inflammatory 
arthropathy, or acute vertebral fracture), or had undergone spinal surgery within the 
previous six months (e.g. multi-level fusion, instrumentation, or discectomy).  Participants 
were also excluded if they had bilateral dorsal wrist or hand pain as the previously 
mentioned longitudinal study from which this baseline data were obtained involved tissue 
sensitivity testing at the wrist (Rabey et al., 2015).  
 
2.2.2 Sample size 
The sample size for this study was predetermined by the aforementioned longitudinal study 
from which baseline data for the current study were obtained (Rabey et al., 2015).  The 
number of participants recruited for this study was similar to previously published studies 
that have investigated the performance of the SBST (Beneciuk et al., 2015, Fritz et al., 2011, 
Morsø et al., 2013b).   
 
2.2.3 Procedures 
Potential participants completed an “inclusion criteria screening checklist” either in paper 
format or online (Qualtrics Research Suite software 
https://curtin.asia.qualtrics.com/ControlPanel/) depending on preference.  Ambiguous 
responses were clarified by telephone.  Eligible participants were subsequently sent a 
standardised self-report questionnaire pack which included questions related to 
demographic information, clinical measures (pain and disability), the SBST, and a battery of 
psychological questionnaires (described below).  All questionnaires are freely available 
online.  Participants attended a laboratory based physical testing session (data not used in 
this study) at the School of Physiotherapy and Exercise Science, Curtin University, Perth, 
Western Australia at which time the questionnaire pack was collected and checked for any 
obvious incomplete questions or questionnaires.   
 
2.2.4 Demographic variables and clinical measures of pain and disability 
Demographic information related to age, sex, education level, employment status, 
occupation, compensation status, pain duration, overall general health, and recruitment 
source into the study (general community or clinical setting) was obtained.    
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Participants were asked about their education level with the following question:  “How 
many years have you spent in education (school, college, university, or professional 
education)?” (Dionne et al., 2001).  With respect to employment status, participants were 
asked:  “Are you currently in work (either paid or unpaid work e.g. student, housewife)?”  
Participants were also asked for their occupation and the responses were dichotomised 
into manual or sedentary occupations based upon the Australian and New Zealand 
Standard Classification of Occupations, Version 1.2 (Australian Bureau of Statistics, 2013).  
Participants who nominated their occupation as “retired”, “student”, or “housewife” were 
grouped together as “not working”.  To determine compensation status, a single question 
(“I have a claim for compensation for my pain”) was taken from the Fear Avoidance Beliefs 
Questionnaire (FABQ) - work subscale (FABQ-W) (Waddell et al., 1993).  Responses were 
then dichotomised as a positive or negative compensation status.  Pain duration was 
elicited by asking participants:  “How long have you had your back pain for?” with 
responses converted to months.  Information on overall general health was collected using 
a reliable and valid single item from the COOP-WONCA charts (Van Weel et al., 2012).  
Participants rated their overall general health in the previous two weeks on a 5-point scale 
ranging from excellent (score of one) to poor (score of five).  Baseline pain intensity in the 
previous week (NRS), RMDQ score, and percentage of LBP versus leg pain was retrieved 
from the inclusion criteria screening checklist.   
 
2.2.5 STarT Back Screening Tool 
The nine items in the SBST (http://www.keele.ac.uk/sbst/startbacktool/) (Keele University) 
can be broadly categorised as either physical or psychological domains and cover eight 
constructs (referred leg pain, comorbid pain, disability [two items], fear avoidance, anxiety, 
catastrophising, depression, and back pain bothersomeness; the last five items represent 
the psychological subscale) (Hill et al., 2008).  Items in the SBST use a dichotomised 
response format, agree (positive) or disagree (negative) with the exception of the question 
on back pain bothersomeness which is rated on a 5-point Likert scale (not at all, slightly, 
moderately, very much or extremely) (Dunn and Croft, 2005).  The response to this question 
is then dichotomised with a positive response equating to very much or extremely 
bothersome.  The overall total score is produced by summing all positive responses with a 
possible overall total score of zero to nine with higher scores indicating greater risk 
complexity (Hill et al., 2008).  The psychological subscale is independently summed for a 
score of zero to five (Hill et al., 2008).  Based on cut-off scores, patients are allocated into 
three subgroups:  low risk (total score less than or equal to three), medium risk (total score 
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greater than or equal to four with a psychological subscale score of less than or equal to 
three), or high risk (total score greater than or equal to four with a psychological subscale 
score of greater than or equal to four) (Hill et al., 2008). 
 
The SBST’s discriminant validity, internal consistency, test re-test reliability, external 
validity, and predictive validity has been reported by the original authors (Hill et al., 2008).  
Concurrent validity against a reference standard, the Örebro Musculoskeletal Pain 
Screening Questionnaire (Örebro), has also been established (Hill et al., 2010b).  Further 
details on the development, validation, and psychometric properties of the SBST can be 
found in Chapter 1. 
 
2.2.6 Psychological measures  
2.2.6.1 Depression Anxiety Stress Scale 
Depression, anxiety, and stress were measured with the 21-item short form of the 
Depression Anxiety Stress Scale (DASS-21) (Lovibond and Lovibond, 1995).  The DASS-21 
was selected as it evaluates all three constructs of psychological distress and the short form 
reduces responder burden.  This questionnaire contains 21 quantitative statements (seven 
items in each subscale) each rated on a 4-point scale with zero indicating did not apply to 
me at all, one indicating applied to me to some degree, two indicating applied to me to a 
considerable degree, and three indicating applied to me very much or most of the time.  
Each subscale is summed and the score doubled (maximum score of 42 for each subscale) 
with higher scores representing higher levels of depression, anxiety, or stress.  Based on the 
total score for each subscale, each construct can be classified as “normal”, “mild”, 
“moderate”, “severe”, or “extremely severe”.  The reliability and validity of the DASS-21 has 
been established (Lovibond and Lovibond, 1995).   
 
2.2.6.2 Fear Avoidance Beliefs Questionnaire 
Fear avoidance beliefs were measured with the FABQ (Waddell et al., 1993).  Statements 
are rated on a 7-point scale using the anchors completely disagree and completely agree.  
The questionnaire contains two subscales:  (a) a 5-item physical activity subscale (FABQ-PA) 
where four items are scored; scores range from zero to 24 and (b) an 11-item work subscale 
(FABQ-W) where seven items are scored; scores range from zero to 42.  Higher scores 
represent higher fear avoidance beliefs on both subscales.  The reliability and validity of this 
questionnaire has been reported (George et al., 2010, Jacob et al., 2001, Swinkels-
Meewisse et al., 2003, Waddell et al., 1993).  
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2.2.6.3 Pain Catastrophising Scale 
Pain catastrophising was measured with the Pain Catastrophising Scale (PCS) (Sullivan et al., 
1995).  The PCS evaluates negative thoughts and feelings related to rumination, 
magnification, and helplessness (Sullivan et al., 1995).  Rumination is described as worry 
and an inability to inhibit pain related thoughts (Sullivan et al., 1995).  Magnification is an 
exaggeration of the unpleasantness of pain situations and expectancies for negative 
outcome (Sullivan et al., 1995).  Helplessness is the inability to deal with painful situations 
(Sullivan et al., 1995).  The PCS is the only instrument dedicated to the assessment of 
catastrophising and examines the three different components (rumination, magnification, 
and helplessness).  Thirteen statements are rated on a 5-point scale ranging from not at all 
to all the time with the total score ranging from zero to 52.  Higher scores indicate greater 
levels of pain catastrophising.  The PCS’s reliability and validity has been reported (Osman 
et al., 2000, Sullivan et al., 1995). 
 
2.2.6.4 Perceived risk of pain persistence  
Perceived risk of pain persistence was measured by a single self-report item taken from the 
Örebro (Linton and Boersma, 2003).  Participants were asked:  “In your view, how large is 
the risk that your current pain will become persistent?” (Linton and Boersma, 2003).  A NRS 
is used, anchored at one end with zero indicating no risk and 10 at the other end indicating 
a very large risk. 
 
2.2.6.5 Pain Self-efficacy Questionnaire 
Pain self-efficacy was measured with the Pain Self-efficacy Questionnaire (PSEQ) (Nicholas, 
2007).  This questionnaire appears to be the most commonly used tool to assess this 
construct.  The PSEQ measures confidence in performing 10 activities despite pain 
(Nicholas, 2007).  Each statement is rated on a 7-point scale where zero equates to not 
confident at all and six equates to completely confident.  Scores for each statement are 
summed with the total score ranging from zero to 60 with higher scores indicating stronger 
self-efficacy beliefs.  The reliability and validity of the PSEQ has been established (Asghari 
and Nicholas, 2001, Kaivanto et al., 1995, Nicholas, 2007).   
 
2.2.6.6 Chronic Pain Acceptance Questionnaire 
Chronic pain acceptance was measured with the short form of the Chronic Pain Acceptance 
Questionnaire (CPAQ), the CPAQ-8 (Fish et al., 2010).  The CPAQ is the most common tool 
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used to measure acceptance in chronic pain and its short form was selected to reduce 
responder burden.  The CPAQ-8 consists of eight statements that are rated on a 7-point 
scale ranging from never true to always true.  The questionnaire measures a person’s ability 
to be in ongoing pain without trying to avoid it or control it and contains two subscales 
(pain willingness and activity engagement) each with four items.  Each subscale is summed 
and has a score range of zero to 24.  The total score on the CPAQ-8 ranges from zero to 48.  
Higher scores indicate higher levels of activity engagement and pain willingness (Fish et al., 
2010, McCracken et al., 2004).  The reliability and validity of the CPAQ has been reported 
(Fish et al., 2010). 
 
2.2.7 Rationale for the chosen psychological measures 
The constructs of depression, anxiety, fear avoidance, and catastrophising are core 
constructs found in the SBST with the DASS-21, FABQ, and PCS used as unidimensional 
reference standards in this study.  The use of different questionnaires to measure these 
constructs compared to the SBST’s original developmental and validation study ensured 
that the results were able to be generalised to the constructs measured rather than to the 
specific instrument (Hill et al., 2008).  To date, no study has used the DASS or DASS-21 as a 
reference standard to evaluate the SBST.   
 
Perceived risk of pain persistence, self-efficacy, and chronic pain acceptance are not core 
constructs found in the SBST.  However, the question “I feel that my back pain is terrible 
and it’s never going to get any better” may in part reflect a patient’s perceived risk of pain 
persistence.  To date, no study has investigated the relationship between the SBST risk 
subgroups and these psychological measures.  Perceived risk of pain persistence has been 
linked to poorer outcomes in chronic LBP disorders (Costa et al., 2009, Foster et al., 2010, 
Laisne et al., 2012).  Low self-efficacy has been shown to be predictive of disability 
outcomes in LBP (Foster et al., 2010).  In a recent systematic review, higher levels of self-
efficacy were reported to be associated with less functional impairment, less distress, and 
lower pain severity in chronic pain samples (Jackson et al., 2014).  Greater pain acceptance 
has been shown to be associated with less distress and pain related disability in persistent 
chronic musculoskeletal pain disorders (McCracken and Eccleston, 2006, Wright et al., 
2011).  Greater pain acceptance has also been reported to be associated with better 
functioning at a future point in time in chronic musculoskeletal pain disorders, including 
chronic LBP (McCracken and Eccleston, 2005).   
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2.2.8 Data analysis 
When calculating the total score of each questionnaire, any missing data were managed as 
suggested in the questionnaire’s original manuscript where described.  Otherwise, when 
one item was missing, the imputed average of the relevant scale or subscale was used in 
the calculation of the total score.  If two or more items were missing, the questionnaire 
total was coded as missing.  If answers to single question items were not given, they were 
coded as missing.    
 
Descriptive statistics were calculated for the demographic variables, clinical measures of 
pain and disability, and all the psychological measures with respect to the total cohort and 
with respect to each SBST risk subgroup.  Histograms and box plots were inspected for all 
continuous variables with normally distributed data expressed as means and standard 
deviations (SD).  Skewed and nominal variables were expressed as medians and 
interquartile ranges (IQR).  Frequency counts and percentages were used to express 
categorical variables.   
 
STarT Back Screening Tool subgroup differences for the continuous demographic variables, 
clinical measures, and the psychological measures were examined using a one-way analysis 
of variance (AVOVA) for normally distributed variables and the Kruskal-Wallis test for 
variables with skewed data.  STarT Back Screening Tool subgroup differences for categorical 
variables were examined using the Chi Squared test. 
 
All data analyses were performed using Stata 13.1 (Statacorp, Texas, USA) for Windows.  
Statistical significance was considered to be p<0.05 for all analyses.   
 
2.3 Ethics 
This study was approved by the Curtin University Human Research Ethics Committee 
(Approval Number PT262/2013) (Appendix A).  The longitudinal study from which this study 
obtained baseline data (Rabey et al., 2015) was also approved by the Curtin University 
Human Research Ethics Committee (Approval Number HR112/2012).  All participants 
received a Participant Information Sheet in plain language outlining the purpose of the 
study, methods, risks and discomforts, and the benefits of the research (Appendix B).  
Confidentiality was guaranteed and participants were made aware that they were able to 
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withdraw at any time without prejudice.  Written informed consent was obtained from 
each participant (Appendix C).   
 
2.4 Results 
The flow of participants through the study is shown in Figure 2.1.  During the study period, 
586 volunteers were screened for study eligibility.  Of these, 237 were excluded because 
they did not meet the inclusion criteria with the most common reason being a score of less 
than five on the RMDQ (n=130 [54.9%]) (Table 2.1).  Four participants were excluded from 
data analysis as they were recruited from local public hospitals for which this study did not 
have ethics approval (Figure 2.1).  Fifty five participants did not complete baseline data 
collection and were excluded from the study (Table 2.2).  A comparison of the 
characteristics of the participants who did and did not complete baseline data collection 
indicated that there were no significant differences between these groups on age 
(p=0.326), sex (p=0.566), pain intensity (p=0.282), disability (p=0.149), or percentage of LBP 
versus leg pain (p=0.667) (Table 2.2).  A total of 290 participants were eligible for inclusion 
in this study with 228 (78.6%) participants recruited from the general community and 62 
(21.4%) from a clinical setting.  Of the participants recruited from a clinical setting, 59 
(20.3%) were recruited from private physiotherapy clinics with the remaining three 
participants recruited from private pain management or psychology clinical settings.   
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Figure 2.1.  Flow of participants through the cross sectional study. 
  
Screened and not eligible (n=237), n (%): 
 Age >70 years, 42 (17.7) 
 Low pain intensity score, 6 (2.5) 
 Low disability score, 130 (54.9) 
 Leg pain > back pain, 28 (11.8) 
 Serious spinal pathology, 8 (3.4) 
 Bilateral dorsal wrist or hand pain, 
23 (9.7) 
Participants from public hospitals without 
ethics approval to participate in this study 
(n=4) 
 
 
Screened for eligibility 
during the recruitment 
period (n=586) 
 
 
Enrolled in study (n=349) 
 
 
Included in baseline 
analysis (n=290) 
 
 
Did not complete baseline data collection 
(n=55) with stage completed, n (%): 
 Inclusion criteria screening checklist, 
50 (90.9) 
 Self-report questionnaire pack, 5 
(9.1) 
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Table 2.1.  Descriptive Characteristics of Potential Participants Screened but not Eligible 
Demographic variable Summary statistic (n=237) 
Age (years), median (IQR) 51.0 (34.0-65.0) 
Sex*, n (%) female 126 (55.5) 
Reason for exclusion, n (%)  
     Age > 70 42 (17.7) 
     Low pain intensity score (NRS) 6 (2.5) 
     Low disability score (RMDQ) 130 (54.9) 
     Leg pain > back pain 28 (11.8) 
     Serious spinal pathology 8 (3.4) 
     Bilateral dorsal wrist or hand pain 23 (9.7) 
IQR = interquartile range; NRS = Numerical Rating Scale; RMDQ = Roland Morris Disability 
Questionnaire. 
* 10 missing (n=227 for sex). 
 
Table 2.2.  Descriptive Characteristics of Participants who did and did not Complete 
Baseline Assessment 
 Summary statistic  
Demographic variable Non-completers 
(n=55) 
Completers 
(n=290) 
p-value* 
Age (years), median (IQR) 48.0 (31.0-63.0) 50.5 (37.0-60.0) 0.326 
Sex†, n (%) female 29 (61.7) 166 (57.2) 0.566 
Pain intensity (NRS), mean (SD); 
range 0-10 
6.1 (1.9) 5.8 (1.9) 0.282 
Disability (RMDQ), median (IQR); 
range 0-24 
9.0 (7.0-15.0) 9.0 (6.0-13.0) 0.149 
Percent LBP (vs. leg pain), n (%)   0.667 
     100% 26 (47.3) 145 (50.0)  
     80% 24 (43.6) 110 (38.0)  
     60% 5 (9.1) 35 (12.1)  
IQR = interquartile range; NRS = Numerical Rating Scale; SD = standard deviation; RMDQ = 
Roland Morris Disability Questionnaire; LBP = low back pain. 
* Independent t-test, Mann-Whitney U, or Chi Squared test depending on data type and 
distribution. 
† 8 missing from the non-completers (n=47 for sex for the non-completers). 
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Table 2.3.  Baseline Descriptive Characteristics of Included Participants – Total Cohort and Stratified by STarT Back Screening Tool Risk Subgroup* 
  Risk subgroup†  
Variable Total cohort 
n=290† 
Low 
n=82 (28.3%) 
Medium 
n=116 (40.0%) 
High 
n=92 (31.7%) 
p-value  
Demographic variables      
Age (years) 50.5 (37.0-60.0) 49.0 (40.0-61.0) 51.5 (41.0-58.0) 50.0 (32.0-60.0) 0.556 
Sex, n (%) female 166 (57.2) 49 (59.8) 73 (62.9) 44 (47.8) 0.079 
Education level1 (years), mean (SD) 14.8 (3.6) 15.7 (3.9) 14.7 (3.3) 14.1 (3.5) 0.012a 
Employment status, n (%) yes working 223 (76.9) 65 (79.3) 89 (76.7) 69 (75.0) 0.799 
Occupation2, n (%)     ≤0.001 
     Manual  72 (26.2) 13 (16.1) 24 (22.2) 35 (40.7)  
     Sedentary 174 (63.3) 61 (75.3) 76 (70.4) 37 (43.0)  
     Not working 29 (10.6) 7 (8.6) 8 (7.4) 14 (16.3)  
Compensation status3, n (%) yes compensated 45 (15.8) 15 (18.5) 15 (13.2) 15 (16.9) 0.712 
Pain duration4 (months) 120.0 (42.0-240.0) 120.0 (42.0-240.0) 120.0 (48.0-300.0) 120.0 (36.0-192.0) 0.481 
Overall general health (COOP-WONCA)‡;  
range 1-5 
3.0 (2.0-4.0) 2.0 (2.0-3.0) 3.0 (2.0-3.5) 3.0 (3.0-4.0) ≤0.001 
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  Risk subgroup†  
Variable Total cohort 
n=290† 
Low 
n=82 (28.3%) 
Medium 
n=116 (40.0%) 
High 
n=92 (31.7%) 
p-value  
Clinical measures      
Pain intensity (NRS), mean (SD);  
range 0-10 
5.8 (1.9) 4.7 (1.8) 6.0 (1.8) 6.5 (1.6) ≤0.001 
Disability (RMDQ);  
range 0-24 
9.0 (6.0-13.0) 6.0 (5.0-8.0) 9.0 (7.0-13.0) 12.0 (8.5-15.0) ≤0.001 
Percent LBP (vs. leg pain), n (%)     0.091 
     100% 145 (50.0) 51 (62.2) 49 (42.2) 45 (48.9)  
     80% 110 (38.0) 23 (28.1) 50 (43.1) 37 (40.2)  
     60% 35 (12.1) 8 (9.8) 17 (14.7) 10 (10.9)  
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  Risk subgroup†  
Variable Total cohort 
n=290† 
Low 
n=82 (28.3%) 
Medium 
n=116 (40.0%) 
High 
n=92 (31.7%) 
p-value  
Psychological measures      
Depression (DASS-21); range 0-42  6.0 (2.0-14.0) 4.0 (2.0-6.0) 6.0 (2.0-12.0) 14.0 (6.0-24.0) ≤0.001 
Anxiety (DASS-21); range 0-42 4.0 (2.0-8.0) 2.0 (0.0-6.0) 4.0 (2.0-8.0) 6.0 (2.0-11.0) ≤0.001b 
Stress (DASS-21); range 0-42 12.0 (6.0-20.0) 8.0 (4.0-14.0) 12.0 (6.0-18.0) 16.0 (10.0-24.0) ≤0.001 
Fear avoidance beliefs-PA (FABQ-PA); range 0-24  15.0 (11.0-19.0) 13.0 (7.0-17.0) 13.5 (10.0-17.0) 18.0 (14.0-21.0) ≤0.001c 
Fear avoidance beliefs-W5 (FABQ-W); range 0-42 16.0 (8.0-27.0) 13.0 (6.5-24.0) 15.0 (6.0-24.0) 20.0 (9.0-32.0) 0.010c 
Pain catastrophising6 (PCS total); range 0-52 17.0 (9.0-27.0) 9.0 (4.0-15.0) 16.0 (10.0-23.0) 28.0 (20.5-36.0) ≤0.001 
Rumination6 (PCS); range 0-16  6.0 (3.0-10.0) 3.0 (1.0-7.0) 6.0 (3.0-9.0) 10.0 (5.0-13.5) ≤0.001 
Magnification6 (PCS); range 0-12  3.0 (1.0-5.0) 2.0 (1.0-4.0) 3.0 (1.0-5.0) 5.0 (4.0-7.0) ≤0.001 
Helplessness6 (PCS); range 0-24 8.0 (4.0-13.0) 4.0 (2.0-6.0) 7.0 (4.0-11.0) 13.0 (9.0-16.5) ≤0.001 
Perceived risk of persistence (NRS 0-10) 9.0 (8.0-10.0) 8.0 (7.0-9.0) 9.0 (8.0-10.0) 9.0 (8.0-10.0) ≤0.001 
Self-efficacy (PSEQ)§; range 0-60 42.0 (32.0-50.0) 49.0 (44.0-53.0) 43.0 (32.0-49.0) 34.0 (24.5-41.0) ≤0.001 
Chronic pain acceptance (CPAQ-total)§;  
range 0-48 
26.0 (21.0-31.0) 30.0 (26.0-36.0) 27.0 (23.0-31.0) 21.0 (15.5-25.5) ≤0.001 
Chronic pain acceptance-pain willingness 
(CPAQ)§; range 0-24 
9.0 (6.0-12.0) 11.0 (8.0-15.0) 9.0 (7.0-12.5) 6.0 (3.0-9.0) ≤0.001 
Chronic pain acceptance-activity engagement 
(CPAQ)§; range 0-24 
18.0 (14.0-21.0) 20.0 (17.0-22.0) 18.0 (15.0-21.0) 15.0 (11.0-19.0) ≤0.001 
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SD = standard deviation; NRS = Numerical Rating Scale; RMDQ = Roland Morris Disability Questionnaire; LBP = low back pain; DASS-21 = Depression Anxiety 
Stress Scale; FABQ-PA = Fear Avoidance Beliefs Questionnaire – Physical Activity; FABQ-W = Fear Avoidance Beliefs Questionnaire – Work; PCS = Pain 
Catastrophising Scale; PSEQ = Pain Self-efficacy Questionnaire; CPAQ = Chronic Pain Acceptance Questionnaire. 
* Values represent median (interquartile range) unless otherwise indicated.  Evaluation of subgroup differences were performed using a one-way Analysis of 
Variance (ANOVA), Kruskal-Wallis test, or Chi Squared test depending on data type and distribution.  Where there are statistically significant differences 
between groups, group contrasts indicated a significant difference between all three subgroups unless otherwise indicated by a b c.  Boldface indicates 
statistical significance (p<0.05). 
† n=290 (total cohort), n=82 (low risk group), n=116 (medium risk group), and n=92 (high risk group) except where there are missing values. 
‡ COOP-WONCA charts lower scores indicate better health. 
§ PSEQ higher scores indicate greater confidence. 
§ CPAQ higher scores indicate greater acceptance. 
Group contrasts: 
Education levela = significant difference between the low and the high risk group only (no significant difference between the low and the medium risk group; 
no significant difference between the medium and the high risk group). 
DASS-21 anxiety scoreb = significant differences between the low and the medium risk group and the low and the high risk group (no significant difference 
between the medium and the high risk group). 
FABQ-PA/W scoresc = significant differences between the medium and the high risk group and the low and the high risk group (no significant difference 
between the low and the medium risk group). 
Missing values: 
Educational level1 = 14 missing (6, 1, and 7 missing respectively from the low, medium, and high risk group). 
Occupation2 = 15 missing (1, 8, and 6 missing respectively from the low, medium, and high risk group). 
Compensation status3 = 6 missing (1, 2, and 3 missing respectively from the low, medium, and high risk group). 
Pain duration4 = 4 missing (0, 2, and 2 missing respectively from the low, medium, and high risk group). 
Fear avoidance beliefs-work5 = 9 missing (2, 2, and 5 missing respectively from the low, medium, and high risk group). 
Pain catastrophising6 = 1 missing (1 missing from the medium risk group). 
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The characteristics of the participants included in the analysis with respect to the total 
cohort and each SBST risk subgroup can be seen in Table 2.3.  The SBST categorised 82 
participants (28.3%) as low risk, 116 (40.0%) as medium risk, and 92 (31.7%) as high risk.  
The SBST risk subgroups did not significantly differ for the majority of the demographic 
variables.  There was no significant difference (p≥0.05) in age, sex, employment status, 
compensation status, or pain duration between the three SBST risk subgroups.  However, 
there was a significant difference (p=0.012) in mean years of education.  Group contrasts 
indicated that the high risk group had significantly fewer years in education compared to 
the low risk group.  The SBST risk subgroups were significantly different (p≤0.001) with 
respect to occupation with a higher than expected proportion of participants with a manual 
occupation in the high risk group and a higher than expected proportion of participants 
with a sedentary occupation in the low risk group.  There was a significant difference 
(p≤0.001) between the three SBST risk subgroups in the median score on the overall 
general health scale of the COOP-WONCA charts.  There were increasingly higher scores 
(equating to poorer health) moving from the low to medium to high risk group. 
 
There was a significant difference in pain intensity (p≤0.001) and self-reported disability 
(p≤0.001) between all three SBST risk subgroups with increasing pain and increasing 
disability in the low to medium to high risk group (Table 2.3).  The SBST risk subgroups did 
not significantly differ (p=0.091) with respect to the percentage of LBP versus leg pain.    
 
With respect to the psychological measures, all three SBST risk subgroups were significantly 
different with greater negative psychological affect and cognitions, decreasing self-efficacy, 
and decreasing chronic pain acceptance in the low to medium to high risk group (Table 2.3).  
The exception to this was the DASS-21 anxiety score and the FABQ-PA/W scores where 
group contrasts indicated that only two of the three groups differed from one another.  
Group contrasts for the DASS-21 anxiety score indicated that the low risk group was 
significantly less anxious than the medium and the high risk group with no significant 
difference between the medium and the high risk group.  On both the physical activity and 
work subscales of the FABQ, the high risk group scored significantly higher than both the 
medium and the low risk group, while there was no significant difference between the low 
and the medium risk group.   
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2.5 Key findings 
The results of this study demonstrated that the risk profile of the SBST subgroups was 
related to clinical measures of pain and disability and to psychological factors.  The SBST 
risk subgroups demonstrated increasingly higher levels of pain, disability, and negative 
psychological affect and cognitions in the low to medium to high risk group.   
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Chapter 3:  Prospective Study 
3.0 Aim 
This study was a prospective design evaluating the predictive and discriminative ability of 
the STarT Back Screening Tool (SBST) for pain intensity, self-reported low back pain (LBP) 
related disability, and global self-perceived change at one year follow-up in an Australian 
population exclusively with chronic non-specific LBP. 
 
It was hypothesised that:  (i) the SBST risk subgroups would predict pain intensity, disability, 
and global perceived change at the one year follow-up with greater pain and disability and 
less self-perceived improvement as risk subgroup categorisation increased from low to 
medium to high; (ii) the SBST would discriminate between those participants who were and 
were not recovered with respect to pain, disability, and global perceived change; (iii) the 
SBST would have stronger predictive and discriminative ability for disability compared to 
pain and global perceived change; and (iv) the overall performance of the SBST would be 
attenuated in a population with chronic LBP in comparison to previous studies undertaken 
in populations with LBP of “mixed” or “variable” episode duration. 
 
3.1 Methods 
The baseline data collection procedures and variables were fully described in the Methods 
in Chapter 2 (section 2.2).  Follow-up data were collected one year after entry into the 
study. 
 
3.1.1 Participants 
The participants were fully described in Chapter 2, section 2.2.1. 
 
3.1.2 Procedures 
At the end of one year, each participant was contacted via mail or email and asked to 
complete a follow-up questionnaire containing the follow-up measures (described below).  
The participants contacted by mail completed a paper copy of the follow-up questionnaire 
which was then returned to Curtin University, Perth, Western Australia in a reply paid 
envelope.  The participants who did not respond to the first mailed follow-up questionnaire 
were sent a second questionnaire.  If the participant failed to respond to the second mailed 
questionnaire, they were then contacted by telephone.   
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The majority of the participants were contacted via email and were provided with a link to 
an online version of the follow-up questionnaire (Qualtrics Research Suite software 
https://curtin.asia.qualtrics.com/ControlPanel/).  Non-response to the first email resulted 
in a second email.  The participants who did not respond to the second email were sent a 
paper copy of the questionnaire.  Further non-response resulted in a second mailed paper 
copy of the follow-up questionnaire.  If there was still no response, the participant was then 
contacted by telephone.   
 
Data was exported from Qualtrics into an excel file and merged with the data recorded 
from the returned paper copies of the follow-up questionnaire.  Participants were matched 
to their baseline data by their initials, date of birth, and postal code.     
 
3.1.3 Follow-up measures 
In line with recommended measures for research involving participants with chronic pain 
(Dworkin et al., 2005), the follow-up questionnaire included the following measures:  (a) 
average pain intensity in the previous week measured on an 11-point Numerical Rating 
Scale (NRS) where zero indicates no pain and 10 the worst pain imaginable (Dworkin et al., 
2005, Manniche et al., 1994), (b) LBP related disability measured by the Roland Morris 
Disability Questionnaire (RMDQ) (Kuijer et al., 2005, Roland and Fairbank, 2000, Roland and 
Morris, 1983), and (c) global perceived change measured by a single self-report item on a 7-
point Global Rating of Change Scale (GRCS) (Dworkin et al., 2005).  Adapted from Kamper 
and colleagues (2009), participants were asked:  “With respect to your low back pain, how 
would you describe yourself now compared to one year ago when we examined you for the 
research project (laboratory session at Curtin University)?”  The responses on the GRCS 
range from negative three (very much worse) to positive three (very much improved) 
(Dworkin et al., 2008).  The SBST (http://www.keele.ac.uk/sbst/startbacktool/) (Keele 
University) was also readministered at the one year follow-up.  Participants were also given 
the opportunity to outline any treatment they had in the previous year. 
 
Each of the follow-up measures described above were dichotomised into “recovered” and 
“not recovered”.  Not recovered with respect to pain was defined as a score of greater than 
or equal to three on the NRS (Mehling et al., 2015, Mehling et al., 2011).  Not recovered 
with respect to disability was defined as a score of greater than or equal to seven on the 
RMDQ.  This disability cut-off score was also used in the SBST’s original developmental and 
validation study (Hill et al., 2008) and in more recent studies that have investigated the 
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SBST (Hill et al., 2010b, Morsø et al., 2013b, Morsø et al., 2014, Mehling et al., 2015, 
Wideman et al., 2012).  The use of the same threshold for disability as previous studies 
facilitated comparison with existing literature.  Not recovered/not improved with respect to 
global perceived change was defined as a score of less than or equal to zero on the GRCS 
(i.e. no change, minimally worse, much worse, and very much worse).  This cut-off score on 
the GRCS was selected to ensure participants who had not recovered were accurately 
captured.  This threshold was thought to be appropriate for a sample with chronic LBP 
where any improvement, even if minimally improved, would be considered positive rather 
than negative.    
 
3.1.4 Data analysis 
The online survey software did not allow for missing values, prompting completion of all 
fields prior to allowing submission.  If on the paper copy of the follow-up questionnaire the 
NRS for pain or the GRCS were incomplete, these measures were coded as missing.  For 
paper copies of the SBST, if one item was missing the most common score (i.e. positive or 
negative) for the other items was used and if two or more items were missing, the SBST was 
coded as missing.   
 
Comparisons between the participants who completed follow-up data collection with those 
who did not were made for demographic variables, baseline clinical measures (pain and 
disability), and baseline SBST risk subgroup stratification.  Depending on data type and 
distribution, an independent sample t-test, Mann-Whitney U, or Chi Squared test was used 
to evaluate for differences between “non-completers” and “completers” for the 
aforementioned variables. 
 
Descriptive statistics for the one year follow-up data were calculated for pain, disability, 
and global perceived change with respect to the total cohort and with respect to each 
baseline SBST risk subgroup.  The SBST risk subgroup stratification at follow-up was also 
described and compared to the baseline stratification.  The proportion of participants who 
were not recovered (as defined above) at the one year follow-up with respect to pain, 
disability, and global perceived change was calculated at a cohort level and by baseline 
SBST risk subgroup.  Histograms and box plots were inspected for all continuous variables 
with normally distributed data expressed as means and standard deviations (SD).  Skewed 
and nominal variables were expressed as medians and interquartile ranges (IQR).   
Frequency counts and percentages were used to express categorical variables.     
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In order to evaluate the predictive and discriminative ability of the SBST, a number of 
statistical methods were used.  The predictive ability of the SBST was evaluated by 
calculating the additional risk (i.e. risk ratio [RR]) of non-recovery (as defined above) for 
participants classified by the SBST as medium risk or high risk at baseline.  The low risk 
subgroup was used as the reference category.  Comparisons between the medium and the 
high risk group were also made.  A RR of less than 2.0 is unlikely to have much practical 
value, a RR of 3.0 can be considered a moderate effect, and a RR of 4.0 can be considered a 
strong effect (Ferguson, 2009). 
 
In order to evaluate the accuracy of the SBST total score and the psychological subscale 
score to discriminate between participants who were recovered and not recovered at the 
one year follow-up with respect to pain, disability, and global perceived change, receiver 
operating characteristic (ROC) curves were constructed and the area under the curve (AUC) 
was calculated.  The positive likelihood ratio (LR+), negative likelihood ratio (LR-), 
sensitivity, specificity, and the diagnostics odds ratio (DOR) for:  (a) the low risk group 
versus the medium/high risk group and (b) the low/medium risk group versus the high risk 
group was calculated for the follow-up measures with significant AUC values.  The SBST risk 
subgroups were collapsed into low/medium and medium/high as this reflects the risk 
subgroup cut-offs and facilitated comparison with previous studies (Hill et al., 2008, 
Mehling et al., 2015, Page et al., 2015).  The DOR is a combined measure of discrimination 
and is calculated by dividing the LR+ by the LR- (Glas et al., 2003).  As a single measure of 
test performance, the DOR was included to facilitate comparison of the results of this study 
with the results of previously published studies.  The DOR ranges from zero to infinity (Glas 
et al., 2003).  A higher DOR indicates better test discrimination, a value of one indicates 
that the test has no ability to discriminate, and a value lower than one indicates that the 
test incorrectly classifies (more negative test results amongst those with the condition or 
outcome of interest) (Glas et al., 2003).  With respect to the AUC, an AUC of 0.50 suggests 
no discrimination, > 0.50 but < 0.70 poor discrimination, ≥ 0.70 but < 0.80 acceptable 
discrimination, ≥ 0.80 but < 0.90 excellent discrimination, and ≥ 0.90 outstanding 
discrimination (Hosmer et al., 2013).  Based on the recommendations by Hosmer and 
colleagues (2013) and previously reported AUC values for disability and pain outcomes for 
other screening tools evaluated in populations with LBP, an AUC of less than 0.60 is 
considered non-informative (Traeger et al., 2015).  Higher LR+ and lower LR- indicate better 
discrimination (Hill et al., 2008).  Likelihood ratios above five or below 0.2 are generally 
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seen as supporting a strong test, whereas values close to one indicate poor test 
performance (Mehling et al., 2015).   
 
All data analyses were performed using Stata 13.1 (Statacorp, Texas, USA) for Windows.  
Statistical significance was considered to be p<0.05 for all analyses.   
 
3.2 Ethics 
This study was approved by the Curtin University Human Research Ethics Committee 
(Approval Number PT262/2013) (Appendix A).  The longitudinal study from which this study 
obtained baseline data (Rabey et al., 2015) was also approved by the Curtin University 
Human Research Ethics Committee (Approval Number HR112/2012).  All participants 
received a Participant Information Sheet in plain language outlining the purpose of the 
study, methods, risks and discomforts, and the benefits of the research (Appendix B).  
Confidentiality was guaranteed and participants were made aware that they were able to 
withdraw at any time without prejudice.  Written informed consent was obtained from 
each participant (Appendix C).  
 
3.3 Results 
The flow of participants through the study is shown in Figure 3.1.  One year follow-up data 
were available for 264 of the 290 (91.0%) participants enrolled in the study.  Of the 26 
(9.0%) participants lost to follow-up, three (11.5%) were from the low risk group, seven 
(26.9%) from the medium risk group, and 16 (61.5%) from the high risk group.  There was 
no significant difference (p>0.05) in age, sex, or baseline pain intensity between the 
participants who were lost to follow-up and the participants who completed the study 
(Table 3.1).  However, the participants lost to follow-up had significantly higher baseline 
disability then the participants who completed the study (RMDQ median score of 10.5 
versus 8.0, p=0.034) (Table 3.1).  The SBST subgroup proportions also differed significantly 
(p=0.002) between the participants who did and did not complete the study with a higher 
proportion of non-completers (61.5%) than completers (28.8%) allocated to the high risk 
group (Table 3.1).    
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Figure 3.1.  Flow of participants through the prospective study. 
  
Screened for eligibility 
during the recruitment 
period (n=586) 
 
 
Enrolled in study (n=349) 
 
 
Included in baseline 
analysis (n=290) 
 
 
Did not complete baseline data collection 
(n=55) with stage completed, n (%): 
 Inclusion criteria screening checklist, 
50 (90.9) 
 Self-report questionnaire pack, 5 
(9.1) 
 
 
Included in the one year follow-up 
analysis, n (%):  264 (91.0) 
 
 
Lost to follow-up at one year, n (%):  26 (9.0) 
 
 
Screened and not eligible (n=237), n (%): 
 Age >70 years, 42 (17.7) 
 Low pain intensity score, 6 (2.5) 
 Low disability score, 130 (54.9) 
 Leg pain > back pain, 28 (11.8) 
 Serious spinal pathology, 8 (3.4) 
 Bilateral dorsal wrist or hand pain, 
23 (9.7) 
Participants from public hospitals without 
ethics approval to participate in this study 
(n=4) 
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Table 3.1.  Baseline Descriptive Characteristics of Participants who did and did not 
Complete Follow-up 
 Summary statistic  
Demographic variable Non-completers 
n=26 (9.0%) 
Completers 
n=264 (91.0%) 
p-value* 
Age (years), median (IQR) 49.0 (33.0-59.0) 51.0 (39.0-60.0) 0.416 
Sex, n (%) female 11 (42.3) 155 (58.7) 0.107 
Pain intensity (NRS), median (SD); 
range 0-10 
5.8 (1.7) 5.8 (1.9) 0.938 
Disability (RMDQ), median (IQR); 
range 0-24 
10.5 (7.0-15.0) 8.0 (6.0-12.5) 0.034 
Baseline SBST risk subgroup, n (%)   0.002 
     Low  3 (11.5) 79 (29.9)  
     Medium 7 (26.9) 109 (41.3)  
     High 16 (61.5) 76 (28.8)  
IQR = interquartile range; NRS = Numerical Rating Scale; SD = standard deviation; RMDQ = 
Roland Morris Disability Questionnaire; SBST = STarT Back Screening Tool.  Boldface 
indicates statistical significance (p<0.05). 
* Independent t-test, Mann-Whitney U, or Chi Squared test depending on data type and 
distribution. 
 
Table 3.2.  Baseline vs. Follow-up STarT Back Screening Tool Risk Subgroup Stratification, n 
(row %) 
 Follow-up risk subgroup  
Baseline risk subgroup Low Medium High Total 
Low  65 (82.3) 7 (8.9) 7 (8.9) 79 (100.0) 
Medium  72 (66.1) 23 (21.1) 14 (12.8) 109 (100.0) 
High 31 (40.8) 29 (38.2) 16 (21.1) 76 (100.0) 
Total 168 (63.6) 59 (22.4) 37 (14.0) 264 (100.0) 
 
When comparing SBST stratification at baseline to that at the one year follow-up, there 
were more participants in the low risk group and less in the medium risk and the high risk 
group at follow-up.  Specifically, at follow-up there were 168 (63.6%) participants in the low 
risk group, 59 (22.4%) in the medium risk group, and 37 (14.0%) in the high risk group 
(Table 3.2).  Comparatively, at baseline there were 82 (28.3%), 116 (40.0%), and 92 (31.7%) 
participants respectively in the low, medium, and high risk group (Table 2.3).  Looking closer 
at the stability of the SBST risk subgroups over one year, 82.3% (n=65) of the low risk group 
at baseline remained in the low risk group at the one year follow-up with 8.9% (n=7) 
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moving into the medium risk group and 8.9% (n=7) moving into the high risk group.  In the 
medium risk group, 78.9% (n=86) changed risk category at follow-up with 66.1% (n=72) 
moving into the low risk group and 12.8% (n=14) moving into the high risk group.  In the 
high risk group, 78.9% (n=60) changed risk category at follow-up with 38.2% (n=29) moving 
into the medium risk group and 40.8% (n=31) moving into the low risk group (Table 3.2). 
 
Table 3.3.  Descriptive Characteristics at One Year Follow-up – Total Cohort and Stratified 
by Baseline STarT Back Screening Tool Risk Subgroup 
  Risk subgroup* 
Follow-up measure Total cohort 
n=264 
Low 
n=79 
Medium 
n=109 
High 
n=76 
Pain (NRS), mean (SD); 
range 0-10 
4.2 (2.1) 3.5 (2.0) 4.4 (2.1) 4.5 (2.2) 
   n (%) not recovered (≥3) 201 (76.1) 51 (64.6) 88 (80.7) 62 (81.6) 
     
Disability (RMDQ), 
median (IQR); 
range 0-24 
4.0 (2.0-8.0) 3.0 (1.0-5.0) 5.0 (2.0-8.0) 6.0 (3.0-10.5) 
   n (%) not recovered (≥7) 83 (31.4) 12 (15.2) 38 (34.9) 33 (43.4) 
     
Global perceived 
change† (GRCS), median 
(IQR); 
range -3 to 3‡ 
1.0 (0.0-2.0) 1.0 (0.0-2.0) 1.0 (0.0-2.0) 0.5 (-1.0-2.0) 
   n (%) not improved (≤0) 117 (44.5) 31 (39.7) 48 (44.0) 38 (50.0) 
NRS = Numerical Rating Scale; SD = standard deviation; RMDQ = Roland Morris Disability 
Questionnaire; IQR = interquartile range; GRCS = Global Rating of Change Scale. 
* Lost to follow-up by risk subgroup = 3 from the low risk group, 7 from the medium risk 
group, and 16 from the high risk group. 
† 1 missing from the low risk group (n=263 and n=78 for the low risk group). 
‡ Where -3 equates to very much worse and 3 equates to very much improved. 
 
At a total cohort level, 76.1% (n=201) of the participants were not recovered with respect 
to pain (NRS greater than or equal to three), 31.4% (n=83) were not recovered with respect 
to disability (RMDQ greater than or equal to seven), and 44.5% (n=117) were not improved 
as measured by the GRCS (less than or equal to zero) at the one year follow-up (Table 3.3).  
When stratified by baseline SBST subgroup, 64.6% (n=51) of the low risk group, 80.7% 
(n=88) of the medium risk group, and 81.6% (n=62) of the high risk group were not 
recovered with respect to pain.  With respect to disability, 15.2% (n=12) of the low risk 
group, 34.9% (n=38) of the medium risk group, and 43.4% (n=33) of the high risk group 
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were considered disabled at follow-up.  With respect to global perceived change, 39.7% 
(n=31) of the low risk group, 44.0% (n=48) of the medium risk group, and 50.0% (n=38) of 
the high risk group rated themselves as unchanged or worse (Table 3.3).  A total of 215 
(81.4%) participants reported receiving some form of intervention or treatment during the 
study period.     
 
The RRs for pain, disability, and global perceived change at the one year follow-up for the 
medium and the high risk SBST subgroup, using the low risk group as the reference 
category, are shown in Figure 3.2.  With respect to pain, the RR [95% confidence interval 
(CI)] was 1.25 [1.04, 1.51], p=0.013 for the medium risk group and 1.26 [1.03, 1.52], 
p=0.020 for the high risk group.  The participants in both the medium and the high risk 
group had a 25% increased risk of being not recovered with respect to pain compared to 
the low risk group.  When using the medium risk group as the reference category, the 
proportion of participants in the medium and the high risk group not recovered with 
respect to pain at the one year follow-up was similar with a RR of 1.01 [0.88, 1.16], p=0.885 
(not shown in Figure 3.2).     
 
 
Figure 3.2.  Relative risk of non-recovery at the one year follow-up by SBST risk subgroup.  
Risk ratios [95% confidence interval].  The low risk subgroup is the reference category.  
SBST = STarT Back Screening Tool; RR = risk ratio; NRS = Numerical Rating Scale; RMDQ = 
Roland Morris Disability Questionnaire; GRCS = Global Rating of Change Scale.  *p<0.05. 
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Participants in the medium risk group (RR 2.30 [1.28, 4.10], p=0.003) and the high risk 
group (RR 2.86 [1.60, 5.11], p≤0.001) at baseline had a significantly increased risk of being 
considered disabled at the one year follow-up compared to the low risk group.  The 
participants in the medium risk group had a 130% increased risk and the participants in the 
high risk group had a 190% increased risk of being considered disabled compared to the low 
risk group.  The high risk group did not have a significantly higher risk of being considered 
disabled compared to the medium risk group with a RR of 1.25 [0.87, 1.79], p=0.239 (not 
shown in Figure 3.2).     
 
Although a higher proportion of both the medium and the high risk group perceived 
themselves as not improved at the one year follow-up compared to the low risk group, the 
difference in risk was not significant with a RR for the medium risk group of 1.12 [0.78, 
1.57], p=0.558 and a RR for the high risk group of 1.26 [0.88, 1.79], p=0.201.  The high risk 
group was also not at an increased risk of not having improved at the one year follow-up 
compared to the medium risk group with a RR of 1.14 [0.83, 1.55], p=0.424 (not shown in 
Figure 3.2).     
 
The ability of the SBST’s total score and psychological subscale score at baseline to 
discriminate between participants who had and had not recovered at the one year follow-
up with respect to each of the follow-up measures is shown in Table 3.4.  The respective 
ROC curves are shown in Figure 3.3.  The SBST’s discriminative ability was the highest for 
disability with an AUC [95% CI] of 0.71 [0.64, 0.77] for the total score and 0.67 [0.60, 0.73] 
for the psychological subscale score.  The AUC for pain was lower at 0.63 [0.55, 0.71] for 
both the total and the psychological subscale score.  The ability of the SBST to discriminate 
global perceived change was the lowest with an AUC of 0.56 [0.49, 0.63] for the total score 
and 0.55 [0.48, 0.62] for the psychological subscale score.   
 
  
78 
 
Table 3.4.  Discriminative Ability of the STarT Back Screening Tool Baseline Total Score and 
Psychological Subscale Score using the AUC 
   STarT Back Screening Tool AUC 
[95% CI] 
Follow-up measure Case 
definition 
n (%) Total score Psychological 
subscale score 
Pain NRS ≥ 3 201 (76.1) 0.63 
[0.55, 0.71] 
0.63 
[0.55, 0.71] 
Disability RMDQ ≥ 7 83 (31.4) 0.71 
[0.64, 0.77] 
0.67 
[0.60, 0.73] 
Global perceived 
change*† 
GRCS ≤ 0 117 (44.5) 0.56 
[0.49, 0.63] 
0.55 
[0.48, 0.62] 
AUC = area under the curve; 95% CI = 95% confidence interval; NRS = Numerical Rating 
Scale; RMDQ = Roland Morris Disability Questionnaire; GRCS = Global Rating of Change 
Scale. 
* 1 missing from the low risk group (n=117/263). 
† Where -3 equates to very much worse and 3 equates to very much improved. 
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Figure 3.3.  ROC curves for the SBST baseline total score and psychological subscale score 
for pain (NRS ≥ 3), disability (RMDQ ≥ 7), and global perceived change (GRCS ≤ 0) at the one 
year follow-up.  ROC = receiver operating characteristic; SBST = STarT Back Screening Tool; 
NRS = Numerical Rating Scale; RMDQ = Roland Morris Disability Questionnaire; GRCS = 
Global Rating of Change Scale. 
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A score of less than or equal to one on the GRCS (i.e. minimally improved, no change, 
minimally worse, much worse, and very much worse) has been recommended to indicate a 
not recovered/not improved status (Dworkin et al., 2005, Dworkin et al., 2008).  However, 
this study selected a cut-off score of less than or equal to zero on the GRCS to indicate non-
recovery.  This choice of cut-off score was rationalised in section 3.1.3.  If this study had 
selected a cut-off score of less than or equal to one on the GRCS, the proportion of 
participants not recovered/not improved at the one year follow-up would have been higher 
with 66.2% (n=174) of the total cohort and 61.5% (n=48), 65.1% (n=71), and 72.4% (n=55) of 
the low, medium, and high risk group respectively not recovered/not improved.  The RRs if 
selecting a cut-off score of less than or equal to one on the GRCS and using the low risk 
group as the reference category would have been:  RR medium risk group 1.06 [0.85, 1.32], 
p=0.614 and RR high risk group 1.18 [0.94, 1.47], p=0.153.  Using the medium risk group as 
the reference category:  RR high risk group 1.11 [0.91, 1.35], p=0.299.  The discriminative 
ability (AUC) of the SBST for global perceived change using less than or equal to one on the 
GRCS:  0.45 [0.38, 0.52] for the SBST total score and 0.43 [0.36, 0.51] for the psychological 
subscale score.  Hence, the results of this study would be similar regardless of which cut-off 
score on the GRCS was selected. 
 
The likelihood ratios, sensitivity, specificity, and DORs for the SBST risk subgroups for pain 
and disability at the one year follow-up are shown in Table 3.5.  With respect to pain, the 
LR+ [95% CI] was 1.34 [1.06, 1.70] and the LR- [95% CI] was 0.57 [0.40, 0.82] for the low risk 
group versus the medium/high risk group with a sensitivity of 74.6%, specificity of 44.4%, 
and DOR of 2.35.  The LR+ was 1.39 [0.84, 2.30] and the LR- was 0.89 [0.76, 1.05] for the 
low/medium risk group versus the high risk group with a sensitivity of 30.9%, specificity of 
77.8%, and DOR of 1.56.  With respect to disability, the LR+ was 1.36 [1.18, 1.57] and the 
LR- was 0.39 [0.22, 0.68] for the low risk group versus the medium/high risk group with a 
sensitivity of 85.5%, specificity of 37.0%, and DOR of 3.48.  The LR+ was 1.67 [1.15, 2.43] 
and the LR- was 0.79 [0.65, 0.96] for the low/medium risk group versus the high risk group 
with a sensitivity of 39.8%, specificity of 76.2%, and DOR of 2.12.   
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Table 3.5.  Discriminative Ability of the STarT Back Screening Tool Risk Subgroups - 
Likelihood Ratios, Sensitivity, Specificity, and the Diagnostic Odds Ratio 
Subgroups LR+ [95% CI] LR- [95% CI] Sensitivity 
(%) 
Specificity 
(%) 
DOR 
Pain  
(NRS ≥ 3) 
     
L vs. M/H 1.34 [1.06, 1.70] 0.57 [0.40, 0.82] 74.6 44.4 2.35 
L/M vs. H 1.39 [0.84, 2.30] 0.89 [0.76, 1.05] 30.9 77.8 1.56 
Disability 
(RMDQ ≥ 7) 
     
L vs. M/H 1.36 [1.18, 1.57] 0.39 [0.22, 0.68] 85.5 37.0 3.48 
L/M vs. H 1.67 [1.15, 2.43] 0.79 [0.65, 0.96] 39.8 76.2 2.12 
LR+ = positive likelihood ratio; 95% CI = 95% confidence interval; LR- = negative likelihood 
ratio; DOR = diagnostic odds ratio; NRS = Numerical Rating Scale; L = low risk group; M = 
medium risk group; H = high risk group; RMDQ = Roland Morris Disability Questionnaire. 
 
3.4 Key findings 
The results of this study demonstrated that the SBST had moderate predictive and 
acceptable discriminative ability for disability at the one year follow-up.  The SBST’s 
predictive and discriminative ability was relatively weak for future pain and the tool was 
unable to identify those participants who perceived themselves as improved versus not 
improved at the one year follow-up.   
 
  
82 
 
3.5 References 
DWORKIN, R., TURK, D., FARRAR, J., HAYTHORNTHWAITE, J., JENSEN, M., KATZ, N., KERNS, 
R., STUCKI, G., ALLEN, R., BELLAMY, N., CARR, D., CHANDLER, J., COWAN, P., 
DIONNE, R., GALER, B., HERTZ, S., JADAD, A., KRAMER, L., MANNING, D., MARTIN, 
S., MCCORMICK, C., MCDERMOTT, M., MCGRATH, P., QUESSY, S., RAPPAPORT, B., 
ROBBINS, W., ROBINSON, J., ROTHMAN, M., ROYAL, M., SIMON, L., STAUFFER, J., 
STEIN, W., TOLLETT, J., WERNICKE, J. & WITTER, J. 2005. Core outcome measures 
for chronic pain clinical trials: IMMPACT recommendations. Pain, 113, 9-19. 
DWORKIN, R., TURK, D., WYRWICH, K., BEATON, D., CLEELAND, C., FARRAR, J., 
HAYTHORNTHWAITE, J., JENSEN, M., KERNS, R., ADER, D., BRANDENBURG, N., 
BURKE, L., CELLA, D., CHANDLER, J., COWAN, P., DIMITROVA, R., DIONNE, R., 
HERTZ, S., JADAD, A., KATZ, N., KEHLET, H., KRAMER, L., MANNING, D., 
MCCORMICK, C., MCDERMOTT, M., MCQUAY, H., PATEL, S., PORTER, L., QUESSY, S., 
RAPPAPORT, B., RAUSCHKOLB, C., REVICKI, D., ROTHMAN, M., SCHMADER, K., 
STACEY, B., STAUFFER, J., VON STEIN, T., WHITE, R., WITTER, J. & ZAVISIC, S. 2008. 
Interpreting the clinical importance of treatment outcomes in chronic pain clinical 
trials: IMMPACT recommendations. The Journal of Pain, 9, 105-121. 
FERGUSON, C. 2009. An effect size primer: a guide for clinicians and researchers. 
Professional Psychology - Research and Practice, 40, 532-538. 
GLAS, A., LIJMER, J., PRINS, M., BONSEL, G. & BOSSUYT, P. 2003. The diagnostic odds ratio: a 
single indicator of test performance. Journal of Clinical Epidemiology, 56, 1129-
1135. 
HILL, J., DUNN, K., LEWIS, M., MULLIS, R., MAIN, C., FOSTER, N. & HAY, E. 2008. A primary 
care back pain screening tool: identifying patient subgroups for initial treatment. 
Arthritis and Rheumatism, 59, 632-641. 
HILL, J., DUNN, K., MAIN, C. & HAY, E. 2010b. Subgrouping low back pain: a comparison of 
the STarT Back Tool with the Örebro Musculoskeletal Pain Screening Questionnaire. 
European Journal of Pain, 14, 83-89. 
HOSMER, D., LEMESHOW, S. & STURDIVANT, R. 2013. Wiley series in probability and 
statistics: applied logistic regression (3rd edition), New York, NY, USA, John Wiley & 
Sons. 
KAMPER, S., MAHER, C. & MACKAY, G. 2009. Global Rating of Change Scales: a review of 
strengths and weaknesses and considerations for design. Journal of Manual and 
Manipulative Therapy, 17, 163-170. 
KEELE UNIVERSITY. STarT Back [Online]. Available: 
http://www.keele.ac.uk/sbst/startbacktool/ [Accessed 21 October 2015]. 
KUIJER, W., BROUWER, S., DIJKSTRA, P., JORRITSMA, W., GROOTHOFF, J. & GEERTZEN, J. 
2005. Responsiveness of the Roland-Morris Disability Questionnaire: consequences 
of using different external criteria. Clinical Rehabilitation, 19, 488-495. 
MANNICHE, C., ASMUSSEN, K., LAURITSEN, B., VINTERBERG, H., KREINER, S. & JORDAN, A. 
1994. Low Back Pain Rating Scale: validation of a tool for assessment of low back 
pain. Pain, 57, 317-326. 
83 
 
MEHLING, W., AVINS, A., ACREE, M., CAREY, T. & HECHT, F. 2015. Can a back pain screening 
tool help classify patients with acute pain into risk levels for chronic pain? European 
Journal of Pain, 19, 439-446. 
MEHLING, W., GOPISETTY, V., ACREE, M., PRESSMAN, A., CAREY, T., GOLDBERG, H., HECHT, 
F. & AVINS, A. 2011. Acute low back pain and primary care: how to define recovery 
and chronification? Spine, 36, 2316-2323. 
MORSØ, L., KENT, P., ALBERT, H., HILL, J., KONGSTED, A. & MANNICHE, C. 2013b. The 
predictive and external validity of the STarT Back Tool in Danish primary care. 
European Spine Journal, 22, 1859-1867. 
MORSØ, L., KENT, P., MANNICHE, C. & ALBERT, H. 2014. The predictive ability of the STarT 
Back Screening Tool in a Danish secondary care setting. European Spine Journal, 23, 
120-128. 
RABEY, M., SLATER, H., O'SULLIVAN, P., BEALES, D. & SMITH, A. 2015. Somatosensory 
nociceptive characteristics differentiate subgroups in people with chronic low back 
pain: a cluster analysis. Pain, 156, 1874-1884. 
ROLAND, M. & FAIRBANK, J. 2000. The Roland-Morris Disability Questionnaire and the 
Oswestry Disability Questionnaire. Spine, 25, 3115-3124. 
ROLAND, R. & MORRIS, R. 1983. A study of the natural history of back pain. Part I: 
development of a reliable and sensitive measure of disabiliy in low back pain. Spine, 
8, 141-144. 
TRAEGER, A., HENSCHKE, N., HUBSCHER, M., WILLIAMS, C., KAMPER, S., MAHER, C., 
MOSELEY, G. & MCAULEY, J. 2015. Development and validation of a screening tool 
to predict the risk of chronic low back pain in patients presenting with acute low 
back pain: a study protocol. BMJ Open, 5, e007916. 
WIDEMAN, T., HILL, J., MAIN, C., LEWIS, M., SULLIVAN, M. & HAY, E. 2012. Comparing the 
responsiveness of a brief, multidimensional risk screening tool for back pain to its 
unidimensional reference standards: the whole is greater than the sum of its parts. 
Pain, 153, 2182-2191. 
 
Every reasonable effort has been made to acknowledge the owners of copyright material.  I 
would be pleased to hear from any copyright owner who has been omitted or incorrectly 
acknowledged. 
  
84 
 
Chapter 4:  Discussion 
4.1 Summary of key findings 
This was the first large study to investigate the utility of the STarT Back Screening Tool 
(SBST) in a population exclusively with chronic non-specific low back pain (LBP) and the first 
to evaluate the tool in an Australian context.  This study aimed to:  (i) profile the SBST risk 
subgroups with respect to demographic variables, pain intensity, disability, and 
psychological measures and (ii) evaluate the SBST’s predictive and discriminative ability for 
pain intensity, self-reported LBP related disability, and global self-perceived change at one 
year follow-up.   
 
The results of the cross sectional study demonstrated that the risk profile of the SBST 
subgroups was related to clinical measures of pain and disability and to psychological 
factors.  As hypothesised, the SBST risk subgroups demonstrated increasingly higher levels 
of pain, disability, and negative psychological affect and cognitions in the low to medium to 
high risk group.  
 
The results of the prospective study demonstrated that the SBST had moderate predictive 
and acceptable discriminative ability for disability at the one year follow-up.  As 
hypothesised, the SBST’s predictive and discriminative ability was weaker for future pain.  
The tool was unable to identify those participants who perceived themselves as improved 
versus not improved at the one year follow-up.   
 
This study adds to the body of research around the utility of the SBST.  The results provide 
valuable information to clinicians on the usefulness and limitations of using the SBST in 
patients with chronic LBP in an Australian setting.  The SBST has value as a substitute for 
the administration of multiple full-length, unidimensional questionnaires for first-line 
screening to help identify patients presenting with higher levels of pain, disability, and 
negative psychological affect and cognitions.  The SBST provides an acceptable indication of 
future disability. 
 
The results of this study (i.e. the “current study”) in comparison to previously published 
studies will be discussed with comparisons focused on, but not limited to, the SBST’s 
original developmental and validation study in a UK primary care setting (Hill et al., 2008) 
and the two studies undertaken in populations with predominantly (Morsø et al., 2014) or 
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exclusively (Page et al., 2015) chronic LBP.  The strengths, limitations, and clinical 
implications of the current study along with recommendations for future research will also 
be discussed. 
 
4.2 Baseline sample characteristics 
In order to interpret and compare the results of the current study with previously published 
studies, it is necessary to examine more closely the recruitment method and the baseline 
characteristics of the sample including the SBST risk subgroup proportions and the 
demographic and clinical profile of the risk subgroups.   
 
4.2.1 Recruitment considerations and baseline risk subgroup proportions 
Participants in the current study were self-selecting volunteers primarily from the general 
community (n=228 [78.6%]) with 59 of the remaining 62 (20.3%) participants recruited from 
private physiotherapy clinics.  Other studies that have evaluated the SBST have recruited 
care seeking patients with LBP from specific clinical settings.  These clinical settings have 
included General Practice (GP) (Hill et al., 2008, Mehling et al., 2015, Morsø et al., 2013b, 
Morsø et al., 2013a, Morsø et al., 2016, Von Korff et al., 2014, Wideman et al., 2012), 
physiotherapy (Beneciuck et al., 2014, Beneciuk et al., 2013, Beneciuk et al., 2015, Fritz et 
al., 2011, George and Beneciuk, 2015, Morsø et al., 2013b, Morsø et al., 2016), chiropractic 
(Field and Newell, 2012, Kongsted et al., 2015, Kongsted et al., 2011, Morsø et al., 2016, 
Newell et al., 2015), or secondary care (Morsø et al., 2013a, Morsø et al., 2014, Morsø et 
al., 2016).  Only one of the studies reviewed recruited more generally from the community 
through newspaper advertisements (Page et al., 2015).  In the current study, 81.4% (n=215) 
of the participants reported having received some form of intervention or treatment during 
the study period.  This indicates that the majority of the participants in the current study 
were care seekers however, they were not recruited from one specific care setting.   
 
To be included in the current study, participants were required to have dominant axial LBP 
and were only included if they had 60% or more LBP versus leg pain.  This criterion was 
used to reduce the likelihood of including participants with radiculopathy or radicular leg 
pain and therefore increase the likelihood of recruiting a sample with non-specific LBP.  The 
original development and validation of the SBST was in a group who had non-specific LBP 
(Hill et al., 2008).  The majority of studies that have evaluated the SBST have included 
participants with leg pain but did not appear to have used specific criteria related to the 
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relative proportion of LBP versus leg pain (Beneciuck et al., 2014, Beneciuk et al., 2013, 
Beneciuk et al., 2015, Field and Newell, 2012, Fritz et al., 2011, George and Beneciuk, 2015, 
Hill et al., 2008, Kongsted et al., 2015, Kongsted et al., 2011, Morsø et al., 2013b, Morsø et 
al., 2014, Newell et al., 2015).  Hence, this sample may differ from other studies with 
respect to the nature of any referred leg pain. 
 
A large number of the volunteers screened for inclusion were not eligible to participate, 
predominantly due to a low disability score (less than or equal to five) on the Roland Morris 
Disability Questionnaire (RMDQ), n=130 (54.9%) (Table 2.1).  In the literature reviewed, 
only Wideman and colleagues (2012) limited inclusion to participants with clinically 
meaningful levels of pain (Numerical Rating Scale [NRS] score greater than three) and 
disability (RMDQ score greater than or equal to seven) making the current study somewhat 
unique in its inclusion criteria.  In the current study, a large number of “low risk” 
participants may have been excluded relative to other studies due to the inclusion criteria 
used.  A comparison of the baseline SBST risk subgroup proportions in the current study 
and in previously published studies follows and is supplemented by a summary of this data 
which can be found in Appendix D.   
 
In studies that have investigated the SBST in a population with LBP of a “mixed” or 
“variable” episode duration (i.e. participants reported acute, subacute, or chronic LBP), the 
baseline subgroup proportions have ranged from 26%-59% for the low risk group, 29%-48% 
for the medium risk group, and 11%-28% for the high risk group (Beneciuk et al., 2015, 
Beneciuk et al., 2013, Field and Newell, 2012, Fritz et al., 2011, George and Beneciuk, 2015, 
Hill et al., 2008, Hill et al., 2011, Kongsted et al., 2011, Morsø et al., 2011, Morsø et al., 
2013b, Newell et al., 2015).  In studies that have investigated the SBST in a population with 
predominantly or exclusively chronic LBP, the baseline subgroup proportions have ranged 
from 28%-66% for the low risk group, 21%-33% for the medium risk group, and 13%-40% 
for the high risk group (Morsø et al., 2014, Page et al., 2015).  In a study that investigated 
an item set analogous to the SBST in a population exclusively with acute LBP, the subgroup 
proportions were 32%, 46%, and 22% respectively for the low, medium, and high risk group 
(Mehling et al., 2015).   
 
The current study had a relatively lower proportion of participants in the low risk group 
(28%) and a relatively higher proportion in the medium risk group (40%) and the high risk 
group (32%) at baseline compared to Hill and colleagues (2008) (developmental and 
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external sample:  40% and 47% respectively in the low risk group; 34% and 37% respectively 
in the medium risk group; 25% and 15% respectively in the high risk group).  However, the 
SBST risk subgroup proportions in the current study were comparable to the subgroup 
proportions reported in the randomised controlled trial (RCT) (26%, 46%, and 28% 
respectively in the low, medium, and high risk group) undertaken in a UK primary care 
setting which evaluated stratified care using the SBST (Hill et al., 2011).  This RCT recruited 
participants in the same manner and from the same population as Hill and colleagues 
(2008), yet the SBST risk subgroup proportions were different in these two studies.  The 
SBST risk subgroup proportions in the current study were also comparable to Morsø and 
colleagues (2014) (28%, 33%, and 40% respectively in the low, medium, and high risk 
group), a study performed in Denmark in a secondary care setting where approximately 
80% of the participants reported chronic LBP.  Page and colleagues (2015) recruited 
participants exclusively with chronic LBP in a similar manner to the current study (i.e. 
community newspaper advertisements) but reported a larger proportion in the low risk 
group (66%) and a smaller proportion in the medium risk group (21%) and the high risk 
group (13%) in comparison to the current study.  In summary, baseline SBST risk subgroup 
proportions varied amongst studies.  This is not surprising and suggests differences in 
cohorts across countries and settings, regardless of the duration of LBP reported by the 
participants.  In the current study, the SBST risk subgroups were well represented and the 
subgroup proportions did not demonstrate extremes in comparison to other studies. 
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Table 4.1.  Baseline Descriptive Characteristics across Key Studies 
Variable Current study 
n=290 
Hill et al., 2008 
Developmental 
sample n=131 
Hill et al., 2008 
External sample 
n=500 
Hill et al., 2011 
RCT sample n=851 
Morsø et al., 2014 
n=960 
Page et al., 2015 
n=53 
Age (years) 50.5 (37.0-60.0) 
(median [IQR]) 
44.0 (10.0)  
(mean [SD]) 
45.0 (9.7)    
(mean [SD]) 
49.8 (14.8)* 
(mean [SD]) 
52.0 (14.1) 
(mean [SD]) 
44.1 (13.3) 
(mean [SD]) 
Sex, n (%) female 166 (57.2) 77 (58.8) 293 (58.6) 500 (58.8) 521 (54.3) 23 (43.4) 
Working, n (%) yes 246 (89.5)† 95 (72.5) 370 (74.0) 524 (61.6) – 38 (71.7) 
Pain duration (months) 120.0 (42-240)† 
(median [IQR]) 
Range 3-720 
– – – – 130.7 (112.0) 
(mean [SD]) 
Range 4-360 
Pain duration stratified 
(months), n (%) 
3-6: 8 (2.8) 
7-36: 63 (22.0) 
>36: 215 (75.2)† 
4-6: 15 (11.5) 
7-36: 29 (22.1) 
 >36: 34 (26.0) 
4-6: 77 (15.4) 
7-36: 125 (25.0) 
>36: 112 (22.4) 
4-6: 123 (14.5) 
7-36: 209 (24.6) 
>36: 178 (20.9) 
≈ 80% chronic 
(> 3 months) 
– 
Pain (NRS); 
range 0-10 
5.8 (1.9) 
(mean [SD]) 
– – 5.3 (2.2)* 
(mean [SD]) 
6.0 (4.0-7.0) 
 (median [IQR]) 
2.8 (2.3) 
(mean [SD]) 
Disability (RMDQ); 
range 0-24 
9.0 (6.0-13.0) 
(median [IQR]) 
8.6 (6.6) 
(mean [SD]) 
9.1 (5.9) 
(mean [SD]) 
9.8 (5.7)* 
(mean [SD]) 
60.9 (44.0-78.0)‡ 
(median [IQR]) 
18.4% (10.3%)§ 
(mean [SD]) 
Leg pain, n (%) 145 (50.0) 75 (57.3) 303 (60.6) 530 (62.3) – – 
 
 
 
 
 
89 
 
Variable Current study 
n=290 
Hill et al., 2008 
Developmental 
sample n=131 
Hill et al., 2008 
External sample 
n=500 
Hill et al., 2011 
RCT sample n=851 
Morsø et al., 2014 
n=960 
Page et al., 2015 
n=53 
SBST total score; 
range 0-9 
5.0 (3.0-7.0) 
(median [IQR]) 
4.3 (2.6) 
(mean [SD]) 
3.8 (2.3) 
(mean [SD]) 
– – – 
SBST psych subscale 
score; range 0-5 
3.0 (1.0-4.0) 
(median [IQR]) 
2.2 (1.6) 
(mean [SD]) 
1.8 (1.5) 
(mean [SD]) 
– – – 
Low risk, n (%) 82 (28.3) 52 (39.7) 234 (46.8) 221 (26.0) 252 (27.7) 35 (66.0) 
Medium risk, n (%) 116 (40.0) 45 (34.4) 186 (37.2) 394 (46.3) 296 (32.5) 11 (20.8) 
High risk, n (%) 92 (31.7) 33 (25.2) 74 (14.8) 236 (27.7) 363 (39.9) 7 (13.2) 
IQR = interquartile range; SD = standard deviation; – = data not available; NRS = Numerical Rating Scale; RMDQ = Roland Morris Disability Questionnaire; 
SBST = STarT Back Screening Tool. 
* Weighted average and SD. 
† Working = 15 missing; pain duration = 4 missing. 
‡ 100-point RMDQ used which equates to 14.6 on the 24-point RMDQ. 
§ Oswestry Disability Questionnaire used. 
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4.2.2 Baseline demographic and clinical characteristics 
Baseline descriptive characteristics for a number of key studies that have evaluated the 
SBST in comparison to the current study are shown in Table 4.1.  The key studies included in 
Table 4.1 are the SBST’s original developmental and validation study (Hill et al., 2008), the 
SBST RCT (Hill et al., 2011), and the two studies undertaken in populations with 
predominantly (Morsø et al., 2014) or exclusively (Page et al., 2015) chronic LBP.  The age of 
the participants, the proportion of females, and the proportion of working participants in 
the current study were similar to the studies described in Table 4.1. 
 
In the current study, the SBST risk subgroups did not show statistically significant 
differences for the majority of the demographic variables including age, sex, and pain 
duration (Table 2.3).  Similar results were reported by Beneciuk and colleagues (2015), Field 
and Newell (2012), and Kongsted and colleagues (2011).  However, Morsø and colleagues 
(2014) reported a significant difference between the SBST risk subgroups for sex and pain 
duration but not for age.  In the current study, the SBST risk subgroups also did not show 
statistically significant differences for employment status (Table 2.3).  Similar results were 
reported by Beneciuk and colleagues (2015).   
 
The current study was the first to evaluate for differences between the SBST risk subgroups 
for compensation status.  There was no significant difference between the SBST risk 
subgroups on compensation status with only 15.8% (n=45) of the total cohort having a 
positive compensation status (Table 2.3).  Conflicting results are reported in the literature 
with respect to the relationship between compensation status and outcomes in LBP 
disorders.  A cross sectional comparison of compensation involvement versus no 
compensation involvement demonstrated an adverse effect on self-reported pain, 
depression, and disability for the compensation group (Rainville et al., 1997).  A large 
prospective study in a primary care setting in Australia reported that the presence of 
compensation was independently associated with a longer recovery time (Henschke et al., 
2008).  Similarly, in a systematic review, Hayden and colleagues (2009) reported a 
consistent association between the presence of compensation and poorer outcomes.  In 
contrast to the aforementioned, a systematic review by Ramond and colleagues (2011) 
reported that compensation issues did not independently influence outcomes.   
 
In the current study, there were significant differences in education level, occupation, and 
self-reported overall general health between the SBST risk subgroups (Table 2.3).  To this 
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investigator’s knowledge, SBST risk subgroup differences on these demographic variables 
have not been previously reported.  The high risk group had fewer years in education than 
the low risk group.  A higher proportion of the high risk group had a manual occupation and 
a higher proportion of the low risk group had a sedentary occupation.  Self-reported overall 
general health was increasingly poor across the three risk groups; the high risk group 
reported the poorest general health.  There are likely to be many potential factors, 
interactions, and mechanisms to explain these findings that are well beyond the scope of 
this research.  However, these findings are broadly in line with other studies.  Costa and 
colleagues (2009) reported that patients with chronic LBP with a lower level of education 
were more likely to have a delayed recovery.  A less favourable course of LBP amongst 
persons with less formal education has also been reported in an early review (Dionne et al., 
2001).  Dionne and colleagues (2001) postulated that level of education may have an 
influence on pain and disability because lower socio-economic status (education being a 
surrogate measures of socio-economic status) may be associated with factors such as 
physically demanding occupations and differences in access to or use of healthcare.  
Education level may also influence health literacy.  Access to health services and health 
literacy may have implications for implementing targeted treatment pathways but 
speculating further on this is beyond the scope of this research.  Other studies have 
reported that higher physical work demands were prognostic of an unfavourable outcome 
in LBP (Hayden et al., 2009, Shaw et al., 2001) and were a barrier to return to work (Shaw et 
al., 2011).  In a systematic review of LBP prognosis, poorer general health was reported to 
be associated with poorer outcomes (Hayden et al., 2009). 
 
In the current study, the baseline mean pain intensity of the total cohort was similar to that 
reported by Hill and colleagues (2011) and Morsø and colleagues (2014) (Table 4.1).  The 
baseline median disability score for the total cohort was also comparable to that reported 
by Hill and colleagues (2008 and 2011) (Table 4.1).  In contrast, in comparison to the 
current study, the secondary care cohort with predominantly chronic LBP showed higher 
disability at baseline (Morsø et al., 2014) (Table 4.1).  Despite the inclusion criteria for the 
current study stipulating a minimum score of five on the RMDQ, the sample had a relatively 
low level of disability compared to normative data reported for a sample with chronic LBP 
recruited from a multidisciplinary tertiary-referral pain management center in Australia 
(Nicholas et al., 2008).  The study by Page and colleagues (2015) reported relatively low 
baseline pain and disability (Table 4.1) however, the small sample size (n=53) in this study 
may have influenced these results.  The proportion of the sample in the current study that 
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reported leg pain was similar to that reported in studies by Hill and colleagues (2008 and 
2011) (Table 4.1). 
 
4.3 Cross sectional profile of the STarT Back Screening Tool risk subgroups 
The aim of the cross sectional study was to describe the distribution of clinical and 
psychological measures in relation to the SBST risk subgroups.  Specifically, this study aimed 
to examine whether the three SBST risk subgroups differed with respect to pain, disability, 
and psychological profile.  The results of this study demonstrated that from a statistical 
perspective, the SBST risk subgroups were successful in distinguishing elevated levels of 
pain, disability, and negative psychological affect and cognitions with reference to 
unidimensional questionnaires.  To gain an appreciation of the clinical utility of the SBST, 
consideration should be given to whether or not these subgroup differences can be 
considered clinically relevant or meaningful in addition to being statistically different.  In 
order to make this judgement, a number of factors related to the median (or mean) scores 
on the questionnaires for each of the SBST risk subgroups have been taken into 
consideration.  These factors include qualitative descriptors, normative data in a clinical 
group with chronic LBP, the minimal clinically important difference (MCID) or minimal 
important change (MIC) where this information is available, and clinical opinion.  As a 
preface to this discussion, this investigator acknowledges the limitations associated with 
MCID (or MIC) values and applying these values to baseline subgroups.  The definition of a 
MCID varies in the literature with the common construct being a lowest amount of change 
that is important in some way (Beaton et al., 2002).  The MCID typically relates to within-
person change over time but could also relate to between-person differences (Beaton et 
al., 2002).  However, other studies have looked at differences between people at one point 
in time (Beaton et al., 2002).  There are a wide range of MCID values reported in the 
literature which vary based on the population studied and the methods used to derive 
these values (Wright et al., 2012, Beaton et al., 2002).  These values are context specific 
rather than a fixed number (Beaton et al., 2002).  Hence, caution is required when 
interpreting MCID values (Terwee et al., 2010).  In the context of the following discussion, 
although MCID (or MIC) values are not typically used to compare groups on baseline values, 
they provide some perspective on subgroup differences observed in the current study. 
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4.3.1 Clinical measures of pain and disability 
The results of the current study demonstrated increasingly higher pain and disability scores 
across the SBST risk subgroups with statistically significant differences between all three 
groups (Table 2.3).  The mean pain intensity scores on the NRS for the SBST risk subgroups 
were 4.7, 6.0, and 6.5 respectively for the low, medium, and high risk group (Table 2.3).  
These scores suggest that all three risk subgroups had clinically meaningful levels of pain 
(Hush et al., 2009, Wideman et al., 2012).  Normative pain data (as measured on a NRS) in a 
large Australian sample with chronic LBP has been reported as a mean (standard deviation 
[SD]) of 6.2 (2.0) (Nicholas et al., 2008).  In the current study, the low risk group scored 
below this normative mean but the medium and the high risk group were close to this 
value.  In LBP, the MIC on the NRS for pain has been reported as two (Ostelo et al., 2008).  
Given the aforementioned information, it is unlikely that the differences in pain score 
between the medium and the high risk group and the medium and the low risk group 
would be considered clinically meaningful.  However, the difference in pain score between 
the low and the high risk group may be considered clinically meaningful.   
 
The median scores on the RMDQ differed by three points between each of the three SBST 
risk subgroups with scores of 6.0, 9.0, and 12.0 respectively for the low, medium, and high 
risk group (Table 2.3).  In comparison, the weighted mean RMDQ score was 4.5, 9.9, and 
14.5 respectively for the low, medium, and high risk group in the SBST RCT (Hill et al., 2011).  
A median score of 14 on the RMDQ has been reported as normative in a large Australian 
sample with chronic LBP (Nicholas et al., 2008).  Overall, the participants in the current 
study did not have a high level of disability at a cohort level or at an individual subgroup 
level.  However, the median disability scores in the current study can be considered 
clinically meaningful particularly for the medium and the high risk group (Hush et al., 2009, 
Wideman et al., 2012).  The MIC for the RMDQ has been reported as five points (Ostelo et 
al., 2008).  Given the aforementioned information, the differences in disability between the 
low and the high risk group in the current study may be considered clinically meaningful.   
 
The current study did not demonstrate a statistically significant difference between the 
three SBST risk subgroups for the percentage of LBP versus leg pain although the low risk 
group had the largest proportion of participants with 100% LBP (Table 2.3).  Beneciuk and 
colleagues (2015) also reported no significant difference in symptom location (LBP versus 
leg pain) between the SBST risk subgroups.  These findings are somewhat unexpected given 
that the presence of leg pain is a question in the SBST (“My back pain has spread down my 
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leg(s) at some time in the last two weeks”).  Furthermore, in the original developmental 
and validation study, the SBST total score showed an excellent ability to discriminate the 
presence of referred leg pain (area under the curve [AUC] = 0.84) (Hill et al., 2008).  In 
addition, a systematic review reported that the presence of radiating leg pain compared to 
LBP alone was associated with poorer outcomes (Konstantinou et al., 2013).  The inclusion 
criteria for the current study may partially explain the results.  In order to reduce the 
likelihood of participants with radiculopathy or radicular leg pain being included, 
participants were required to have dominant axial LBP (i.e. 60% or more LBP compared to 
leg pain).  The result was 50% of the total cohort reported having 100% LBP; this profile was 
maintained across the risk subgroups.   
 
4.3.2 Psychological measures 
The results of the current study demonstrated increasingly higher scores across the SBST 
risk subgroups for the measures of depression, anxiety, stress, fear avoidance beliefs, pain 
catastrophising, and perceived risk of pain persistence (Table 2.3).  The results also 
demonstrated lower scores for the measures of self-efficacy and chronic pain acceptance as 
SBST risk sub-group categorisation increased from low to medium to high (Table 2.3).  
There were statistically significant differences between all three risk subgroups for all 
psychological measures with the exception of the Depression Anxiety Stress Scale-21 (DASS-
21) anxiety score and the Fear Avoidance Beliefs Questionnaire (FABQ) scores where the 
group contrasts indicated statistically significant differences between two groups only.  
Significant differences for the DASS-21 anxiety score were only found between the low risk 
group and the medium and the high risk group with no significant difference between the 
medium and the high risk group.  The scores on the physical activity and work subscales of 
the FABQ demonstrated that the high risk group had significantly greater fear avoidance 
beliefs than both the medium and the low risk group with no significant difference between 
the low and the medium risk group.  Although statistically significant, whether or not the 
subgroup differences on the psychological measures can be considered clinically relevant or 
meaningful is discussed below. 
 
The current study was the first to use the DASS-21 as the reference questionnaire to 
measure depression, stress, and anxiety.  The median depression scores on the DASS-21 
were considered “normal” for both the low and the medium risk group and “moderate” for 
the high risk group (Lovibond and Lovibond, 1995) (Table 2.3).  This suggests that the high 
risk group may have clinically meaningful higher levels of depression when compared to the 
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low and the medium risk group.  The low and the medium risk group had median stress 
scores on the DASS-21 that were considered normal while the high risk group was 
considered “mildly” stressed (Lovibond and Lovibond, 1995) (Table 2.3).  This suggests that 
there may be a small, but clinically relevant difference between the stress levels of the high 
risk group and the other two risk groups.  With respect to the anxiety scores on the DASS-
21, the total cohort (median score of 4.0 out of a maximum score of 42) and each of the 
SBST risk subgroups (median score of 2.0, 4.0, and 6.0 respectively for the low, medium, 
and high risk group) had low levels of anxiety with all scores considered normal (Lovibond 
and Lovibond, 1995) (Table 2.3).  Given this information, a clinically meaningful difference 
in anxiety between the risk subgroups is unlikely.  Reported normative data in a large 
Australian sample with chronic LBP were a median DASS score of 10.0 for depression, 6.0 
for anxiety, and 13.0 for stress (Nicholas et al., 2008).  In the current study, only the high 
risk group scored at or above these values.   
 
In the current study, the median scores on the physical activity subscale of the FABQ were 
13.0, 13.5, and 18.0 respectively for the low, medium, and high risk group (Table 2.3).  The 
median scores on the work subscale of the FABQ were 13.0, 15.0, and 20.0 respectively for 
the low, medium, and high risk group (Table 2.3).  It appears that the high risk group may 
have clinically meaningful greater fear avoidance beliefs than both the low and the medium 
risk group.  This is consistent with where the statistically significant differences were found 
with the group contrasts (Table 2.3).  In the current study, extracting information on fear 
avoidance beliefs using a single question in the SBST was not adequate to distinguish 
between the three risk subgroups.  This is in keeping with the findings from Kent and 
colleagues (2014) who evaluated the concurrent validity of brief psychosocial screening 
questions against full-length reference questionnaires.  These authors reported that for the 
construct of fear of movement, a combination of two questions rather than a single one 
resulted in a stronger correlation with its reference questionnaire (FABQ) (Spearman 
Correlation Coefficient = 0.926) (Kent et al., 2014).  The current study did not compare 
individual SBST constructs/questions to their respective full-length reference 
questionnaires.  The complexities and ambiguities around measuring the construct of fear 
has previously been highlighted (Lundberg et al., 2011).   
 
In the current study, the median scores on the Pain Catastrophising Scale (PCS) were 9.0, 
16.0, and 28.0 for the low, medium, and high risk group respectively (Table 2.3).  According 
to the PCS User Manual, a total score of 20 is the 50th percentile (Sullivan, 2009).  Only the 
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high risk group scored above the 50th percentile.  Hill and colleagues (2008) used a score of 
greater than or equal to 20 on the PCS to indicate non-recovery.  Taking this information 
into account, it would suggest that only the high risk group had relatively high levels of pain 
catastrophising.  It appears that the high risk group may have clinically meaningful higher 
levels of pain catastrophising than both the low and the medium risk group.   
 
The current study was the first to investigate the relationship between perceived risk of 
pain persistence and SBST stratification.  The results demonstrated statistically significant 
differences between all three SBST risk subgroups on this variable (Table 2.3).  However, 
the median score on the NRS for this measure was 8.0 for the low risk group and 9.0 for 
both the medium and the high risk group.  This suggests that the differences between the 
three risk groups are unlikely to be clinically meaningful.  The median duration of LBP for all 
three risk groups was 10 years.  It is therefore not surprising that all groups scored very high 
on the NRS for the risk of pain persistence.  Although this measure is not a construct found 
in the SBST, the question “I feel that my back pain is terrible and it’s never going to get any 
better” may in part reflect the construct of perceived risk of pain persistence.   
 
The current study was also the first to investigate the relationship between the positive 
constructs of self-efficacy and chronic pain acceptance and the SBST risk subgroups.  These 
constructs are not included in the SBST but the results of this study supported that the risk 
subgroups were inversely related to these positive constructs.  There were statistically 
significant differences in self-efficacy and chronic pain acceptance (total score, pain 
willingness subscale, and activity engagement subscale) between the three risk subgroups.  
The high risk group had the lowest self-efficacy and chronic pain acceptance score.  A 
relationship between lower self-efficacy and greater functional impairment, distress, and 
pain severity in chronic pain samples has been reported (Jackson et al., 2014).  Lower 
chronic pain acceptance has been shown to be associated with greater distress and pain 
related disability in persistent chronic musculoskeletal pain disorders (McCracken and 
Eccleston, 2006, Wright et al., 2011).  A normative median total score of 24.0 on the Pain 
Self Efficacy Questionnaire (PSEQ) has been reported in a large Australian sample with 
chronic LBP (Nicholas et al., 2008).  In the current sample, all three SBST risk subgroups had 
a median score higher than 24.0 indicating that this sample had higher levels of self-efficacy 
than the sample in the study by Nicholas and colleagues (2008).  Although the SBST risk 
subgroups were statistically different with respect to both of these positive constructs, it 
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appears that only the high risk group may have clinically meaningful lower levels of self-
efficacy and chronic pain acceptance compared to the other two groups.  
 
4.3.3 Summary - clinically meaningful differences between risk subgroups 
Although statistically significant, the differences between the three SBST risk subgroups for 
the clinical measures of pain and disability and the psychological measures may not be 
clinically meaningful differences between all three subgroups.  It appears that:  (a) the high 
and the low risk subgroup may have clinically meaningful differences in pain and disability 
with the medium risk group approximating the high risk group; (b) the high risk group may 
have clinically meaningful higher levels of depression, stress, fear avoidance beliefs, and 
catastrophising compared to the other two groups; (c) all three risk subgroups had a similar 
low (normal) level of anxiety; (d) all three risk subgroups perceived a similar high risk of 
pain persistence; and (e) the high risk group may have clinically meaningful lower self-
efficacy and chronic pain acceptance compared to the other two groups.  Broadly, the high 
risk group appears to stand separate from the other two groups with respect to the 
psychological measures suggesting the tool can identify a low and a high contribution of 
psychological factors to a patient’s presentation.  The SBST may be more effective at 
distinguishing between two risk subgroups rather than three in a population with chronic 
LBP.   
 
4.3.4 Comparisons to other studies 
The results of the current cross sectional study are in keeping with the results from 
previously published cross sectional studies that have investigated the profile of the SBST 
risk subgroups.  Studies that have investigated samples with LBP of variable duration in 
physiotherapy and chiropractic clinical settings have demonstrated that the SBST risk 
subgroups were related to pain intensity (Field and Newell, 2012, Fritz et al., 2011) and 
disability (Field and Newell, 2012, Fritz et al., 2011, Beneciuk et al., 2015).  These studies 
reported increasing pain and disability from the low to medium to high risk group.  
However, these studies did not comment on whether or not the differences in pain and 
disability between the SBST risk subgroups were clinically meaningful in addition to being 
statistically different.  In a cohort exclusively with chronic LBP, baseline SBST total score 
was correlated with baseline disability but not with baseline pain (Page et al., 2015).  The 
absence of a correlation between the SBST total score and baseline pain intensity in this 
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study may have been due to the small sample size (n=53) or the low level of pain present at 
baseline (mean pain intensity 27.6%). 
 
With respect to psychological measures, earlier studies that have investigated participants 
with LBP of variable duration have reported that depression (Beneciuk et al., 2015, 
Kongsted et al., 2011), fear avoidance beliefs (Beneciuk et al., 2015, Kongsted et al., 2011), 
catastrophising (Beneciuk et al., 2015, Kongsted et al., 2011), kinesiophobia (Beneciuk et 
al., 2015), and anxiety (Beneciuk et al., 2015) were related to the SBST risk subgroups.  
These studies also did not comment on whether or not the SBST risk subgroup differences 
were clinically meaningful in addition to being statistically different.  Beneciuk and 
colleagues (2013) showed that the SBST total score and psychological subscale score were 
positively correlated with fear avoidance beliefs, catastrophising, kinesiophobia, and 
depression.  Page and colleagues (2015) reported that the SBST total score was positively 
correlated with kinesiophobia. 
 
The results of the current study suggest that the SBST may be more effective at 
distinguishing between two risk subgroups rather than three in a population with chronic 
LBP.  Similar to the results of the current study, Beneciuk and colleagues (2015) reported 
the presence of two rather than three distinctive patterns among psychological and 
disability measures in a cohort with variable duration LBP in a physiotherapy setting in the 
USA. 
 
In summary, the results from the current study are in keeping with the results from 
previously published studies.  When evaluated in a cross sectional manner, pain, disability, 
and psychological measures have consistently demonstrated a relationship with the SBST 
risk subgroups and/or SBST score.   
 
4.3.5 STarT Back Screening Tool as a substitute for full-length, unidimensional 
measures  
The SBST was developed as a practical way to subgroup patients with LBP based on 
modifiable prognostic indicators which are appropriate targets for intervention.  The 
practicality of the SBST is derived from its multidimensional nature and low responder and 
assessor burden making it feasible for use in busy clinical practice.  The tool was designed 
to reduce the need to administer multiple full-length, unidimensional questionnaires in 
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order to determine risk profile for screening purposes and subsequently assist in care 
decisions.  The SBST’s acceptability as a surrogate measure for multiple full-length 
measures as first-line screening has been previously reported in samples with LBP of 
variable duration in a physiotherapy setting (Beneciuk et al., 2015) and a UK primary care 
setting (Wideman et al., 2012).  In a cross sectional study, Beneciuk and colleagues (2015) 
reported that the SBST adequately distinguished between a number of full-length, 
unidimensional psychological and disability measures to identify elevated levels of 
psychological distress, maladaptive coping, and disability.  These authors concluded that 
the SBST was a suitable replacement for the administration of multiple unidimensional 
questionnaires (Beneciuk et al., 2015).  Wideman and colleagues (2012) demonstrated that 
the SBST was responsive to change at the four month follow-up and could be used instead 
of its reference standards to imply changes in pain severity, disability, fear of movement, 
and catastrophising therefore improving the efficiency of assessment and reassessment in a 
clinical setting.  Although the study by Wideman and colleagues (2012) was prospective in 
nature, these results lend support to using the SBST for baseline screening assessment 
rather than multiple full-length, unidimensional questionnaires.   
 
In keeping with previous studies, the results of the current cross sectional study support 
that the SBST has value as a substitute for the administration of multiple full-length, 
unidimensional questionnaires for first-line screening to assist in the identification of 
patients presenting with low or high levels of pain, disability, and negative psychological 
affect and cognitions.  The clinical implications of this will be discussed in detail in section 
4.8.   
 
4.4 The one year follow-up sample characteristics 
In order to interpret and compare the results of the current prospective study with 
previously published studies, it is necessary to examine more closely the follow-up sample 
characteristics.  The low attrition rate at the one year follow-up (n=26 [9.0%]) is one of the 
strengths of this study.  Although the participants that were lost to follow-up had 
statistically significant higher baseline disability (RMDQ median of 10.5 versus 8.0 for 
participants who completed the study) and were more likely to be from the high risk group 
(61.5% versus 28.8% for participants who completed the study), given the overall low 
attrition rate, this is unlikely to have influenced the results (Table 3.1).   
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4.4.1 STarT Back Screening Tool risk subgroup stratification at follow-up 
At the one year follow-up there were 168 (63.6%) participants in the low risk group, 59 
(22.4%) in the medium risk group, and 37 (14.0%) in the high risk group (Table 3.2).  
Comparatively, at baseline there were 82 (28.3%), 116 (40.0%), and 92 (31.7%) participants 
respectively in the low, medium, and high risk group (Table 2.3).  Given that participants in 
the current study had a baseline LBP duration median of 10 years, it was unexpected to see 
such a large proportion in the low risk group and a relatively smaller proportion in the 
medium and the high risk group at the one year follow-up in comparison to baseline 
stratification.  Although speculative, the reasons for this may have been related to the 
natural history of the disorder, treatment effects (81.4% [n=215] of the participants 
reported having received some form of treatment during the study period), or self-
reporting inconsistencies.  The fluctuating nature of LBP over time with respect to both pain 
and disability (Dunn et al., 2006) may have also influenced SBST stratification as the tool 
was only administered at baseline and at one follow-up time point.   
 
In a cohort undergoing physiotherapy treatment, Beneciuk and colleagues (2013) reported 
a larger proportion of patients in the low risk group (n=77 [69.4%]) and a smaller proportion 
of patients in the medium risk (n=23 [20.7%]) and high risk group (n=11 [9.9%]) at the six 
month follow-up compared to baseline stratification (baseline stratification:  low risk n=53 
[36.3%], medium risk n=55 [37.7%], and high risk n=38 [26.0%]).  These results are similar to 
those seen in the current study at the one year follow-up time point.     
 
Other studies have reported on changes in SBST stratification at intake compared to a short 
time after receiving either chiropractic or physiotherapy treatment.  Newell and colleagues 
(2015) showed that approximately one third of chiropractic patients changed SBST risk 
subgroups between the initial chiropractic visit and two days post initial visit with equal 
numbers improving or worsening.  Similarly, Beneciuk and colleagues (2014) described SBST 
categorisation “change” following four weeks of physiotherapy treatment.  In this study, 
the majority of patients “improved” (n=60 [48.8%]) or remained “stable” (n=50 [40.6%]) 
with only 13 (10.6%) participants “worse” as indicated by moving up a risk group or 
remaining in the high risk subgroup following four weeks of physiotherapy treatment 
(Beneciuck et al., 2014).  The high risk group was the least stable as 81.8% of this group 
changed to low or medium risk from intake to four weeks post intake (Beneciuck et al., 
2014).  In the medium risk group, 76.0% changed with 71.7% moving to low risk (Beneciuck 
et al., 2014).  In the low risk group, 11.3% changed, all to the medium risk group (Beneciuck 
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et al., 2014).  These authors concluded that relying solely on intake SBST, particularly if 
initially categorised as high or medium risk, could be misleading as the majority of the 
participants improved after four weeks of physiotherapy (Beneciuck et al., 2014).  The 
results of the study by Beneciuk and colleagues (2014) suggest that repeated screening may 
provide additional prognostic information and more accurately capture the risk profile of 
the patient.  In the current study, short term stability of the SBST risk subgroups was not 
evaluated. 
 
4.4.2 Non-recovery rates at follow-up 
The results of the current study showed different rates of non-recovery for the total cohort 
for the follow-up measures of pain (NRS score greater than or equal to three; n=201 
[76.1%]), disability (RMDQ score greater than or equal to seven; n=83 [31.4%]), and global 
perceived change (global rating of change scale [GRCS] less than or equal to zero; n=117 
[44.5%]) (Table 3.3).  This pattern of non-recovery was maintained when stratified by SBST 
risk subgroup.  Whereas a large proportion of this cohort rated themselves as not 
recovered with respect to pain, a much smaller proportion rated themselves as not 
recovered with respect to disability.  Neither the pain nor the disability domain seemed to 
easily translate into the participant’s perception of improvement on a GRCS.  The findings 
of the current study are comparable to George and Beneciuk (2015) who reported that 
non-recovery with respect to pain (NRS) was much higher than non-recovery with respect 
to disability (RMDQ) although the recovery criteria in this study were much more stringent 
than the current study (i.e. non-recovery defined as NRS score greater than 0 and RMDQ 
score of greater than or equal to three).   
 
In the current study, the proportion of participants who rated themselves as improved on 
the GRCS was 50.0% (n=38) for the high risk group, 56.0% (n=61) for the medium risk group, 
and 60.3% (n=47) for the low risk group.  In contrast, the perceived risk of pain persistence 
at baseline (on an 11-point NRS with 10 indicating a very large risk) was 9.0, 9.0, and 8.0 for 
the high, medium, and low risk group respectively.  It appears that the participants in this 
study expected their pain to persist when evaluated at baseline yet a large proportion felt 
that they had improved one year later.  This suggests that other factors informed perceived 
global change despite a high perceived risk of pain persistence at baseline and a high rate of 
non-recovery with respect to pain at the one year follow-up.   
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The construct of LBP recovery is complex, multidimensional, and highly individualised (Hush 
et al., 2009, Kamper et al., 2010).  Measures of pain and disability may capture different 
aspects of recovery to that of the patient’s perceived recovery (Kamper et al., 2010).  It has 
been previously reported that pain and disability do not align with or easily translate into 
self-rated perceived recovery (Hush et al., 2009, Mehling et al., 2011).  The results of the 
current study clearly support these statements.   
 
The variability in the proportion of participants not recovered with respect to the three 
follow-up measures may also be related to the cut-off scores that were selected to indicate 
recovered versus not recovered.  There is no consensus on a NRS for pain score or RMDQ 
score that equates to recovered or not recovered (Kamper et al., 2010).  In fact, a 
systematic review that evaluated measures used to assess recovery from non-specific LBP 
found a striking lack of consistency amongst measures used, making comparisons across 
studies problematic (Kamper et al., 2011).  Even when the domain measured was identical, 
it was often measured differently across studies (Kamper et al., 2011).  The justification for 
selecting the cut-off scores for the current study is outlined in detail in section 3.1.3.  In 
brief, the cut-off scores were considered clinically relevant and in line with those used in 
previous studies, therefore facilitating comparisons between this study and earlier 
publications on the SBST (Hill et al., 2008, Hill et al., 2010b, Mehling et al., 2015, Mehling et 
al., 2011, Morsø et al., 2013b, Morsø et al., 2014, Wideman et al., 2012).  Inter-study 
comparisons are discussed below. 
 
A number of studies have used greater than or equal to seven on the RMDQ (or equivalent) 
to indicate non-recovery at follow-up (Appendix E-H) (Hill et al., 2008, Mehling et al., 2015, 
Morsø et al., 2013b, Morsø et al., 2014, Page et al., 2015).  A comparison of the current 
study with previously published studies on the proportion of participants considered 
disabled at follow-up, as indicated by greater than or equal to seven on the RMDQ, is 
summarised in Appendix E.  In the current study, the proportion of participants considered 
disabled at follow-up was lower than that reported by Hill and colleagues (2008), Morsø 
and colleagues (2013b), and Morsø and colleagues (2014) at a total cohort level and at the 
level of each of the SBST risk subgroups (Appendix E).  The proportion of participants 
considered disabled at follow-up in the high risk subgroup (43%) in the current study was 
particularly low compared to Hill and colleagues (2008) (78%), Morsø and colleagues 
(2013b) (64%), and Morsø and colleagues (2014) (80%) (Appendix E).  In comparison to the 
current study, only the study by Mehling and colleagues (2015) that investigated a modified 
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SBST item set in a population exclusively with acute LBP, had a lower proportion of 
participants considered disabled at both the three month and the two year follow-up time 
points (Appendix E).  In the only other study that has investigated the SBST in a population 
exclusively with chronic LBP, the proportion of participants not recovered was not reported 
for any of the follow-up measures at any of the follow-up time points (Page et al., 2015).   
 
There are a number of factors that may account for the differences seen across studies with 
respect to the proportion of participants with future disability.  These include baseline 
psychological profile, the timing of follow-up, the potential effects of treatment, cultural 
influences, and other factors related to the setting in which the study was undertaken.  
Baseline disability may have also influenced the level of disability at follow-up.  As an 
example, in the secondary care cohort investigated by Morsø and colleagues (2014), 
baseline disability was higher than in the current study (Table 4.1).  At follow-up, the 
proportion of participants considered disabled in the total cohort and in each SBST risk 
subgroup was also higher than in the current study (Appendix E). 
 
4.5 Predictive and discriminative ability of the STarT Back Screening Tool 
The SBST had better predictive and discriminative ability for future disability in comparison 
to future pain.  The SBST was unable to identify those participants who had rated 
themselves as improved versus not improved at the one year follow-up.  A comparison of 
the SBST’s performance with respect to the follow-up measures of pain, disability, and 
global perceived change within the current study and in comparison to other studies will be 
discussed.  Possible reasons for differences in the predictive and discriminative ability will 
be considered.  The clinical implications of the findings from this study will be discussed in 
detail in section 4.8. 
 
4.5.1 Pain and disability 
The predictive ability of the SBST was evaluated by calculating the additional risk (i.e. risk 
ratio [RR]) of non-recovery for participants classified as medium or high risk at baseline with 
the low risk group used as the reference category.  The results indicated that the high risk 
group (RR 2.86) and medium risk group (RR 2.30) had a meaningfully greater relative risk of 
being considered disabled at the one year follow-up compared to the low risk group (Figure 
3.2).  The high risk group (RR 1.26) and medium risk group (RR 1.25) had a statistically 
greater risk of non-recovery with respect to pain but this relative risk is unlikely to be of any 
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clinical significance.  The lower RRs for pain may have been due to the relatively high 
proportion of participants (n=51 [64.6%]) who were not recovered in the low risk group; 
this would have attenuated the RRs because the low risk group was used as the reference 
category.   
 
Two studies that have investigated the predictive ability of the SBST have reported RRs 
using the same RMDQ cut-off score as the current study to indicate future disability, as well 
as using the low risk group as the reference category (Morsø et al., 2013b, Morsø et al., 
2014).  A comparison of the predictive ability (using RRs) of the SBST for future disability 
between the current study, Morsø and colleagues (2013b), and Morsø and colleagues 
(2014) is summarised in Appendix F.  The RRs for disability in the current study were higher 
than those reported by Morsø and colleagues (2014) (medium risk group RR 1.5 and high 
risk group RR 1.7) for the six month disability outcome in a secondary care setting in 
Denmark where participants reported predominantly chronic LBP.  Morsø and colleagues 
(2014) compared the predictive ability of the SBST in the Danish secondary care setting to a 
Danish primary care setting with participants who reported variable duration LBP.  The SBST 
performed better in the Danish primary care setting (medium risk group RR 2.3 and high 
risk group RR 3.5) when compared to the secondary care setting (Morsø et al., 2014).  The 
weak predictive ability of the SBST demonstrated in the secondary care setting in Denmark 
may have been because the proportion of participants considered disabled at the six month 
follow-up was high at both a cohort and subgroup level with a particularly high proportion 
(almost 50%) of the low risk group considered disabled at follow-up (Morsø et al., 2014).  
Morsø and colleagues (2013b) investigated the predictive ability of the SBST for disability 
outcome at the three month follow-up in a Danish primary care setting.  Participants were 
recruited from GP and physiotherapy clinics for this study and reported LBP of variable 
duration (Morsø et al., 2013b).  The RR was 2.4 for the medium risk group and 2.7 for the 
high risk group (Morsø et al., 2013b).  Morsø and colleagues (2013b) then compared the 
predictive ability of the SBST in the Danish primary care setting to that in a UK primary care 
setting.  The RRs were higher in the UK primary care setting, especially for the high risk 
group (medium risk group RR 3.1 and high risk group RR 4.5) (Morsø et al., 2013b).  In 
summary, the SBST showed better predictive ability for disability in the current study than 
in a Danish secondary care setting (Morsø et al., 2014), similar predictive ability to that 
reported in a Danish primary care setting (Morsø et al., 2013b, Morsø et al., 2014), and 
weaker predictive ability compared to a UK primary care setting as reported in the study by 
Morsø and colleagues (2013b).   
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In the current study, there was no significant difference in the risk of experiencing greater 
pain intensity or disability at the one year follow-up between the medium risk group and 
the high risk group (high risk group RR 1.01 for pain and 1.25 for disability).  The distinction 
between medium and high risk stratification is made based on higher scores on the 
psychological subscale.  Hence, it may be that the psychological subscale did not 
discriminate between the medium and the high risk subgroup in the current study.  This 
may be linked to the cross sectional study results that demonstrated statistically significant 
but not necessarily clinically meaningful differences between the risk subgroups for the 
psychological measures.  Alternatively, other potential confounding factors at baseline or 
positive treatment effects during the study period may help explain these results, however 
these were not explored in this study.  
 
The results from the current study demonstrated that the SBST had better discriminative 
ability for disability than for pain at the one year follow-up (Table 3.4).  The AUC for the 
SBST total score was 0.71 for disability, indicating acceptable discriminative ability.  The 
AUC for the psychological subscale score was 0.67 for disability, indicating slightly poorer 
discrimination.  Both the SBST total score and psychological subscale score had relatively 
poor discriminative ability for pain at the one year follow-up with an AUC of 0.63 for both 
scores.  While other studies have evaluated the ability of the SBST total score to 
discriminate future measures of pain and disability, the current study is the only study to 
evaluate the discriminative ability of the psychological subscale score as well.   
 
A comparison of the discriminative ability of the SBST total score (using the AUC) for future 
disability between the current study and previously published studies (Mehling et al., 2015, 
Morsø et al., 2013b, Morsø et al., 2014, Page et al., 2015) is summarised in Appendix G.  
The discriminative accuracy of the SBST total score for disability in the current study was 
similar to that reported in a Danish primary care setting (AUC 0.71) (Morsø et al., 2013b), a 
Danish primary care setting with participants recruited from physiotherapy clinics (AUC 
0.73) (Morsø et al., 2014), and a Danish secondary care setting (AUC 0.69) (Morsø et al., 
2014).  However, the discriminative accuracy of the SBST total score was lower than that 
reported by Morsø and colleagues (2013b) in a UK primary care setting (AUC 0.81).  In 
comparison to the current study, Page and colleagues (2015) reported that the SBST total 
score had an excellent ability to discriminate six month and 12 month disability outcome 
with an AUC [95% confidence interval (CI)] of 0.84 [0.69, 1.00] and 0.82 [0.61, 1.00] 
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respectively in a sample exclusively with chronic LBP.  However, the confidence intervals 
were large which may have been due to the small sample size in the study.  Page and 
colleagues (2015) measured disability with the Oswestry Disability Questionnaire (ODQ) 
using a cut-off score equivalent to greater than or equal to seven on the RMDQ which may 
also have influenced the results.  In the study by Page and colleagues (2015), the SBST total 
score also had better discriminative ability for pain (case definition was greater than or 
equal to 37%) than the current study with an AUC of 0.73 [0.58, 0.86] for six month pain 
outcome and an AUC of 0.71 [0.54, 0.88] for 12 month pain outcome; the confidence 
intervals were also large.   
 
Kongsted and colleagues (2015) investigated the discriminative ability of the SBST total 
score for pain and disability outcome in a sample predominantly with acute LBP; only 3% of 
the participants reported chronic LBP.  The case definitions for poor outcome were 
stringent.  A NRS for pain score equivalent to greater than zero and a RMDQ score 
equivalent to greater than two indicated a poor outcome.  The SBST performed poorly as it 
was unable to discriminate pain cases at the three and the 12 month follow-up time points 
(Kongsted et al., 2015).  The SBST also had a poor ability to discriminate future disability 
with an AUC of 0.59 [0.55, 0.63] and 0.60 [0.56, 0.64] respectively at the three month and 
the 12 month follow-up.  Poor performance of the SBST in populations with acute LBP has 
been reported in other studies (Mehling et al., 2015, Morsø et al., 2016). 
 
The discriminative ability of other screening tools for pain and disability outcomes in 
populations with LBP, using the AUC statistic, has been reported.  The AUC in these studies 
has typically ranged from the low 0.60s to the high 0.80s (Gabel et al., 2011, Grotle et al., 
2006, Hockings et al., 2008, Linton and Boersma, 2003, Nonclercq and Berquin, 2012).  
Based on the recommendations by Hosmer and colleagues (2013) and previously reported 
AUC values for disability and pain outcomes, an AUC of less than 0.60 can be considered 
non-informative (Traeger et al., 2015).  Hence, the AUC values from the current study 
suggest that the SBST has value in discriminating future disability but is only somewhat 
informative in discriminating future pain in a population with chronic LBP.  Consistent with 
other studies, the SBST demonstrated better discriminative ability for future disability.  
 
In order to further evaluate the discriminative ability of the SBST for future pain and 
disability, the positive likelihood ratio (LR+), negative likelihood ratio (LR-), sensitivity, 
specificity, and the diagnostics odds ratio (DOR) for:  (a) the low risk group versus the 
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medium/high risk group and (b) the low/medium risk group versus the high risk group was 
calculated (Table 3.5).  With respect to pain, a positive test (membership in the 
medium/high risk group at baseline) resulted in a minimal increase (LR+ 1.34 [95% CI 1.06, 
1.70]) and a negative test (not in the medium/high risk group at baseline) resulted in a 
minimal decrease (LR- 0.57 [95% CI 0.40, 0.82]) in the likelihood of being not recovered at 
the one year follow-up with a sensitivity of 74.6% (i.e. correctly identified as not recovered 
by a positive test result), specificity of 44.4% (i.e. correctly identified as recovered by a 
negative result), and DOR of 2.35.  A positive test (membership in the high risk group at 
baseline) resulted in no significant increase (LR+ 1.39 [0.84, 2.30]) and a negative test (not 
in the high risk group at baseline) resulted in no significant decrease (LR- 0.89 [0.76, 1.05]) 
in the likelihood of being not recovered with respect to pain at the one year follow-up with 
a sensitivity of 30.9%, specificity of 77.8%, and DOR of 1.56. 
 
With respect to disability, a positive test (membership in the medium/high risk group at 
baseline) resulted in a minimal increase (LR+ 1.36 [1.18, 1.57]) and a negative test (not in 
the medium/high risk group at baseline) resulted in a small decrease (LR- 0.39 [0.22, 0.68]) 
in the likelihood of being not recovered at the one year follow-up with a sensitivity of 
85.5%, specificity of 37.0%, and DOR of 3.48.  A positive test (membership in the high risk 
group at baseline) resulted in a minimal increase (LR+ 1.67 [1.15, 2.43]) and a negative test 
(not in the high risk group at baseline) resulted in a minimal decrease (LR- 0.79 [0.65, 0.96]) 
in the likelihood of being not recovered with respect to disability at the one year follow-up 
with a sensitivity of 39.8%, specificity of 76.2%, and DOR of 2.12.   
 
In the current study, the LR+s were higher and the LR-s were lower for disability compared 
to pain, again indicating that the SBST performed better with respect to the disability 
measure.  The overall performance of the SBST was the strongest for future disability for 
the low risk group versus the medium/high risk group with a DOR of 3.48 (Table 3.5).  A 
higher DOR indicates better test discrimination (Glas et al., 2003).  From a clinical practice 
perspective, a negative screening result (i.e. not being in the medium or the high risk 
subgroup) would have a moderate to high sensitivity (85.5%) to “rule out” an unfavourable 
disability outcome.  High sensitivity is useful from an initial screening point of view where it 
is important to identify a potentially at risk patient for whom further assessment would be 
of value. 
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A comparison of the discriminative ability of the SBST (using LR+, LR-, sensitivity, specificity, 
and the DOR) for future disability between the current study and previously published 
studies (Hill et al., 2008, Mehling et al., 2015, Page et al., 2015) is summarised in Appendix 
H.  In the original developmental and validation study by Hill and colleagues (2008), the 
likelihood ratios, sensitivity, specificity, and DORs for the SBST’s subgroup cut-off scores to 
discriminate poor disability outcome at the six month follow-up were:  (a) low risk group 
versus medium/high risk group LR+ 2.32 [1.96, 2.76], LR- 0.30 [0.23, 0.40], sensitivity 80.1%, 
specificity 65.4%, and DOR 7.73 and (b) low/medium risk group versus high risk group LR+ 
5.51 [3.30, 9.28], LR- 0.74 [0.67, 0.81], sensitivity 29.6% (corrected value reported as noted 
by Mehling and colleagues (2015)), specificity 94.6%, and DOR 7.45.  In comparison to Hill 
and colleagues (2008), the current study had likelihood ratios for disability that were lower 
for the LR+ and higher for the LR-.  The DORs were correspondingly lower indicating that 
the SBST performed better in the UK primary care setting in a population with LBP of 
variable duration than in the current study.  The likelihood ratios and DORs in the current 
study were marginally better than those reported by Mehling and colleagues (2015) in a 
study that evaluated a modified SBST item set in a sample where the participants reported 
acute LBP.   
 
In summary, the SBST was better able to predict and discriminate future disability 
compared to future pain in the current study.  This is in keeping with results reported in 
previously published studies.  In comparison to a UK primary care setting where patients 
reported variable duration LBP, the SBST’s performance was attenuated in the current 
study in a population with chronic LBP.  Possible explanations for these results are 
considered in section 4.5.3.  The clinical implications of these results are discussed in 
section 4.8.   
 
4.5.2 Global perceived change 
In the current study, the SBST was unable to identify participants who perceived 
themselves as improved versus not improved at the one year follow-up with the RRs not 
showing statistically significance (Figure 3.2) and a poor AUC with a CI that crossed 0.50 
(Table 3.4).  Other studies that have looked at the ability of the SBST to predict global 
perceived change or discriminate between those who perceived themselves as improved or 
not improved have reported similar results regardless of the setting, population, or follow-
up period (Field and Newell, 2012, Newell et al., 2015, Page et al., 2015).  Clearly the SBST 
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does not have utility as a predictor of this measure of recovery or non-recovery.  Possible 
explanations for these results are discussed in section 4.5.3. 
 
4.5.3 Reasons for the relatively weak performance of the STarT Back Screening Tool 
in the current study 
In the current study, the SBST provided an acceptable indication of future disability but the 
tool was not as useful for identifying future pain and was unable to identify self-perceived 
global change.  Previous publications have also demonstrated that the SBST’s performance 
differed depending on the outcome measured.  The SBTS’s performance has also differed 
across studies with the tool’s predictive and discriminative ability overall weaker in this 
study compared to studies undertaken in a UK primary care setting.    
 
There are a number of possible reasons as to why the SBST was relatively weak in its 
predictive and discriminative ability in the current study.  These reasons include the follow-
up measures evaluated, possible effects of treatment, the constructs included in the SBST, 
cross cultural influences on the tool’s performance, the cut-off scores used to derive the 
SBST risk subgroups, the typical natural course of chronic LBP, the response format of the 
SBST, and consideration of the complex and multidimensional nature of chronic LBP.   
 
The ability of a questionnaire to predict outcome is likely to be dependent on the outcome 
domain evaluated (Dworkin et al., 2008).  The SBST was originally developed and validated 
to predict future disability so it is not surprising that the tool performed best with respect 
to this follow-up measure.  Furthermore, the SBST includes items related to the pain and 
disability domains and therefore the tool can be expected to perform better with respect to 
these measures in comparison to global perceived change which is conceptually different 
from the instrument itself.  This has also been demonstrated with the Örebro 
Musculoskeletal Pain Screening Questionnaire (Örebro).  The discriminative ability of the 
Örebro for self-rated recovery has been shown to be poor in comparison to pain, disability, 
or work-related outcomes which are all constructs included in the Örebro (Heneweer et al., 
2007, Jellema et al., 2007).  A systematic review of the Örebro reported that the tool had 
moderate predictive ability for future pain, disability, and sick leave but poor predictive 
ability for self-reported global recovery (Hockings et al., 2008).   
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The participants in the current study were free to pursue any intervention or treatment 
they wanted.  A large proportion of the sample (81.4% [n=215]) received some form of 
treatment during the study period.  Given that the tool stratifies based on modifiable risk 
factors, if these factors were effectively treated, purposely or coincidentally, the predictive 
performance of the tool would decrease (Morsø et al., 2013b, Morsø et al., 2016).   
 
The constructs included in the SBST were those shown to be the strongest independent 
predictors of future LBP related disability in a UK primary care setting where participants 
reported LBP of variable duration (Hill et al., 2008).  The SBST’s performance may have 
been weaker in the current study because the constructs included in the SBST may not be 
as important in chronic LBP.  Although predictors of outcome are likely to be similar for 
acute and chronic LBP (Balague et al., 2012), it is likely that the specific factors involved, 
which combination of factors, or the strength of association of these factors with future 
outcomes are likely to differ depending on the duration of the LBP episode.   
 
Cross cultural influences on the predictive performance of the SBST have been previously 
reported (Morsø et al., 2013b).  The current study was the first to evaluate the SBST in an 
Australian context and this may have influenced the tool’s performance in comparison to 
how the tool performed in a UK primary care setting where the SBST was initially developed 
and validated.   
 
It may be that the cut-off scores used to derive the low, medium, and high risk subgroup 
are not as appropriate for use in a population with exclusively chronic LBP.  However, given 
the relatively low values for the AUC (Table 3.4) and the location of the other potential cut-
points on the ROC curves (Figure 3.3), using different cut-off scores is unlikely to have 
improved the tool’s performance in the current study. 
 
The natural course of acute and chronic LBP has been shown to differ (Costa et al., 2012, 
Dunn and Croft, 2006, Grotle et al., 2010, Hayden et al., 2010).  Grotle and colleagues 
(2010) reported that disability improved from baseline to 12 month follow-up in both a 
group with acute/subacute LBP and a group with chronic LBP.  However, the improvement 
in disability was smaller in the group with chronic LBP in comparison to the group with 
acute/subacute LBP (Grotle et al., 2010).  Similarly, previous studies have reported that 
those with chronic LBP showed a more “persistent course” compared to those with acute 
LBP (Costa et al., 2009, Hayden et al., 2010).  Hence, if a patient with chronic LBP typically 
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does not change in their presentation much over time, the predictive ability of the SBST will 
be relatively low.  An alternative explanation relates to the potential fluctuating nature of 
LBP.  Dunn and colleagues (2006) recruited a sample with variable duration LBP and 
identified four different clusters that characterised the course of LBP over a twelve month 
period.  One of these clusters demonstrated a fluctuating course of pain and disability 
(Dunn et al., 2006).  In the current study, the follow-up measures were only collected at 
one point in time and therefore may not have best captured the “true” outcome.   
 
Chronic LBP is complex and multidimensional (Waddell, 2006).  It may be that the 
dichotomised response option (agree or disagree) used in the SBST was not sensitive 
enough to accurately or fully capture the risk profile of patients with chronic LBP.  
Furthermore, there are a large number of factors that may influence prognosis prediction 
and future recovery that are unrelated to the content of the SBST.  Although the brevity 
and simplicity of the SBST is arguably one of its strengths, it is not unexpected that a 
screening tool as brief and as simple as the SBST was not able to strongly predict or 
discriminate the follow-up measures of interest in a population with chronic LBP. 
 
In summary, there are a number of possible explanations as to why the SBST’s performance 
differed depending on the follow-up measure evaluated and why the SBST’s performance 
was relatively weaker in an Australian population with chronic LBP in comparison to 
previous reports.  
   
4.6 Strengths of the current study 
The current study has a number of strengths.  A large sample was recruited with a very low 
attrition rate at the one year follow-up.  There were a low number of missing values for 
both the baseline and the follow-up measures.  Strengths of the cross sectional study were 
that it collected data on pain, disability, and a diverse range psychological measures 
including three novel measures not previously investigated in relation to the SBST 
(perceived risk of pain persistence, self-efficacy, and chronic pain acceptance).  Follow-up 
measures were multi-domain, patient relevant, and in line with recommendations for 
research involving participants with chronic pain (Dworkin et al., 2005).  The recovery 
indices selected, particularly for disability, allowed for direct comparisons across multiple 
studies.  The follow-up period of one year after entry into the study made this one of the 
few studies that has evaluated the predictive and discriminative ability of the SBST at a 
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follow-up time point greater than six months.  A range of statistical methods were used to 
explore the SBST’s predictive and discriminative ability, facilitating comparison with 
previous research. 
 
4.7 Limitations of the current study 
There are a number of limitations related to the current study.  The participants in this 
study were self-selecting volunteers predominantly from the general community with 
21.4% (n=62) of the study participants recruited from a specific clinical setting, mostly 
private physiotherapy clinics.  This may limit the ability to generalise the results to specific 
clinical populations.  However, as stated previously, this cohort was largely a care seeking 
group and therefore is broadly representative of those suffering from chronic LBP in a 
primary care setting.  In order to elicit information on LBP duration, participants were asked 
to recall how long they had had their back pain for.  This may have resulted in recall bias.  
The participants in the current study had a median duration of LBP of 10 years suggesting 
that the results may be most generalisable to a group with similar duration LBP.  This study 
recruited participants with dominant axial LBP therefore the results are most able to be 
generalised to this group.  To be eligible to participate in this study, a minimum level of pain 
and disability was required.  Hence, the results may not be generalisable to those suffering 
from chronic LBP who have very low levels of pain or disability.  As discussed previously, the 
cohort in the current study was not highly disabled and therefore the results may also not 
be generalisable to those suffering from chronic LBP who are more severely disabled.  
Despite the aforementioned, each of the SBST risk subgroups were well represented and 
each subgroup had clinically meaningful levels of pain and disability.     
 
Although a number of important and novel psychological measures were collected at 
baseline, other important constructs such as coping strategies and social factors were not 
evaluated.  Cut-off scores to indicate non-recovery at the one year follow-up may not have 
accurately represented all participants who viewed themselves as recovered or not 
recovered.  This was evident when considering the variability in the proportion of 
participants deemed recovered versus not recovered for the three follow-up measures.  
This study dichotomised the follow-up measures, which makes the results easy for readers 
to understand and interpret but may have resulted in a loss of information.  As an example, 
a participant sitting just above and another sitting just below the cut-off point on a follow-
up measure would have had a very similar score but would have been categorised 
113 
 
differently.  Furthermore, using different operational definitions for recovery/non-recovery 
may have influenced the results of this study.  Other patient centered measures of recovery 
such as quality of life and psychological measures were also not investigated.   
 
The participants were free to pursue any intervention or treatment they wanted to 
throughout the study period.  This study did not collect robust data on the type of 
treatments participants received or how helpful they perceived any treatment to have 
been.  Hence, it is unknown what influence, if any, treatment may have had on recovery or 
the performance of the SBST.  Nonetheless, the SBST was designed to be used to guide 
decision-making in primary or first contact care settings regardless of what treatment the 
patient may or may not have in the future.    
 
Finally, this study does not provide any information on the clinical or economic benefits of 
stratified care.  However, if the SBST has relatively weak prognostic ability, its usefulness to 
stratify care may be limited in this group (Kent et al., 2015).   
 
4.8 Implications for clinical practice 
In light of the strengths and despite the limitations acknowledged above, the results of this 
study have a number of important implications for clinical practice, both for health care 
providers and health care systems.  The cross sectional study demonstrated that the SBST 
risk subgroups were able to differentiate increasing levels of pain, disability, and negative 
psychological affect and cognitions however, the differences between all three risk 
subgroups may not have been clinically meaningful or relevant.  Subgroup differences 
appeared to have been limited to a low and a high risk group, rather than a low, medium, 
and high risk group in this cohort with chronic LBP.  The prospective study demonstrated 
that the SBST had moderate predictive and acceptable discriminative ability for disability at 
the one year follow-up.  The SBST’s ability to predict and discriminate future pain intensity 
was relatively weak and the tool was unable to identify those participants who perceived 
themselves as improved versus not improved at the one year follow-up.  In considering the 
aforementioned, the SBST should be applied with caution in patients presenting with 
chronic LBP.  In considering the results from the current study, the implications for clinical 
practice are as follows: 
 The SBST has value as a substitute for the administration of multiple full-length, 
unidimensional questionnaires for first-line screening to help identify patients 
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presenting with higher levels of pain, disability, and negative psychological affect 
and cognitions.  Therefore the tool can alert the clinician to the need for further 
assessment.  
 Clinicians may need to consider screening with alternative tools or use full-length 
questionnaires to elicit more detailed information to guide interventions. 
 Reliance on the SBST as a sole indicator of prognosis in chronic axial LBP is not 
recommended.  Although the SBST provided an acceptable indication of future 
disability, clinicians should be aware that patient relevant outcomes extend beyond 
disability.  Therefore, the SBST may not capture a high risk of poor outcome from 
every patient’s perspective.  
 Although stratified care based on the SBST risk subgroups has shown promising 
results in other populations (Hill et al., 2011, Whitehurst et al., 2012), the design of 
health care systems or care pathways that stratify care based exclusively on the 
SBST in populations with chronic LBP in Australia cannot be recommended due to 
the relatively weak prognostic ability of the SBST in this population in comparison 
to a UK primary care setting where patients reported LBP of variable duration. 
 
Clinician’s need to consider the complex, multidimensional, and potentially fluctuating 
nature of chronic LBP.  The brevity and simplicity of the SBST is one of its strengths but the 
tool may not adequately capture prognostic risk in more complex patient presentations.  
The SBST was designed to identify potentially modifiable prognostic indicators for poor 
outcome however, certain factors shown to demonstrate prognostic capability may not be 
modifiable through direct treatment such as age, sex, and pain episode duration.  In 
addition, screening for risk of poor prognosis at a single point in time may not be adequate.  
Screening assessment over a number of time points may provide better prognostic 
information and more accurately capture the risk profile of the patient.  This would also 
facilitate the implementation of targeted interventions that adapt to the patient’s 
presentation over time.  The SBST should not be used as a standalone tool but alongside 
the clinical examination and in conjunction with sound clinical reasoning, clinical intuition, 
and expert judgement. 
 
4.9 Recommendations for future research 
A number of avenues for future research are recommended.  Two SBST risk subgroups 
rather than three may be more appropriate in different healthcare settings.  A prospective 
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comparison of the predictive and discriminative ability of the SBST using two risk subgroups 
as opposed to three and the way in which this may translate into care pathways could be 
evaluated.  Other authors have suggested the need to evaluate the appropriateness of two 
SBST risk categories to guide decision-making (Beneciuk et al., 2015). 
 
This study demonstrated that the SBST risk subgroups were inversely related to the positive 
constructs of self-efficacy and chronic pain acceptance.  Further research evaluating the 
role of adaptive coping and resiliency factors in predicting outcomes in chronic LBP is 
warranted.  Further to this, evaluating whether or not the integration of these modifiable 
positive constructs into screening questionnaires is of value would be an interesting avenue 
of research.  Targeted treatment strategies aimed at increasing self-efficacy and pain 
acceptance may be just as important as reducing the negative prognostic indicators such 
anxiety, depression, and fear.  Outcomes may be improved by facilitating resilience 
mechanisms which strengthen a person’s ability to cope with pain (Sturgeon and Zautra, 
2010).  This area of research has been previously recommended (Wideman et al., 2012).  
   
One of the limitations of the original development and validation of the SBST was that it 
was developed to predict future LBP related disability to the exclusion of other important 
measures such as pain, global perceived change/improvement, health related quality of life, 
psychological health, return to work/future sick leave, or healthcare utilisation.  It has been 
suggested that defining recovery solely in terms of pain and/or disability may limit 
individual relevance (Kamper et al., 2010).  Furthermore, standardised measures such as 
the RMDQ may not adequately capture the goals or interests of the patient (Nicholas and 
George, 2011).  Studies investigating the ability of the SBST to predict the aforementioned 
outcomes are lacking as only future pain and global perceived change have received 
attention.  Furthermore, a complex construct such as recovery is unlikely to be adequately 
or accurately captured by single item measures (Kamper et al., 2011).  Therefore, research 
evaluating the ability of the SBST to predict or discriminate combined or composite 
measures of recovery is indicated.  To date, only one study involving the SBST has used a 
composite measure of pain and disability as an outcome measure (George and Beneciuk, 
2015).  George and Beneciuk (2015) reported that the SBST was a robust predictor of this 
composite measure at the six month follow-up.  Combined measures of global perceived 
change with pain and/or disability may also demonstrate better discriminatory ability 
between recovery and non-recovery (Mehling et al., 2011).  
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The prognostic value of repeated assessment with the SBST and the use of change scores 
has preliminary support (Beneciuck et al., 2014, Beneciuk et al., 2013, Wideman et al., 
2012).  Repeated assessment with the SBST over multiple time points may provide further 
prognostic information for patients with chronic LBP beyond that achieved by screening at 
initial intake only.  However, further research is necessary to confirm this. 
 
Finally, conflicting results are reported in the literature with respect to the value of using 
screening tools compared to using clinician’s impression, judgement, and intuition in order 
to identify risk factors for poor prognosis or individuals at risk of a poor outcome.  The 
majority of studies have compared clinicians and screening tools (Bishop and Foster, 2005, 
Calley et al., 2010, Dagfinrud et al., 2013, Daubs et al., 2010, Fersum et al., 2009, Grevitt et 
al., 1998, Haggman et al., 2004, Hill et al., 2010a, Jellema et al., 2007, Kongsted et al., 2015, 
Newell et al., 2013).  A combination approach of the use of a screening questionnaire such 
as the SBST, clinical examination, and clinician judgement may be optimal (Beales et al., 
2016) although pragmatic studies are lacking in this area.  Research that investigates 
whether or not prognostic accuracy is improved if screening questionnaire results are 
integrated with clinical assessment would be of value from a clinical practice point of view.  
 
4.10 Conclusions 
The results of this study provide valuable information to clinicians on the usefulness and 
limitations of using the SBST in patients with chronic LBP in an Australian setting.  The SBST 
should be applied with caution for patients presenting with chronic LBP.  The SBST has 
value as a substitute for the administration of multiple full-length, unidimensional 
questionnaires to initially screen for high levels of pain, disability, and negative 
psychological affect and cognitions in clinical practice.  Therefore the tool can alert the 
clinician to the need for further assessment.  The SBST has moderate predictive and 
acceptable discriminative ability for future disability.  However, clinicians need to be aware 
that patient relevant outcomes extend beyond disability and therefore the SBST may not 
capture a high risk of poor outcome from every patient’s perspective.  The SBST should be 
used alongside the clinical examination and in conjunction with sound clinical reasoning, 
clinical intuition, and expert judgement when making care decisions.   
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PARTICIPANT INFORMATION SHEET 
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Low Back Pain:  Identifying Factors Associated With Persistent Low Back Pain 
 
 
Principal Investigator:  Martin Rabey 
Project Supervisor:   Professor Peter O’Sullivan 
Co-Supervisors:  Dr. Darren Beales, Dr. Anne Smith, Associate Professor 
Helen Slater 
 
 
Purpose of Research: Back pain can come from strained muscles or sprained joints. 
These usually heal and then the pain gets better. However, in some people back pain can 
carry on. This is called persistent or chronic back pain. It is a difficult problem and why 
some people have ongoing pain is not clear. There is not a strong link between what we 
see on x-rays or scans and the pain people feel. People with persistent pain often have 
other problems like low mood, fear of moving in certain ways, or worries about work.  
 
This research is to try to increase what we know about the complex mix of factors 
involved in persistent back pain. We need to study people with persistent low back pain 
and see how these factors interact. If we study a lot of people with back pain, we may be 
able to identify different groups. We will measure many different factors in 300 people 
and then look at this information. We are also interested in any treatment people have 
for their back pain in the year after you join the study. So one year later we will contact 
you to see if your pain has changed, and find out what treatments you had. You can have 
any treatment you like during this time.  
 
Your role: We would like you to be a participant in our research. We need to measure 
different factors to do with your pain. The study has 3 parts: 
Part 1 involves you completing some questions at home. It takes 30-40 minutes.  
Part 2 involves a visit to Curtin University for some tests of different sensations (pressure, 
touch, heat and cold). This takes 60-90 minutes.  
Part 3 involves completing some more questions one year later. This takes 10 minutes. 
 
Part 1: We will give you some questions to complete in your own time. They ask about 
your pain, how it makes you feel, and how it affects your work and hobbies. If you lose 
concentration you can take a break and finish the questions later. Some questions ask if 
you feel “low or down” or anxious. Depending on your response, we might send a letter 
to your doctor to make sure you get the best care for your pain problem. We will inform 
you if we send a letter. 
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School of Physiotherapy and Exercise Science 
 
Telephone +61 8 9266 4644 
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Part 2: We will arrange for you to come to the School of Physiotherapy at Curtin 
University, Bentley. We will conduct some sensory (e.g.; touch, pressure) tests with you. 
We will ask you to lie on your tummy to test these sensations on your back and your 
wrist. We test the wrist because you have no pain there. 
 
These are the sensation tests: 
1) Touch: We lightly touch the skin in one place or two places. We ask you how 
many places you felt.  
2) Touch: Using plastic “hairs” we touch your skin and ask if you can feel it. We will 
also repeatedly touch your skin with the “hairs” and see if you feel any pain. 
3) Pressure: Using a pencil, a make-up brush, a toothpick, and a tuning fork, we will 
see if you can feel the pencil, the brushing, the toothpick and the fork’s 
vibrations. We will ask whether these cause any pain. 
4) Pressure: Using a special device we will find the point at which pressure changes 
to pain. The test stops the moment you feel pain. 
5) Heat/cold: Using another device we will find the point at which hot and cold 
becomes painful. Each test stops the moment you feel pain. 
6) Body’s own pain control: Tests 4 and 5 are combined to see how effective your 
body’s own pain control is. We will put the warm probe on your wrist. Then we 
measure how much discomfort you feel when we put pressure to your back. This 
lasts about one minute. 
7) We will then ask you to lie still and focus your attention on your back pain for 
one minute. We will measure if focusing changes your pain. 
 
You may feel some discomfort during these last two tests. This should not last long. You 
can stop any time you wish. 
 
Finally we will ask you to do some movements.  You will be asked to try 20 forward 
bends and 20 backward bends.  If your pain gets too strong you may stop at any time.  
During the movements video cameras will record how you move. We will ask you if your 
pain changes as you move. 
 
Part 3: One year later we will send you a few questions in the mail. You complete them 
and mail them back to us. The questions ask about your pain and the treatments you 
have had. 
 
Risks and Discomforts: You may feel some discomfort or pain during some tests.  This is 
similar to what you might feel if you went to see your doctor or physiotherapist for your 
back pain, and they asked you to move your back and pressed to see where it hurts. Any 
increase in pain should settle down quickly once we have finished. If any tests are too 
painful you can tell the researcher and stop the tests. We will ask you some questions 
about your mood or your feelings.  
 
Benefits: After your visit to the School of Physiotherapy we will tell you about your 
results.  When we have all of the results we will tell you about the outcomes. We will 
hold a talk, which you can attend, where we discuss the results. The aim of the research 
is to improve our understanding of back pain. This may help find better treatments for 
back pain in time. 
 
Confidentiality: We keep your details confidential by giving you an identification 
number. Your name will not be on any questionnaires or record sheets. It will only be on 
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the consent form. All forms and video tapes will be stored in a locked cabinet in the 
School of Physiotherapy. Information on computer will be protected by a password. Only 
the researchers will have access to the information. Information will be kept for seven 
years after we have published the results. 
 
Refusal or Withdrawal: We ask you to sign a consent form. This says that you agree to 
take part in the research.  Whether you take part in the research or not is up to you.  You 
may refuse to ever be involved in the research. You may withdraw your consent 
whenever you like, without prejudice.  Please ask any questions before signing the 
consent form. 
 
Further Information: If you would like more information please contact Martin Rabey at: 
School of Physiotherapy, Curtin University, Kent St., Bentley, Western Australia 6102; Tel: 
0487007116; e-mail: martin.rabey@postgrad.curtin.edu.au. 
 
This study has been approved by the Curtin University Human Research Ethics 
Committee (Approval Number HR112/2012). The Committee is composed of members of 
the public, academics, lawyers, doctors and pastoral carers. If needed, verification of 
approval can be obtained either by writing to the Curtin University Human Research 
Ethics Committee, c/- Office of Research and Development, Curtin University, GPO Box 
U1987, Perth 6845, or by telephoning 9266 9223 or by e-mailing hrec@curtin.edu.au. 
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CONSENT SHEET 
 
 
This study has been approved by the Curtin University Human Research Ethics 
Committee (Approval Number HR112/2012). 
 
 
 I understand the purpose and procedures of the study.  
 I have been provided with the participant information sheet.  
 I understand that the procedure itself may not benefit me.  
 I understand that my involvement is voluntary and I can withdraw at any 
time without problem. 
 I understand that a letter will be sent to my family doctor if I score highly 
on the questionnaire concerned with anxiety or depression. 
 I understand that no personal identifying information like my name and 
address will be used and that all information will be securely stored for 7 
years before being destroyed.  
 I have been given the opportunity to ask questions.  
 I agree to participate in the study outlined to me.  
 
  
  
 
Signature          Date   
 
 
 
Witness Signature        Date   
  
  
  
Appendix C:  Written 
Informed Consent Sheet 
Note:  Baseline data for the current 
study was obtained from this study 
(see Methods, Chapter2) 
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Appendix D:  Discussion Supplement - Subgroup Proportions 
Summary of Baseline STarT Back Screening Tool Risk Subgroup Proportions  
 STarT Back Screening Tool risk subgroup (%) 
Study Low Medium High 
Current study 28 40 32 
Studies in chronic LBP    
     Morsø et al., 2014 28 33 40 
     Page et al., 2015 66 21 13 
Studies in LBP of variable duration    
     Hill et al., 2008    
          Developmental sample 40 34 25 
          External sample 47 37 15 
     Hill et al., 2011 26 46 28 
     Fritz et al., 2011 33 48 19 
     Kongsted et al., 2011 59 29 11 
     Morsø et al., 2011 40 34 26 
     Field and Newell, 2012 42 32 27 
     Morsø et al., 2013b 38 39 23 
     Beneciuk et al., 2013, Beneciuk et al.,  
     2015, George and Beneciuk, 2015 
36 38 26 
     Newell et al., 2015 39 37 24 
Studies in acute LBP    
     Mehling et al., 2015 32 46 22 
LBP = low back pain. 
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Appendix E:  Discussion Supplement - Follow-up Disability 
Proportion of Participants Disabled at Follow-up (RMDQ ≥7) – Total Cohort and Stratified by 
Baseline STarT Back Screening Tool Risk Subgroup 
 
    STarT Back Screening Tool 
risk subgroup (%) 
Study LBP 
duration 
Follow-
up 
period 
Total 
cohort 
(%) 
Low Medium High 
Current study 
 
Chronic 1 year 31  15  35  43 
Hill et al., 2008 
UK primary care* 
Variable 6 
months 
40 17 53 78 
Morsø et al., 2013b 
Danish primary care 
Variable 3 
months 
47 24 57 64 
Morsø et al., 2013b 
UK primary care 
Variable 3 
months 
36 17 54 78 
Morsø et al., 2014 
Danish secondary care 
≈ 80% 
Chronic 
6 
months 
68 48 71 80 
Morsø et al., 2014 
Danish primary care† 
Variable 6 
months 
40 20 47 69 
Mehling et al., 2015‡ 
USA primary care 
Acute 6 
months 
22 15 27 13 
Mehling et al., 2015‡ 
USA primary care 
Acute 2 years 25 15 31 15 
RMDQ = Roland Morris Disability Questionnaire; LBP = low back pain. 
* External sample. 
† Participants recruited from physiotherapy clinics. 
‡ A modified item set of the STarT Back Screening Tool used. 
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Appendix F:  Discussion Supplement - Disability Risk Ratios 
Predictive ability of the STarT Back Screening Tool for Disability (RMDQ ≥7) using Risk Ratios 
 
   STarT Back Screening Tool risk 
subgroup 
Study LBP 
duration 
Follow-up 
period 
Low* Medium  
RR [95% CI] 
High  
RR [95% CI] 
Current study 
 
Chronic 1 year REF 2.3 [1.3, 4.1] 2.9 [1.6, 5.1] 
Morsø et al., 2013b 
Danish primary care 
Variable 3 months REF 2.4 [1.7, 3.4] 2.7 [1.8, 3.8] 
Morsø et al., 2013b 
UK primary care 
Variable 3 months REF  3.1 [2.5, 3.9] 4.5 [3.6, 5.6] 
Morsø et al., 2014 
Danish secondary care 
≈ 80% 
Chronic 
6 months REF 1.5 [1.3, 1.7] 1.7 [1.5, 2.0] 
Morsø et al., 2014 
Danish primary care† 
Variable 6 months REF 2.3 [1.2, 4.5] 3.5 [1.8, 6.6] 
RMDQ = Roland Morris Disability Questionnaire; LBP = low back pain; RR = risk ratio; 95% CI 
= 95% confidence interval; REF = reference. 
* Low risk subgroup used as the reference category. 
† Participants recruited from physiotherapy clinics. 
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Appendix G:  Discussion Supplement - Disability Area Under 
the Curve 
Discriminative Ability of the STarT Back Screening Tool Baseline Total Score for Disability 
(RMDQ ≥7) using the AUC 
 
Study LBP duration Follow-up period AUC [95% CI] 
Current study 
 
Chronic 1 year 0.71 [0.64, 0.77] 
Morsø et al., 2013b 
Danish primary care 
Variable 3 months 0.71 [0.66, 0.77] 
Morsø et al., 2013b 
UK primary care 
Variable 3 months 0.81 [0.78, 0.84] 
Morsø et al., 2014 
Danish secondary care 
≈ 80% Chronic 6 months 0.69 [0.66, 0.73] 
Morsø et al., 2014 
Danish primary care* 
Variable 6 months 0.73 [0.64, 0.82] 
Page et al., 2015† 
Canada general community 
Chronic 6 months 0.84 [0.69, 1.00] 
Page et al., 2015† 
Canada general community 
Chronic 1 year 0.82 [0.61, 1.00] 
Mehling et al., 2015‡ 
USA primary care 
Acute 6 months Range 0.54-0.63§ 
Mehling et al., 2015‡ 
USA primary care 
Acute 2 years Range 0.54-0.63§ 
RMDQ = Roland Morris Disability Questionnaire; LBP = low back pain; AUC = area under the 
curve; 95% CI = 95% confidence interval. 
* Participants recruited from physiotherapy clinics. 
† Oswestry Disability Questionnaire ≥24% which equates to RMDQ ≥7. 
‡ A modified item set of the STarT Back Screening Tool used. 
§ Specific values for the AUC were not reported for each of the outcome measures.  The 
AUC for disability falls somewhere within this range. 
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Appendix H:  Discussion Supplement - Disability Likelihood 
Ratios 
Discriminative Ability of the STarT Back Screening Tool Risk Subgroups for Disability (RMDQ 
≥7) - Likelihood Ratios, Sensitivity, Specificity, and the Diagnostic Odds Ratio 
 
Study LBP 
duration 
Follow-
up 
period 
LR+ 
[95% CI] 
LR 
[95% CI] 
Sens 
(%) 
Spec 
(%) 
DOR 
Current 
study 
Chronic 1 year      
     L vs. M/H   1.36 
[1.18, 1.57] 
0.39 
[0.22, 0.68] 
85.5 37.0 3.48 
     L/M vs. H   1.67 
[1.15, 2.43] 
0.79 
[0.65, 0.96] 
39.8 76.2 2.12 
Hill et al., 
2008 
Variable  6 
months 
     
     L vs. M/H   2.32 
[1.96, 2.76] 
0.30 
[0.23, 0.40] 
80.1 65.4 7.73 
     L/M vs. H   5.51 
[3.30, 9.28] 
0.74 
[0.67, 0.81] 
29.6* 94.6 7.45 
Page et al., 
2015† 
Chronic 6 
months 
     
     L vs. M/H   ≤2.96‡ ≥0.35‡ ≈ 68‡ ≈ 79‡ ≈ 8‡ 
     L/M vs. H   – – – – – 
Page et al., 
2015† 
Chronic 1 year      
     L vs. M/H   ≤2.96‡ ≥0.35‡ ≈ 77‡ ≈ 75‡ ≈ 10‡ 
     L/M vs. H   – – – – – 
Mehling et 
al., 2015§ 
Acute 6 
months 
     
     L vs. M/H   1.31 0.48 81.7 32.1 2.73 
     L/M vs. H   1.61 0.85 32.1 80.1 1.89 
Mehling et 
al., 2015§ 
Acute 2 years      
     L vs. M/H   1.27 0.58 77.1 39.4 2.19 
     L/M vs. H   1.63 0.82 36.6 77.6 1.99 
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Likelihood ratio confidence intervals are included where available.  RMDQ = Roland Morris 
Disability Questionnaire; LBP = low back pain; LR+ = positive likelihood ratio; LR- = negative 
likelihood ratio; Sens = sensitivity; Spec = specificity; DOR = diagnostic odds ratio; 95% CI = 
95% confidence interval; L = low risk group; M = medium risk group; H = high risk group; – = 
data not available.  
* As noted by Mehling and colleagues (2015), the value of 39.6% in Table 4 in Hill and 
colleagues (2008) appears incorrect.  Sensitivity was recalculated as 58/196 (= 29.6%) based 
on the numbers provided in the text on page 638 in Hill and colleagues (2008). 
† Oswestry Disability Questionnaire ≥24% which equates to RMDQ ≥7. 
‡ Specific values for the likelihood ratios were not reported.  Sensitivity and specificity 
values were not reported in the text and are therefore estimated from Figure 5.  The DOR 
was calculated from the estimated sensitivity and specificity values. 
§ A modified item set of the STarT Back Screening Tool used. 
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